<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?subarticle pone.0268754.r001?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
    <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
    <journal-id journal-id-type="publisher-id">plos</journal-id>
    <journal-title-group>
      <journal-title>PLoS ONE</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1932-6203</issn>
    <publisher>
      <publisher-name>Public Library of Science</publisher-name>
      <publisher-loc>San Francisco, CA USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9159630</article-id>
    <article-id pub-id-type="publisher-id">PONE-D-21-32479</article-id>
    <article-id pub-id-type="doi">10.1371/journal.pone.0268754</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Mathematical and Statistical Techniques</subject>
          <subj-group>
            <subject>Statistical Methods</subject>
            <subj-group>
              <subject>Metaanalysis</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Statistics</subject>
            <subj-group>
              <subject>Statistical Methods</subject>
              <subj-group>
                <subject>Metaanalysis</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Computer and Information Sciences</subject>
        <subj-group>
          <subject>Network Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Computer and Information Sciences</subject>
        <subj-group>
          <subject>Data Management</subject>
          <subj-group>
            <subject>Data Visualization</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Probability Theory</subject>
            <subj-group>
              <subject>Probability Distribution</subject>
              <subj-group>
                <subject>Normal Distribution</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Research Assessment</subject>
          <subj-group>
            <subject>Reproducibility</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Mathematical and Statistical Techniques</subject>
          <subj-group>
            <subject>Statistical Methods</subject>
            <subj-group>
              <subject>Statistical Hypothesis Testing</subject>
              <subj-group>
                <subject>Chi Square Tests</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Statistics</subject>
            <subj-group>
              <subject>Statistical Methods</subject>
              <subj-group>
                <subject>Statistical Hypothesis Testing</subject>
                <subj-group>
                  <subject>Chi Square Tests</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Mathematical and Statistical Techniques</subject>
          <subj-group>
            <subject>Statistical Methods</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Statistics</subject>
            <subj-group>
              <subject>Statistical Methods</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Applied Mathematics</subject>
            <subj-group>
              <subject>Algorithms</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Simulation and Modeling</subject>
          <subj-group>
            <subject>Algorithms</subject>
          </subj-group>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package</article-title>
      <alt-title alt-title-type="running-head">Assessing and visualizing fragility of clinical results with binary outcomes</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3562-9816</contrib-id>
        <name>
          <surname>Lin</surname>
          <given-names>Lifeng</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="cor001" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chu</surname>
          <given-names>Haitao</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
      </contrib>
    </contrib-group>
    <aff id="aff001">
      <label>1</label>
      <addr-line>Department of Statistics, Florida State University, Tallahassee, FL, United States of America</addr-line>
    </aff>
    <aff id="aff002">
      <label>2</label>
      <addr-line>Statistical Research and Innovation, Global Biometrics and Data Management, Pfizer Inc., New York, NY, United States of America</addr-line>
    </aff>
    <aff id="aff003">
      <label>3</label>
      <addr-line>Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, United States of America</addr-line>
    </aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Gagniuc</surname>
          <given-names>Paul Aurelian</given-names>
        </name>
        <role>Editor</role>
        <xref rid="edit1" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="edit1">
      <addr-line>University Politehnica of Bucharest, ROMANIA</addr-line>
    </aff>
    <author-notes>
      <fn fn-type="COI-statement" id="coi001">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <corresp id="cor001">* E-mail: <email>linl@stat.fsu.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>1</day>
      <month>6</month>
      <year>2022</year>
    </pub-date>
    <volume>17</volume>
    <issue>6</issue>
    <elocation-id>e0268754</elocation-id>
    <history>
      <date date-type="received">
        <day>9</day>
        <month>10</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>2</day>
        <month>5</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 Lin, Chu</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Lin, Chu</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="pone.0268754.pdf"/>
    <abstract>
      <p>With the growing concerns about research reproducibility and replicability, the assessment of scientific results’ fragility (or robustness) has been of increasing interest. The fragility index was proposed to quantify the robustness of statistical significance of clinical studies with binary outcomes. It is defined as the minimal event status modifications that can alter statistical significance. It helps clinicians evaluate the reliability of the conclusions. Many factors may affect the fragility index, including the treatment groups in which event status is modified, the statistical methods used for testing for the association between treatments and outcomes, and the pre-specified significance level. In addition to assessing the fragility of individual studies, the fragility index was recently extended to both conventional pairwise meta-analyses and network meta-analyses of multiple treatment comparisons. It is not straightforward for clinicians to calculate these measures and visualize the results. We have developed an R package called “fragility” to offer user-friendly functions for such purposes. This article provides an overview of methods for assessing and visualizing the fragility of individual studies as well as pairwise and network meta-analyses, introduces the usage of the “fragility” package, and illustrates the implementations with several worked examples.</p>
    </abstract>
    <funding-group>
      <award-group id="award001">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000092</institution-id>
            <institution>U.S. National Library of Medicine</institution>
          </institution-wrap>
        </funding-source>
        <award-id>R01 LM012982</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3562-9816</contrib-id>
          <name>
            <surname>Lin</surname>
            <given-names>Lifeng</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award002">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id>
            <institution>National Center for Advancing Translational Sciences</institution>
          </institution-wrap>
        </funding-source>
        <award-id>UL1 TR001427</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3562-9816</contrib-id>
          <name>
            <surname>Lin</surname>
            <given-names>Lifeng</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award003">
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000025</institution-id>
            <institution>National Institute of Mental Health</institution>
          </institution-wrap>
        </funding-source>
        <award-id>R03 MH128727</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3562-9816</contrib-id>
          <name>
            <surname>Lin</surname>
            <given-names>Lifeng</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <funding-statement>This research was supported in part by the US National Institutes of Health/National Institute of Mental Health grant R03 MH128727, National Institutes of Health/National Library of Medicine grant R01 LM012982 (LL and HC), and National Institutes of Health/National Center for Advancing Translational Sciences grant UL1 TR001427 (LL). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="12"/>
      <table-count count="2"/>
      <page-count count="38"/>
    </counts>
    <custom-meta-group>
      <custom-meta id="data-availability">
        <meta-name>Data Availability</meta-name>
        <meta-value>All datasets used in this article are available in the R package “fragility” (<ext-link xlink:href="https://cran.r-project.org/package=fragility" ext-link-type="uri">https://cran.r-project.org/package=fragility</ext-link>).</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <title>Data Availability</title>
    <p>All datasets used in this article are available in the R package “fragility” (<ext-link xlink:href="https://cran.r-project.org/package=fragility" ext-link-type="uri">https://cran.r-project.org/package=fragility</ext-link>).</p>
  </notes>
</front>
<body>
  <sec sec-type="intro" id="sec001">
    <title>Introduction</title>
    <p>Research reproducibility and replicability have been major concerns in many areas of scientific research [<xref rid="pone.0268754.ref001" ref-type="bibr">1</xref>–<xref rid="pone.0268754.ref006" ref-type="bibr">6</xref>]. Such issues may be largely owing to the misuse of <italic toggle="yes">p</italic> values [<xref rid="pone.0268754.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0268754.ref008" ref-type="bibr">8</xref>], which are often misinterpreted as a measure of treatment effects in clinical studies [<xref rid="pone.0268754.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0268754.ref010" ref-type="bibr">10</xref>]. Consequently, studies with smaller <italic toggle="yes">p</italic> values (i.e., statistically more significant effects) are more likely to be published; this phenomenon is often referred to as publication and selective reporting bias or small-study effects [<xref rid="pone.0268754.ref011" ref-type="bibr">11</xref>–<xref rid="pone.0268754.ref018" ref-type="bibr">18</xref>]. This bias may distort clinical conclusions toward an artificially favorable direction and thus greatly threaten their reliability. Due to these concerns, communities across many scientific fields have recently called for more careful interpretations of <italic toggle="yes">p</italic> values and statistical significance [<xref rid="pone.0268754.ref019" ref-type="bibr">19</xref>–<xref rid="pone.0268754.ref022" ref-type="bibr">22</xref>]. In an effect to reduce publication bias, it has been recommended to pre-register clinical trials or publish their protocols before obtaining the final results [<xref rid="pone.0268754.ref023" ref-type="bibr">23</xref>].</p>
    <p>To supplement the use of <italic toggle="yes">p</italic> values and 95% confidence intervals (CIs) for assessing treatment effects in clinical studies with binary outcomes, Walsh et al. [<xref rid="pone.0268754.ref024" ref-type="bibr">24</xref>] proposed the fragility index (FI) to quantify their fragility (or robustness). The FI is defined as the minimal event status modifications that can alter a study result’s statistical significance. For example, if an originally significant treatment effect estimate becomes non-significant by modifying only a single patient’s event status (e.g., from no disease to disease), then the clinical study’s conclusion is highly fragile. In this case, clinicians may need to carefully borrow real-world evidence to assess the likelihood of that patient developing the disease and appraise the reliability of the evidence about treatment effects from this study. Similar concepts have also been considered in the earlier literature [<xref rid="pone.0268754.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0268754.ref026" ref-type="bibr">26</xref>]. With the growing concerns about research reproducibility and replicability, the FI has regained much attention in recent years. It has been applied to assess the fragility of randomized controlled trials in several clinical areas, such as anticancer medicine, critical care, surgery medicine, and obstetrics [<xref rid="pone.0268754.ref027" ref-type="bibr">27</xref>–<xref rid="pone.0268754.ref033" ref-type="bibr">33</xref>].</p>
    <p>The concerns of research reproducibility and replicability also arise in systematic reviews and meta-analyses (MAs). Publications of MAs have been rapidly increasing in the past few decades, because they offer a powerful tool for synthesizing and contrasting existing findings and producing more precise effect estimates [<xref rid="pone.0268754.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0268754.ref035" ref-type="bibr">35</xref>]. However, sometimes different MAs focusing on the same topic can have inconsistent conclusions [<xref rid="pone.0268754.ref036" ref-type="bibr">36</xref>–<xref rid="pone.0268754.ref038" ref-type="bibr">38</xref>]. Similar to pre-registering clinical trials, pre-registered prospective MAs have been recommended [<xref rid="pone.0268754.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0268754.ref040" ref-type="bibr">40</xref>]. Recently, the FI was extended to assess the fragility of conventional pairwise MAs as well as network meta-analyses (NMAs) of multiple treatment comparisons [<xref rid="pone.0268754.ref041" ref-type="bibr">41</xref>, <xref rid="pone.0268754.ref042" ref-type="bibr">42</xref>]. The FI of an MA is defined similarly to that in a clinical trial; however, its estimation is more complicated, because the modifications of event status may occur in different studies within the MA. Therefore, it is computationally challenging for applied scientists to calculate and interpret the FI of an MA.</p>
    <p>It may not be sufficient to rely completely on the numerical value of the FI derived at a specific significance level (e.g., commonly used 0.05) for properly interpreting the fragility. For example, the FI may be highly associated with the <italic toggle="yes">p</italic> value under certain settings [<xref rid="pone.0268754.ref043" ref-type="bibr">43</xref>]. In such cases, the FI may not provide much more information in addition to the <italic toggle="yes">p</italic> value. Nevertheless, the correlation between the FI and <italic toggle="yes">p</italic> value is generally expected, because the FI is derived based on <italic toggle="yes">p</italic> value (or CI); however, as long as the correlation coefficient is not nearly ±1, the FI can still serve as a useful supplement. Its interpretation of “the number of events modified for altering significance” is intuitive for clinicians. This is similar to the common practice of reporting point estimates of treatment effects, their standard errors (SEs), <italic toggle="yes">p</italic> values, and CIs; each of them provides important information for assessing treatment comparisons, although they are associated with one another. Moreover, no widely-accepted guidelines are available to evaluate the extent of fragility based on the FI value [<xref rid="pone.0268754.ref044" ref-type="bibr">44</xref>]. Clinicians’ opinions (e.g., about the clinical importance of an effect) may be incorporated when assessing the fragility [<xref rid="pone.0268754.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0268754.ref046" ref-type="bibr">46</xref>]. For example, it is likely that a non-event may be changed to be an event for common diseases, but it is less likely for rare diseases. In addition, the FI may not be very suitable for analyses of time-to-event data, in which the timing of events, rather than the occurrence of events, is of primary interest [<xref rid="pone.0268754.ref047" ref-type="bibr">47</xref>–<xref rid="pone.0268754.ref049" ref-type="bibr">49</xref>]. In summary, as a relatively new measure, more comprehensive evaluations, including visualizations of the whole process that alters the significance, should be taken into account when interpreting the FI in clinical practice.</p>
    <p>To the best of our knowledge, very limited software packages are available for assessing the fragility of clinical results, and no package has been developed yet for visualizing the fragility. An online calculator (<ext-link xlink:href="https://clincalc.com/Stats/FragilityIndex.aspx" ext-link-type="uri">https://clincalc.com/Stats/FragilityIndex.aspx</ext-link>) offers a simple tool to calculate the FI of individual studies; users only need to input the event counts and sample sizes in the two treatment groups in a clinical study. However, it does not provide options for specifying the statistical significance level, statistical method used for deriving the significance, etc. The significance level is fixed at 0.05, and Fisher’s exact test is the only option to derive the FI. An R package “fragilityindex” [<xref rid="pone.0268754.ref050" ref-type="bibr">50</xref>] is also available to calculate the FI of individual studies; it additionally extends the FI to logistic regression analyses and survival data analyses. Nevertheless, it only permits users to specify the significance level; many other important factors (such as treatment groups in which event status is modified) that may impact the FI cannot be changed. Atal et al. [<xref rid="pone.0268754.ref041" ref-type="bibr">41</xref>] provide a web interface to calculate the FI of a pairwise MA (<ext-link xlink:href="https://clinicalepidemio.fr/fragility_ma/" ext-link-type="uri">https://clinicalepidemio.fr/fragility_ma/</ext-link>); the Stata module “metafrag” [<xref rid="pone.0268754.ref051" ref-type="bibr">51</xref>] can also be used for this purpose.</p>
    <p>We have developed an R package “fragility” [<xref rid="pone.0268754.ref052" ref-type="bibr">52</xref>] that provides many additional options for assessing and visualizing the fragility of individual trials, pairwise MAs, and NMAs. This article gives an overview of these options and introduces the usage of the “fragility” package in detail with several worked examples. The remaining content is organized as follows. First, we review methods for assessing the fragility in various clinical settings. Second, we introduce the structures of different types of datasets and the usage of various functions provided by the “fragility” package. Third, we present several worked examples and display their results to illustrate the usage of these functions. Finally, we provide a brief discussion about future improvements.</p>
  </sec>
  <sec sec-type="materials|methods" id="sec002">
    <title>Materials and methods</title>
    <sec id="sec003">
      <title>Assessing and visualizing the fragility</title>
      <sec id="sec004">
        <title>Fragility of an individual clinical study</title>
        <p>Suppose that a clinical study compares two treatments, denoted by 0 and 1, with a binary outcome. The results are typically reported in a 2×2 table (<xref rid="pone.0268754.t001" ref-type="table">Table 1</xref>). Let <italic toggle="yes">n</italic><sub>0</sub> and <italic toggle="yes">n</italic><sub>1</sub> be the sample sizes in treatment groups 0 and 1, respectively, and <italic toggle="yes">e</italic><sub>0</sub> and <italic toggle="yes">e</italic><sub>1</sub> be the event counts. These counts are non-negative integers, and <italic toggle="yes">e</italic><sub>0</sub> ≤ <italic toggle="yes">n</italic><sub>0</sub> and <italic toggle="yes">e</italic><sub>1</sub> ≤ <italic toggle="yes">n</italic><sub>1</sub>.</p>
        <table-wrap position="float" id="pone.0268754.t001">
          <object-id pub-id-type="doi">10.1371/journal.pone.0268754.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Illustration of a 2×2 table and event status modifications.</title>
          </caption>
          <alternatives>
            <graphic xlink:href="pone.0268754.t001" id="pone.0268754.t001g" position="float"/>
            <table frame="box" rules="all" border="0">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">Treatment</th>
                  <th align="left" rowspan="1" colspan="1">Event</th>
                  <th align="left" rowspan="1" colspan="1">Non-event</th>
                  <th align="left" rowspan="1" colspan="1">Sample size</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" colspan="4" rowspan="1">2×2 table of the original study:</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Group 0</td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">e</italic>
                    <sub>0</sub>
                  </td>
                  <td align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic><sub>0</sub> − <italic toggle="yes">e</italic><sub>0</sub></td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">n</italic>
                    <sub>0</sub>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Group 1</td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">e</italic>
                    <sub>1</sub>
                  </td>
                  <td align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic><sub>1</sub> − <italic toggle="yes">e</italic><sub>1</sub></td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">n</italic>
                    <sub>1</sub>
                  </td>
                </tr>
                <tr>
                  <td align="left" colspan="4" rowspan="1">2×2 table with event status modifications:</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Group 0</td>
                  <td align="left" rowspan="1" colspan="1"><italic toggle="yes">e</italic><sub>0</sub> + <italic toggle="yes">f</italic><sub>0</sub></td>
                  <td align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic><sub>0</sub> − <italic toggle="yes">e</italic><sub>0</sub> − <italic toggle="yes">f</italic><sub>0</sub></td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">n</italic>
                    <sub>0</sub>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Group 1</td>
                  <td align="left" rowspan="1" colspan="1"><italic toggle="yes">e</italic><sub>1</sub> + <italic toggle="yes">f</italic><sub>1</sub></td>
                  <td align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic><sub>1</sub> − <italic toggle="yes">e</italic><sub>1</sub> − <italic toggle="yes">f</italic><sub>1</sub></td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">n</italic>
                    <sub>1</sub>
                  </td>
                </tr>
              </tbody>
            </table>
          </alternatives>
        </table-wrap>
        <p>By modifying some events’ status, the impact on the study result can be used to calculate the FI. The uncertainties in event status are common in practice; for example, if the follow-up periods for some participants are not sufficient, their disease outcomes may occur after the end of study. [<xref rid="pone.0268754.ref024" ref-type="bibr">24</xref>] originally proposed to assess the fragility of a study by modifying event status only in a single treatment group; such a group is chosen as the one with the fewest events. Nevertheless, this restriction may not guarantee that the modifications of event status for altering statistical significance or non-significance are minimal. In general, we may consider event status modifications in both treatment groups, as in <xref rid="pone.0268754.t001" ref-type="table">Table 1</xref>. Specifically, let <italic toggle="yes">f</italic><sub>0</sub> and <italic toggle="yes">f</italic><sub>1</sub> be the numbers of non-events changed to events in groups 0 and 1, respectively. They may take any integer values between −<italic toggle="yes">e</italic><sub><italic toggle="yes">k</italic></sub> and <italic toggle="yes">n</italic><sub><italic toggle="yes">k</italic></sub> − <italic toggle="yes">e</italic><sub><italic toggle="yes">k</italic></sub> (<italic toggle="yes">k</italic> = 0, 1). Negative values of <italic toggle="yes">f</italic><sub>0</sub> or <italic toggle="yes">f</italic><sub>1</sub> indicate decreasing event counts in the corresponding group, while positive values indicate increasing event counts; setting <italic toggle="yes">f</italic><sub>0</sub> or <italic toggle="yes">f</italic><sub>1</sub> to 0 implies no event status modification.</p>
        <p>Many statistical methods can be used to assess the association between a treatment and an outcome in a 2 × 2 table [<xref rid="pone.0268754.ref053" ref-type="bibr">53</xref>]. Fisher’s exact test is commonly used for this purpose; its <italic toggle="yes">p</italic> value is calculated based on a hypergeometric distribution under the null hypothesis. This test is particularly useful for small sample sizes, because many alternative methods use large-sample asymptotic properties and may not perform well for small sample sizes. The chi-squared test is another popular method, and its <italic toggle="yes">p</italic> value is based on the asymptotic chi-squared distribution under the null hypothesis; thus, this test generally requires sufficiently large sample sizes.</p>
        <p>Clinicians also frequently use certain measures to quantify treatment effects for binary outcomes, e.g., the odds ratio (OR), relative risk (RR), and risk difference (RD); <italic toggle="yes">p</italic> values may be produced based on these effect sizes. Without loss of generality, these effect sizes are calculated for the comparison of group 1 vs. group 0 throughout this article. The OR and RR are conventionally analyzed on a logarithmic scale for a better approximation to the normal distribution. Specifically, the log OR is estimated as
<disp-formula id="pone.0268754.e001"><alternatives><graphic xlink:href="pone.0268754.e001.jpg" id="pone.0268754.e001g" position="anchor"/><mml:math id="M1" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>y</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mtext>log</mml:mtext><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
with SE
<disp-formula id="pone.0268754.e002"><alternatives><graphic xlink:href="pone.0268754.e002.jpg" id="pone.0268754.e002g" position="anchor"/><mml:math id="M2" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:msup><mml:mo>)</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
The log RR is estimated as
<disp-formula id="pone.0268754.e003"><alternatives><graphic xlink:href="pone.0268754.e003.jpg" id="pone.0268754.e003g" position="anchor"/><mml:math id="M3" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>y</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mtext>log</mml:mtext><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
with SE
<disp-formula id="pone.0268754.e004"><alternatives><graphic xlink:href="pone.0268754.e004.jpg" id="pone.0268754.e004g" position="anchor"/><mml:math id="M4" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfrac><mml:msup><mml:mo>)</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
The RD is estimated as
<disp-formula id="pone.0268754.e005"><alternatives><graphic xlink:href="pone.0268754.e005.jpg" id="pone.0268754.e005g" position="anchor"/><mml:math id="M5" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>y</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
with SE
<disp-formula id="pone.0268754.e006"><alternatives><graphic xlink:href="pone.0268754.e006.jpg" id="pone.0268754.e006g" position="anchor"/><mml:math id="M6" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>[</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:msubsup><mml:mi>n</mml:mi><mml:mn>0</mml:mn><mml:mn>3</mml:mn></mml:msubsup></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:msubsup><mml:mi>n</mml:mi><mml:mn>1</mml:mn><mml:mn>3</mml:mn></mml:msubsup></mml:mfrac><mml:msup><mml:mo>]</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
In the presence of zero counts, a continuity correction (often 0.5) needs to be applied to all data cells in the 2×2 table for producing these estimates [<xref rid="pone.0268754.ref054" ref-type="bibr">54</xref>].</p>
        <p>Consequently, a certain set of event status modifications <italic toggle="yes">f</italic><sub>0</sub> and <italic toggle="yes">f</italic><sub>1</sub> leads to a <italic toggle="yes">p</italic> value based on each of the above five methods for assessing the association between the treatment and outcome, denoted by <italic toggle="yes">p</italic>(<italic toggle="yes">f</italic><sub>0</sub>, <italic toggle="yes">f</italic><sub>1</sub>). The <italic toggle="yes">p</italic> value of the original study with no event status modification is <italic toggle="yes">p</italic>(0, 0) with <italic toggle="yes">f</italic><sub>0</sub> = <italic toggle="yes">f</italic><sub>1</sub> = 0. For the chi-squared test, OR, RR, and RD, their <italic toggle="yes">p</italic> values may not be accurate when some data cells are small, because they all use large-sample asymptotic null distributions to calculate <italic toggle="yes">p</italic> values. The estimated log OR, log RR, and RD are assumed to approximately follow the normal distribution, so their <italic toggle="yes">p</italic> values are calculated as <inline-formula id="pone.0268754.e007"><alternatives><graphic xlink:href="pone.0268754.e007.jpg" id="pone.0268754.e007g" position="anchor"/><mml:math id="M7" display="inline" overflow="scroll"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>Φ</mml:mo><mml:mo>(</mml:mo><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mo>|</mml:mo><mml:mi>y</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> (two-sided) or <inline-formula id="pone.0268754.e008"><alternatives><graphic xlink:href="pone.0268754.e008.jpg" id="pone.0268754.e008g" position="anchor"/><mml:math id="M8" display="inline" overflow="scroll"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>Φ</mml:mo><mml:mo>(</mml:mo><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mo>|</mml:mo><mml:mi>y</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> (one-sided), where Φ(⋅) denotes the cumulative distribution function of the standard normal distribution. The OR, RR, and RD can indicate the direction of treatment effects; thus, the alternative hypothesis could be two- or one-sided. Fisher’s exact test and the chi-squared test evaluate the association with no specific direction; therefore, their <italic toggle="yes">p</italic> values are two-sided.</p>
        <p>For each method, the <italic toggle="yes">p</italic> values <italic toggle="yes">p</italic>(<italic toggle="yes">f</italic><sub>0</sub>, <italic toggle="yes">f</italic><sub>1</sub>) based on all considered event status modifications can be visualized as a matrix of points; each point represents a <italic toggle="yes">p</italic> value, with the x- and y-axes representing its corresponding event status modifications, and its color distinguishes the magnitude of the <italic toggle="yes">p</italic> value [<xref rid="pone.0268754.ref055" ref-type="bibr">55</xref>]. When event status modifications are restricted to a single treatment group, the <italic toggle="yes">p</italic> values <italic toggle="yes">p</italic>(<italic toggle="yes">f</italic><sub>0</sub>, 0) or <italic toggle="yes">p</italic>(0, <italic toggle="yes">f</italic><sub>1</sub>) can be presented against <italic toggle="yes">f</italic><sub>0</sub> or <italic toggle="yes">f</italic><sub>1</sub> in a scatterplot for visualizing the change of <italic toggle="yes">p</italic> values as event status modifications vary. These plots will be illustrated in our worked examples later.</p>
        <p>Assume the statistical significance level is pre-specified at <italic toggle="yes">α</italic>. Formally, if the original study result is statistically significant with <italic toggle="yes">p</italic>(0, 0) &lt; <italic toggle="yes">α</italic>, then the FI is defined as
<disp-formula id="pone.0268754.e009"><alternatives><graphic xlink:href="pone.0268754.e009.jpg" id="pone.0268754.e009g" position="anchor"/><mml:math id="M9" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mtext>FI</mml:mtext><mml:mo>=</mml:mo><mml:munder><mml:mtext>min</mml:mtext><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>≥</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:munder><mml:mo>{</mml:mo><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>+</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mo>}</mml:mo><mml:mo>;</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
if the original study result is non-significant with <italic toggle="yes">p</italic>(0, 0) ≥ <italic toggle="yes">α</italic>, then the FI is
<disp-formula id="pone.0268754.e010"><alternatives><graphic xlink:href="pone.0268754.e010.jpg" id="pone.0268754.e010g" position="anchor"/><mml:math id="M10" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mtext>FI</mml:mtext><mml:mo>=</mml:mo><mml:munder><mml:mtext>min</mml:mtext><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:munder><mml:mo>{</mml:mo><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>+</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mo>}</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
A smaller value of FI indicates a more fragile result. The above minimization problems are subject to −<italic toggle="yes">e</italic><sub><italic toggle="yes">k</italic></sub> ≤ <italic toggle="yes">f</italic><sub><italic toggle="yes">k</italic></sub> ≤ <italic toggle="yes">n</italic><sub><italic toggle="yes">k</italic></sub> − <italic toggle="yes">e</italic><sub><italic toggle="yes">k</italic></sub> (<italic toggle="yes">k</italic> = 0, 1). These ranges could be adjusted to accommodate with clinicians’ needs. For example, if it is more likely that some events are not observed, then one may restrict the ranges to be non-negative for yielding more events. One may also restrict event status modifications to a single group, as in Walsh et al. [<xref rid="pone.0268754.ref024" ref-type="bibr">24</xref>]. When the modifications are restricted to group 0, the resulting FI is
<disp-formula id="pone.0268754.e011"><alternatives><graphic xlink:href="pone.0268754.e011.jpg" id="pone.0268754.e011g" position="anchor"/><mml:math id="M11" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>FI</mml:mtext><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>min</mml:mtext><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo><mml:mo>≥</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="4pt"/><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:mi>α</mml:mi><mml:mo>;</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>min</mml:mtext><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="4pt"/><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo><mml:mo>≥</mml:mo><mml:mi>α</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo/></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
Similarly, when the modifications are restricted to group 1, the resulting FI is
<disp-formula id="pone.0268754.e012"><alternatives><graphic xlink:href="pone.0268754.e012.jpg" id="pone.0268754.e012g" position="anchor"/><mml:math id="M12" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>FI</mml:mtext><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>min</mml:mtext><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>≥</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="4pt"/><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:mi>α</mml:mi><mml:mo>;</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>min</mml:mtext><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="4pt"/><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo><mml:mo>≥</mml:mo><mml:mi>α</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo/></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
Clearly, 1 ≤ FI ≤ min{FI<sub>0</sub>, FI<sub>1</sub>}. It is possible that the significance or non-significance cannot be altered based on given ranges of event status modifications; in such cases, we define FI as not available (NA). This may happen when sample sizes are small, as they only permit a narrow range of modifications.</p>
        <p>Of note, this article discusses multiple methods for testing the association between treatment and outcome and thus deriving the FI. We hope that they offer flexibility for users when assessing clinical studies’ fragility based on different tools. We do not suggest that users should try all methods because this practice could lead to “fragility-hacking.” Users are recommended to use the statistical method specified in the study protocol for deriving the FI.</p>
        <p>Although the significance level is conventionally set at <italic toggle="yes">α</italic> = 0.05, this choice is arguably arbitrary, and the resulting false positive rate may be considered high in some fields of science. Many researchers propose to lower this standard to <italic toggle="yes">α</italic> = 0.005 for improving research reproducibility and replicability [<xref rid="pone.0268754.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0268754.ref057" ref-type="bibr">57</xref>]. As the FI is derived based on a specific significance level, the significance level should always be reported alongside the associated level. Instead of relying on the FI at a single significance level, clinicians might also be interested in the trend of the FI as the significance level varies (e.g., from 0.005 to 0.05), which can be visualized in a scatterplot [<xref rid="pone.0268754.ref055" ref-type="bibr">55</xref>]. Theoretically, the FI is a function of the significance level, denoted by FI(<italic toggle="yes">α</italic>). This is a step function because the FI must take positive integer values. Suppose the FI is evaluated from <italic toggle="yes">α</italic> = <italic toggle="yes">α</italic><sub>L</sub> (say, 0.005) to <italic toggle="yes">α</italic> = <italic toggle="yes">α</italic><sub>U</sub> (say, 0.05). We may consider the average of the area under the function to quantify the overall fragility among the range of significance levels [<italic toggle="yes">α</italic><sub>L</sub>, <italic toggle="yes">α</italic><sub>U</sub>]. The idea is similar to the area under the receiver operating characteristic curve (AUC) used in diagnostic decision-making. The average FI is <inline-formula id="pone.0268754.e013"><alternatives><graphic xlink:href="pone.0268754.e013.jpg" id="pone.0268754.e013g" position="anchor"/><mml:math id="M13" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>FI</mml:mtext><mml:mtext>avg</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mtext>U</mml:mtext></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mtext>L</mml:mtext></mml:msub></mml:mrow></mml:mfrac><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mtext>L</mml:mtext></mml:msub></mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mtext>U</mml:mtext></mml:msub></mml:msubsup><mml:mtext>FI</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>d</mml:mtext><mml:mi>α</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>. In practice, this quantity can be approximated by the average of FIs at <italic toggle="yes">B</italic> (say, 100) equally-spaced values between <italic toggle="yes">α</italic><sub>L</sub> and <italic toggle="yes">α</italic><sub>U</sub>, denoted by <italic toggle="yes">α</italic><sub><italic toggle="yes">b</italic></sub> for <italic toggle="yes">b</italic> = 1, 2, …, <italic toggle="yes">B</italic> with <italic toggle="yes">α</italic><sub>1</sub> = <italic toggle="yes">α</italic><sub>L</sub> and <italic toggle="yes">α</italic><sub><italic toggle="yes">B</italic></sub> = <italic toggle="yes">α</italic><sub>U</sub>. Because <inline-formula id="pone.0268754.e014"><alternatives><graphic xlink:href="pone.0268754.e014.jpg" id="pone.0268754.e014g" position="anchor"/><mml:math id="M14" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mtext>L</mml:mtext></mml:msub></mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mtext>U</mml:mtext></mml:msub></mml:msubsup><mml:mtext>FI</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>d</mml:mtext><mml:mi>α</mml:mi><mml:mo>≈</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mtext>U</mml:mtext></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mtext>L</mml:mtext></mml:msub></mml:mrow><mml:mi>B</mml:mi></mml:mfrac><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>b</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>B</mml:mi></mml:msubsup><mml:mtext>FI</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mi>b</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> for a sufficient large <italic toggle="yes">B</italic>, the average FI is <inline-formula id="pone.0268754.e015"><alternatives><graphic xlink:href="pone.0268754.e015.jpg" id="pone.0268754.e015g" position="anchor"/><mml:math id="M15" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>FI</mml:mtext><mml:mtext>avg</mml:mtext></mml:msub><mml:mo>≈</mml:mo><mml:msup><mml:mi>B</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>b</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>B</mml:mi></mml:msubsup><mml:mtext>FI</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mi>b</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>, i.e., the arithmetic mean of the values of FI(<italic toggle="yes">α</italic><sub><italic toggle="yes">b</italic></sub>).</p>
        <p>Multiple clinical studies may be conducted on the same topic; they compare the same treatment groups and investigate the same outcome. Clinicians may want to compare the fragility across the multiple studies. As the FI of an individual study depends on the sample size, it might not be sensible to directly compare the FIs of the multiple studies. Alternatively, one may use the relative measure, fragility quotient (FQ), to compare the multiple studies’ fragility [<xref rid="pone.0268754.ref058" ref-type="bibr">58</xref>]. Specifically, <inline-formula id="pone.0268754.e016"><alternatives><graphic xlink:href="pone.0268754.e016.jpg" id="pone.0268754.e016g" position="anchor"/><mml:math id="M16" display="inline" overflow="scroll"><mml:mrow><mml:mtext>FQ</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mtext>FI</mml:mtext><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, where <italic toggle="yes">n</italic><sub>0</sub> + <italic toggle="yes">n</italic><sub>1</sub> is the total sample size of the study. Thus, the FQ represents the minimal percentage change of event status among all participants that can alter the significance (or non-significance), and it ranges within 0%–100%.</p>
      </sec>
      <sec id="sec005">
        <title>Fragility of a meta-analysis</title>
        <p>An MA aims at synthesizing and contrasting findings from multiple independent studies on the same topic. Consider an MA with a binary outcome that contains <italic toggle="yes">N</italic> studies. Each study compares the same two treatment groups (denoted by 0 and 1) and reports its 2×2 table with event counts <italic toggle="yes">e</italic><sub><italic toggle="yes">i</italic>0</sub> and <italic toggle="yes">e</italic><sub><italic toggle="yes">i</italic>1</sub> and sample sizes <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic>0</sub> and <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic>1</sub> in the two groups (<italic toggle="yes">i</italic> = 1, …, <italic toggle="yes">N</italic>). The effect measure can be the (log) OR, (log) RR, or RD. Let <italic toggle="yes">y</italic><sub><italic toggle="yes">i</italic></sub> and <italic toggle="yes">s</italic><sub><italic toggle="yes">i</italic></sub> be the estimated effect size and its SE, respectively, in study <italic toggle="yes">i</italic>. The continuity correction is applied to studies with zero data cells. The estimated effect sizes are conventionally assumed to approximately follow the normal distributions <inline-formula id="pone.0268754.e017"><alternatives><graphic xlink:href="pone.0268754.e017.jpg" id="pone.0268754.e017g" position="anchor"/><mml:math id="M17" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> within studies, where <italic toggle="yes">θ</italic><sub><italic toggle="yes">i</italic></sub> denotes the underlying true effect size of study <italic toggle="yes">i</italic>.</p>
        <p>Here, the within-study SEs <italic toggle="yes">s</italic><sub><italic toggle="yes">i</italic></sub> are assumed to be fixed, known values. Alternative exact methods (without the approximation to the normal distributions) are available via generalized linear mixed models or Bayesian hierarchical models; they can avoid the continuity correction in the presence of zero data cells and may have better performance than the conventional method for sparse data [<xref rid="pone.0268754.ref059" ref-type="bibr">59</xref>–<xref rid="pone.0268754.ref063" ref-type="bibr">63</xref>]. However, to assess the fragility of the MA, this article focuses on the conventional method instead of the alternatives, because many iterations may be needed to derive the FI, and it may be computationally demanding to repeat the exact methods many times. Also, as most MA applications have used the conventional method so far, the FI derived from this method may better reflect the current practice.</p>
        <p>The underlying true effect sizes are further assumed to follow the normal distribution <italic toggle="yes">θ</italic><sub><italic toggle="yes">i</italic></sub> ∼ <italic toggle="yes">N</italic>(<italic toggle="yes">θ</italic>, <italic toggle="yes">τ</italic><sup>2</sup>), where <italic toggle="yes">τ</italic><sup>2</sup> is the between-study variance owing to heterogeneity. A special case is that <italic toggle="yes">τ</italic><sup>2</sup> = 0, which implies <italic toggle="yes">θ</italic><sub><italic toggle="yes">i</italic></sub> = <italic toggle="yes">θ</italic> for all studies; this case is referred to as the fixed-effect or common-effect setting, and <italic toggle="yes">θ</italic> represents the common effect size shared by all studies. On the other hand, <italic toggle="yes">τ</italic><sup>2</sup> &gt; 0 yields the random-effects setting, where <italic toggle="yes">θ</italic> is interpreted as the overall effect size across studies. In both settings, <italic toggle="yes">θ</italic> is of primary interest, and the MA aims at estimating this parameter and its CI. One may refer to Borenstein et al. [<xref rid="pone.0268754.ref064" ref-type="bibr">64</xref>], Riley et al. [<xref rid="pone.0268754.ref065" ref-type="bibr">65</xref>], and many other articles for extensive discussions about the interpretation and selection of the fixed-effect and random-effects settings.</p>
        <p>The between-study variance <italic toggle="yes">τ</italic><sup>2</sup> plays a critical role in the random-effects MA because it greatly impacts the CI of the treatment effect estimate and thus the statistical significance. It can be estimated via several approaches. The DerSimonian–Laird (DL) estimator by [<xref rid="pone.0268754.ref066" ref-type="bibr">66</xref>] is the most popular one; nevertheless, several better alternatives, e.g., the restricted maximum likelihood (REML) estimator, have been shown to perform better in general [<xref rid="pone.0268754.ref067" ref-type="bibr">67</xref>, <xref rid="pone.0268754.ref068" ref-type="bibr">68</xref>]. Let <inline-formula id="pone.0268754.e018"><alternatives><graphic xlink:href="pone.0268754.e018.jpg" id="pone.0268754.e018g" position="anchor"/><mml:math id="M18" display="inline" overflow="scroll"><mml:msup><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup></mml:math></alternatives></inline-formula> be the estimated between-study variance; under the fixed-effect setting, set <inline-formula id="pone.0268754.e019"><alternatives><graphic xlink:href="pone.0268754.e019.jpg" id="pone.0268754.e019g" position="anchor"/><mml:math id="M19" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Each study in the MA is assigned with a weight <inline-formula id="pone.0268754.e020"><alternatives><graphic xlink:href="pone.0268754.e020.jpg" id="pone.0268754.e020g" position="anchor"/><mml:math id="M20" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. The overall effect size is estimated as
<disp-formula id="pone.0268754.e021"><alternatives><graphic xlink:href="pone.0268754.e021.jpg" id="pone.0268754.e021g" position="anchor"/><mml:math id="M21" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
It approximately follows the normal distribution, and its (1 − <italic toggle="yes">α</italic>) × 100% CI is conventionally constructed as
<disp-formula id="pone.0268754.e022"><alternatives><graphic xlink:href="pone.0268754.e022.jpg" id="pone.0268754.e022g" position="anchor"/><mml:math id="M22" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>±</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mo>(</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msup><mml:mo>)</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
where <italic toggle="yes">z</italic><sub>1−<italic toggle="yes">α</italic>/2</sub> denotes the 1 − <italic toggle="yes">α</italic>/2 quantile of the standard normal distribution. Alternatively, [<xref rid="pone.0268754.ref069" ref-type="bibr">69</xref>, <xref rid="pone.0268754.ref070" ref-type="bibr">70</xref>] refined the CI by accounting for the variation in <inline-formula id="pone.0268754.e023"><alternatives><graphic xlink:href="pone.0268754.e023.jpg" id="pone.0268754.e023g" position="anchor"/><mml:math id="M23" display="inline" overflow="scroll"><mml:msup><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup></mml:math></alternatives></inline-formula>. The Hartung–Knapp–Sidik–Jonkman (HKSJ) method constructs the CI as
<disp-formula id="pone.0268754.e024"><alternatives><graphic xlink:href="pone.0268754.e024.jpg" id="pone.0268754.e024g" position="anchor"/><mml:math id="M24" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>±</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>N</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mo>{</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>N</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msup><mml:mo>}</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
where <italic toggle="yes">t</italic><sub><italic toggle="yes">N</italic>−1,1−<italic toggle="yes">α</italic>/2</sub> denotes the 1 − <italic toggle="yes">α</italic>/2 quantile of the <italic toggle="yes">t</italic> distribution with <italic toggle="yes">N</italic> − 1 degrees of freedom. It has been shown to have a better coverage probability than the CI based on the normal distribution, especially when the number of studies <italic toggle="yes">N</italic> is small [<xref rid="pone.0268754.ref071" ref-type="bibr">71</xref>].</p>
        <p>To assess the fragility of an MA, an ideal approach is to exhaustively enumerate all possible event status modifications step by step; however, this procedure may be impractical from the computational perspective if many steps are needed to alter the significance or non-significance. Suppose that the overall effect size is significant and is above the null value. At each step of modifying event status, we may need to consider decreasing one event count in group 1 or increasing one event count in group 0 in a single study; thus, assuming that the event counts have not achieved the bounds (i.e., 0 or sample size), there are 2<italic toggle="yes">N</italic> possible cases for this step. Such iterations will terminate only after the significance is altered, so we need to perform up to (2<italic toggle="yes">N</italic>)<sup>FI</sup> MAs during this process. This is not practical in many real-world applications; for example, even for a relatively small MA with <italic toggle="yes">N</italic> = 10 studies, if the FI is 5, then this exhaustive search needs to perform over 3 million different MAs with modified event status.</p>
        <p>Instead of enumerating all possible event status modifications, Atal et al. [<xref rid="pone.0268754.ref041" ref-type="bibr">41</xref>] proposed a heuristic iterative process based on the CI of the overall effect size estimate to derive the FI. Specifically, suppose that the original MA yields a significant overall effect size estimate, and it is larger than the null value. We initiate the iterative process from the original MA (step 0). In order to move the CI toward the null value, event status is modified to decrease event counts (down to 0) in group 1 or increase those in group 0 (up to the corresponding sample size). At each step, one event is changed to a non-event in group 1, or one non-event is changed to an event in group 0 in a certain study; separate MAs are performed based on the data with each of the above modifications to produce the CIs of the overall effect size estimate. The modification that leads to the smallest lower bound of the CI (i.e., the one closest to the null value if the CI still does not cover it) is selected as the optimal one for facilitating the process of altering the significance. Based on the optimal modifications identified in the previous steps, the iterations continue until the CI covers the null value. Because each step contains up to 2<italic toggle="yes">N</italic> modifications, the above algorithm only needs to perform up to 2<italic toggle="yes">N</italic> × FI MAs to derive the FI, making the process computationally feasible. This number is much smaller than (2<italic toggle="yes">N</italic>)<sup>FI</sup> in the exhaustive search, especially when <italic toggle="yes">N</italic> or the FI value is large. For visualizations of the iterative steps for deriving the FI of the MA, readers may refer to Fig 2 in Atal et al. [<xref rid="pone.0268754.ref041" ref-type="bibr">41</xref>]. We will also provide a worked example later to demonstrate the process.</p>
        <p>On the other hand, suppose that the original MA has a non-significant overall effect size estimate. Unlike the case of a significant overall effect size estimate where the CI is moved toward only one specific direction, now the CI covers the null value, and we may move it toward either the left or right direction for achieving significance. For each direction, a separate FI can be derived via an algorithm similar to the one described above; the final FI is the minimum value of these two FIs.</p>
        <p>In cases that significance or non-significance cannot be altered, the FI is defined as NA. The FQ can be similarly calculated for the MA; it is the FI divided by the total sample size across all studies. To visualize the process of the iterative algorithm for deriving the FI, one may present the changes in event counts in the two treatment groups along with the studies involved in the corresponding modifications against the iterations; we will provide worked examples to illustrate the visualizations.</p>
      </sec>
      <sec id="sec006">
        <title>Fragility of a network meta-analysis</title>
        <p>NMA is an extension of the conventional pairwise MA that compares only a pair of treatments at one time; it aims at comparing multiple treatments simultaneously by synthesizing both direct and indirect evidence about treatment comparisons [<xref rid="pone.0268754.ref072" ref-type="bibr">72</xref>, <xref rid="pone.0268754.ref073" ref-type="bibr">73</xref>]. Suppose a trial compares treatments A and C and another trial compares B and C; these two trials provide indirect evidence for A vs. B via the common comparator C. NMA has been increasingly used in recent years, because many treatments may be available for a specific disease outcome. It is particularly useful when some treatments of interest (e.g., new drugs) have been seldom compared directly, but many trials have compared them with some common treatments (e.g., placebo). It may produce more precise treatment effect estimates than separate pairwise MAs and provide a coherent treatment ranking for decision making [<xref rid="pone.0268754.ref074" ref-type="bibr">74</xref>–<xref rid="pone.0268754.ref077" ref-type="bibr">77</xref>].</p>
        <p>Various methods have been developed to perform NMA under both the frequentist and Bayesian frameworks [<xref rid="pone.0268754.ref078" ref-type="bibr">78</xref>–<xref rid="pone.0268754.ref087" ref-type="bibr">87</xref>]. To assess the fragility of an NMA, similar iterative procedures for a pairwise MA can be used [<xref rid="pone.0268754.ref042" ref-type="bibr">42</xref>]. We focus on the frequentist method by Rücker [<xref rid="pone.0268754.ref079" ref-type="bibr">79</xref>] to produce the CIs of treatment comparisons in the NMA. Although in theory any method can be used to derive the FI, the Bayesian methods could be very time-consuming even for analyzing a single NMA, so it may not be practical to iteratively apply them to many NMAs with modified event status.</p>
        <p>Specifically, unlike the case of a pairwise MA that involves a single treatment comparison, the NMA contains multiple comparisons, each yielding a separate effect size estimate. Let <italic toggle="yes">K</italic> be the number of treatments in the NMA; a total of <italic toggle="yes">K</italic>(<italic toggle="yes">K</italic> − 1)/2 comparisons are estimated. Therefore, the FI is not defined for the whole NMA as in individual studies or pairwise MAs; it is defined for each treatment comparison. Consequently, for a specific pair of treatments, say A and B, we consider event status modifications based on the significance of their comparison B vs. A. Modifying any event status, even for those not in groups A and B, may change the results of all treatment comparisons; thus, in theory, the event status modifications are possible for each study’s each treatment group. However, this would dramatically increase the computation time. Also, it is intuitive to modify event status directly in groups A and B, and such modifications are expected to have a larger impact on the estimated effect size of B vs. A and can alter the significance or non-significance faster. Therefore, during each iteration for deriving the FI for B vs. A, this article only considers event status modifications in these two groups. For example, if the effect size of B vs. A is significantly larger than the null value in the original NMA, then in each iteration, we consider decreasing event counts in group B or increasing those in group A in certain studies until the significance is altered.</p>
        <p>Similar to assessing the fragility of an individual study and a pairwise MA, the FI of an NMA is defined as NA if the significance or non-significance cannot be altered. Of note, as mentioned above, the calculation of the NMA’s FI for comparison B vs. A is based only on modifying event status in groups A and B. It is possible that the change of significance cannot be achieved by any event status modification in groups A and B, but it could be achieved by modifications in other groups. Therefore, users should interpret an FI value of NA in the contexts of the event status modifications in the relevant two groups A and B only.</p>
        <p>The process of deriving the FI can also be visualized for each treatment comparison using a similar approach for a pairwise MA. The relative measure FQ can be calculated as the FI divided by the sample size, but it may have two versions in the NMA. It seems straightforward to use the total sample size <italic toggle="yes">n</italic><sub>NMA</sub> across all studies and all treatment groups in the whole NMA as the denominator for calculating the FQ. However, the FQ derived in this way has an upper bound <inline-formula id="pone.0268754.e025"><alternatives><graphic xlink:href="pone.0268754.e025.jpg" id="pone.0268754.e025g" position="anchor"/><mml:math id="M25" display="inline" overflow="scroll"><mml:mrow><mml:mfrac><mml:msub><mml:mi>n</mml:mi><mml:mtext>AB</mml:mtext></mml:msub><mml:msub><mml:mi>n</mml:mi><mml:mtext>NMA</mml:mtext></mml:msub></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, where <italic toggle="yes">n</italic><sub>AB</sub> denotes the sample size in groups A and B across all studies, because the algorithm only modifies event status in the associated two treatments for a specific comparison. This upper bound differs for different pairs of treatments, implying a methodological limitation. Alternatively, for the comparison B vs. A, we may calculate the FQ as the FI divided by <italic toggle="yes">n</italic><sub>AB</sub>, so that this FQ still ranges within 0%–100% and could be fairly compared across treatment pairs.</p>
      </sec>
    </sec>
    <sec id="sec007">
      <title>Using the R package “fragility”</title>
      <p>The source file of the R package “fragility” and its manual are available on the Comprehensive R Archive Network (CRAN) at <ext-link xlink:href="https://cran.r-project.org/package=fragility" ext-link-type="uri">https://cran.r-project.org/package=fragility</ext-link>. Users can directly install the package by typing <monospace>install.packages(“fragility”)</monospace> in R. Once the package is installed, users can begin to use the package by loading it:</p>
      <p>
        <monospace>&gt; library(“fragility”)</monospace>
      </p>
      <p>The package imports functions from “metafor” [<xref rid="pone.0268754.ref088" ref-type="bibr">88</xref>] for performing pairwise MAs and “netmeta” [<xref rid="pone.0268754.ref089" ref-type="bibr">89</xref>] for performing NMAs. We first introduce example datasets included in “fragility” to demonstrate the data structures, and then provide details about the functions for assessing and visualizing fragility.</p>
      <sec id="sec008">
        <title>Example datasets</title>
        <p>The package “fragility” provides four datasets, <monospace>dat.ad</monospace>, <monospace>dat.ns</monospace>, <monospace>dat.copd</monospace>, and <monospace>dat.sc</monospace>. They all consist of multiple clinical studies, and are used for different illustrative purposes.</p>
        <p>The dataset <monospace>dat.ad</monospace> contains 347 randomized controlled trials of antidepressant drugs with a binary acceptability (dropout due to any cause) outcome; these trials were systematically collected by Cipriani et al. [<xref rid="pone.0268754.ref090" ref-type="bibr">90</xref>]. This dataset is used to illustrate the usage of functions for assessing and visualizing the fragility of individual studies. We display the first six trials as follows:</p>
        <p>
          <monospace>&gt; data(“dat.ad”)</monospace>
        </p>
        <p>
          <monospace>&gt; head(dat.ad)</monospace>
        </p>
        <p>
          <monospace> e0 n0 e1  n1</monospace>
        </p>
        <p>
          <monospace>1 7 107 12 105</monospace>
        </p>
        <p>
          <monospace>2 17 118 18 120</monospace>
        </p>
        <p>
          <monospace>3 30 252 49 263</monospace>
        </p>
        <p>
          <monospace>4 25 109 19 109</monospace>
        </p>
        <p>
          <monospace>5 35 167 35 168</monospace>
        </p>
        <p>
          <monospace>6 17 137 26 140</monospace>
        </p>
        <p>Each row presents the data of a trial. The columns <monospace>e0</monospace>, <monospace>n0</monospace>, <monospace>e1</monospace>, and <monospace>n1</monospace> present event counts and sample sizes in group 0 and those in group 1, respectively. Of note, we use this dataset as an example of (multiple) individual studies, although Cipriani et al. [<xref rid="pone.0268754.ref090" ref-type="bibr">90</xref>] originally performed an NMA based on this dataset. The two treatments (antidepressant drugs or placebo) compared in each study may be different. This dataset does not include multi-arm trials originally collected by Cipriani et al. [<xref rid="pone.0268754.ref090" ref-type="bibr">90</xref>].</p>
        <p>The dataset <monospace>dat.ns</monospace> contains a collection of 564 pairwise MAs on nutrition support retrieved from Feinberg et al. [<xref rid="pone.0268754.ref091" ref-type="bibr">91</xref>]. Each MA may compare different treatments and have different binary outcomes. This dataset is used to illustrate the usage of functions for assessing and visualizing the fragility of pairwise MAs. Its first six rows are:</p>
        <p>
          <monospace>&gt; data(“dat.ns”)</monospace>
        </p>
        <p>
          <monospace>&gt; head(dat.ns)</monospace>
        </p>
        <p>
          <monospace>ma.id e0 n0 e1 n1</monospace>
        </p>
        <p>
          <monospace>1   1 3 24 4 20</monospace>
        </p>
        <p>
          <monospace>2   1 2 10 1 9</monospace>
        </p>
        <p>
          <monospace>3   1 2 28 0 22</monospace>
        </p>
        <p>
          <monospace>4   1 31 265 46 260</monospace>
        </p>
        <p>
          <monospace>5   1 6 32 4 28</monospace>
        </p>
        <p>
          <monospace>6   1 4 35 5 39</monospace>
        </p>
        <p>Each row represents a specific study in a specific MA. The first column <monospace>ma.id</monospace> indexes the MAs, ranging from 1 to 564; the output above is from the first six studies in the first MA. The remaining four columns <monospace>e0</monospace>, <monospace>n0</monospace>, <monospace>e1</monospace>, and <monospace>n1</monospace> have the same interpretations as in the dataset <monospace>dat.ad</monospace> of individual studies. Some MAs may have overlapping studies, and some may be divided into several subgroups.</p>
        <p>Finally, the datasets <monospace>dat.copd</monospace> and <monospace>dat.sc</monospace> are used to illustrate the usage of functions for assessing and visualizing the fragility of NMAs. The dataset <monospace>dat.copd</monospace> is extracted from Woods et al. [<xref rid="pone.0268754.ref092" ref-type="bibr">92</xref>]; it gives a simple NMA with 3 studies comparing 4 treatments for chronic obstructive pulmonary disease. As this dataset is small, the assessment of its fragility does not take much time, and thus it serves as a toy example. The full dataset is:</p>
        <p>
          <monospace>&gt; data(“dat.copd”)</monospace>
        </p>
        <p>
          <monospace>&gt; dat.copd</monospace>
        </p>
        <p>
          <monospace> sid tid e n</monospace>
        </p>
        <p>
          <monospace>1  1  3 1 229</monospace>
        </p>
        <p>
          <monospace>2  1  1 1 227</monospace>
        </p>
        <p>
          <monospace>3  2  2 4 374</monospace>
        </p>
        <p>
          <monospace>4  2  3 3 372</monospace>
        </p>
        <p>
          <monospace>5  2  4 2 358</monospace>
        </p>
        <p>
          <monospace>6  2  1 7 361</monospace>
        </p>
        <p>
          <monospace>7  3  3 1 554</monospace>
        </p>
        <p>
          <monospace>8  3  1 2 270</monospace>
        </p>
        <p>The data structure of the NMA is different from those of individual studies and pairwise MAs introduced above. Specifically, each row represents the data from a specific treatment group in a specific study. The columns <monospace>sid</monospace> and <monospace>tid</monospace> give the indexes of studies and treatments, respectively, and <monospace>e</monospace> and <monospace>n</monospace> give the corresponding event counts and sample sizes. The four treatments in this dataset are indexed as 1) placebo; 2) fluticasone; 3) salmeterol; and 4) salmeterol fluticasone combination. As shown in the output above, studies 1 and 3 are two-armed, while study 2 is four-armed. In addition to this simple dataset, the package “fragility” also includes a larger NMA dataset of smoking cessation, <monospace>dat.sc</monospace>. Its first six rows are displayed as follows:</p>
        <p>
          <monospace>&gt; data(“dat.sc”)</monospace>
        </p>
        <p>
          <monospace>&gt; head(dat.sc)</monospace>
        </p>
        <p>
          <monospace> sid tid e  n</monospace>
        </p>
        <p>
          <monospace>1  1  1 9 140</monospace>
        </p>
        <p>
          <monospace>2  1  3 23 140</monospace>
        </p>
        <p>
          <monospace>3  1  4 10 138</monospace>
        </p>
        <p>
          <monospace>4  2  2 11 78</monospace>
        </p>
        <p>
          <monospace>5  2  3 12 85</monospace>
        </p>
        <p>
          <monospace>6  2  4 29 170</monospace>
        </p>
        <p>This dataset is retrieved from Lu and Ades [<xref rid="pone.0268754.ref093" ref-type="bibr">93</xref>] that used formal methods to perform the NMA, while it was originally reported in Hasselblad [<xref rid="pone.0268754.ref094" ref-type="bibr">94</xref>]. It has the same data structure as in <monospace>dat.copd</monospace>. The NMA contains 24 studies comparing 4 treatments: 1) no contact; 2) self-help; 3) individual counseling; and 4) group counseling. The binary outcome is successful smoking cessation. The first two studies are three-armed as shown in the output above, and the remaining 22 studies are two-armed.</p>
      </sec>
      <sec id="sec009">
        <title>Functions for assessing the fragility of individual studies</title>
        <p>Three functions, <monospace>frag.study()</monospace>, <monospace>frag.study.alpha()</monospace>, and <monospace>frag.studies()</monospace>, are available in the package “fragility” to assess the fragility of individual studies. The function <monospace>frag.study()</monospace> assesses the fragility of a single study; <monospace>frag.study.alpha()</monospace> assesses an individual study’s fragility at different significance levels; and <monospace>frag.studies()</monospace> assesses the fragility of multiple individual studies.</p>
        <p>The arguments of the function <monospace>frag.study()</monospace> include:</p>
        <p>
          <monospace>frag.study(e0, n0, e1, n1, data, all = FALSE, methods,</monospace>
        </p>
        <p>
          <monospace> modify0 = “both”, modify1 = “both”, alpha = 0.05,</monospace>
        </p>
        <p>
          <monospace> alternative = “two.sided”, OR = 1, RR = 1, RD = 0, allcase = TRUE)</monospace>
        </p>
        <p>where <monospace>e0</monospace>, <monospace>n0</monospace>, <monospace>e1</monospace>, and <monospace>n1</monospace> specify event counts and sample sizes in groups 0 and 1. The argument <monospace>data</monospace> is optional for specifying the dataset; if specified, the previous four arguments should be the corresponding column names in <monospace>data</monospace>. The logical argument <monospace>all</monospace> indicates whether all possible event status modifications will be considered for assessing the study’s fragility. If users only need the numerical value of FI or FQ and the corresponding event status modifications that alter the significance or non-significance, then <monospace>all = FALSE</monospace> (the default) is sufficient to produce these results via an iterative algorithm (i.e., starting from modifying one event’s status, until the significance or non-significance is altered). The output of this function is of class <monospace>“frag.study”</monospace>. If <monospace>all = TRUE</monospace>, this function generates <italic toggle="yes">p</italic> values corresponding to all possible event status modifications, so that users are able to visualize the extent of significance based on these <italic toggle="yes">p</italic> values. In this case, the output is of both classes <monospace>“frag.study”</monospace> and <monospace>“frag.study.all”</monospace>. The visualization can be easily performed using the function <monospace>plot()</monospace> via the S3 method for class <monospace>“frag.study.all”</monospace> (detailed later). If the study has large sample sizes (<monospace>n0</monospace> and <monospace>n1</monospace>) in both treatment groups and there may be many possible event status modifications, <monospace>all</monospace> is recommended to be set to <monospace>FALSE</monospace> because R may run out of memory; for example, a study with 1000 samples in each group may lead to up to one million possible event status modifications. Appendix A in <xref rid="pone.0268754.s001" ref-type="supplementary-material">S1 File</xref> includes more details of additional arguments.</p>
        <p>The function <monospace>frag.study.alpha()</monospace> efficiently assesses an individual study’s fragility at different significance levels, and produces the average FI and FQ across these levels. Its arguments include:</p>
        <p>
          <monospace>frag.study.alpha(e0, n0, e1, n1, data, methods,</monospace>
        </p>
        <p>
          <monospace> modify0 = “both”, modify1 = “both”,</monospace>
        </p>
        <p>
          <monospace> alpha.from = 0.005, alpha.to = 0.05, alpha.breaks = 100,</monospace>
        </p>
        <p>
          <monospace> alternative = “two.sided”, OR = 1, RR = 1, RD = 0)</monospace>
        </p>
        <p>All arguments except the second line are the same as their counterparts in <monospace>frag.study()</monospace>; the second line specifies the range of possible significance levels, which may be particularly useful if clinicians have different opinions about defining statistical significance [<xref rid="pone.0268754.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0268754.ref057" ref-type="bibr">57</xref>]. Specifically, <monospace>alpha.from</monospace>, <monospace>alpha.to</monospace>, and <monospace>alpha.breaks</monospace> specify the smallest and largest values of the significance levels to be considered, and the number of levels, respectively. The candidate significance levels are equally spaced within the range. This function produces an object of classes <monospace>“frag.alpha”</monospace> and <monospace>“frag.study.alpha”</monospace>. The FIs or FQs assessed at different significance levels can be visualized as a step-like function using <monospace>plot()</monospace> via the S3 method for class <monospace>“frag.alpha”</monospace> (detailed later).</p>
        <p>The function <monospace>frag.studies()</monospace> permits users to input multiple studies for assessing their fragility. It is particularly useful if users would like to conduct an overall assessment among a collection of studies (e.g., trials belonging to some similar specialties) and investigate the distribution of their fragility measures [<xref rid="pone.0268754.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0268754.ref032" ref-type="bibr">32</xref>]. Its arguments are similar to those of <monospace>frag.study()</monospace>; they are displayed as follows:</p>
        <p>
          <monospace>frag.studies(e0, n0, e1, n1, data, methods,</monospace>
        </p>
        <p>
          <monospace> modify0 = “both”, modify1 = “both”, alpha = 0.05,</monospace>
        </p>
        <p>
          <monospace> alternative = “two.sided”, OR = 1, RR = 1, RD = 0)</monospace>
        </p>
        <p>All arguments have the same usage as in <monospace>frag.study()</monospace>, except that <monospace>e0</monospace>, <monospace>n0</monospace>, <monospace>e1</monospace>, and <monospace>n1</monospace> specify vectors of event counts and sample sizes from the multiple studies, instead of single numerical values. The function output is of classes <monospace>“frag.multi”</monospace> and <monospace>“frag.studies”</monospace>; users can apply <monospace>plot()</monospace> to the output for generating a bar plot or histogram to visualize the overall distribution of the multiple studies’ FIs or FQs via the S3 method for class <monospace>“frag.multi”</monospace>.</p>
      </sec>
      <sec id="sec010">
        <title>Functions for assessing the fragility of pairwise meta-analyses</title>
        <p>Similar to the three functions above for assessing individual studies’ fragility, “fragility” offers <monospace>frag.ma()</monospace>, <monospace>frag.ma.alpha()</monospace>, and <monospace>frag.mas()</monospace> for assessing the fragility of pairwise MAs. The package imports the function <monospace>rma.uni()</monospace> from “metafor” [<xref rid="pone.0268754.ref088" ref-type="bibr">88</xref>] to perform pairwise MAs and obtain the effect size estimates (including CIs), which further determine the FIs or FQs. Users may refer to [<xref rid="pone.0268754.ref095" ref-type="bibr">95</xref>] for many additional arguments that can be used to customize the MAs.</p>
        <p>The major function <monospace>frag.ma()</monospace> for assessing a pairwise MA’s fragility has the following arguments:</p>
        <p>
          <monospace>frag.ma(e0, n0, e1, n1, data, measure = “OR”, alpha = 0.05,</monospace>
        </p>
        <p>
          <monospace> mod.dir = “both”, OR = 1, RR = 1, RD = 0, method = “DL”, test = “z”,</monospace>
        </p>
        <p>
          <monospace> …)</monospace>
        </p>
        <p>where <monospace>e0</monospace>, <monospace>n0</monospace>, <monospace>e1</monospace>, and <monospace>n1</monospace> specify the event counts and sample sizes of each study in the MA, and the optional argument <monospace>data</monospace> can specify the MA dataset. One of the three effect measures, OR, RR, and RD, may be specified for <monospace>measure</monospace>, and the arguments <monospace>OR</monospace>, <monospace>RR</monospace>, and <monospace>RD</monospace> give the corresponding null values. The argument <monospace>alpha</monospace> specifies the significance level; it corresponds to the confidence level (1 − <monospace>alpha</monospace>) × 100% of CIs. The argument <monospace>mod.dir</monospace> indicates the direction of the CI change due to event status modifications when the original MA’s CI covers the null value (i.e., the case of non-significance altered to significance). It is not used if the original MA has a significant estimate. Users may specify <monospace>“left”</monospace> (moving the CI to the left side of the null value), <monospace>“right”</monospace> (moving the CI to the right side), <monospace>“one”</monospace> (based on the direction of the original point estimate of the overall effect size), or <monospace>“both”</monospace> (both directions) for <monospace>mod.dir</monospace>. The default option <monospace>“both”</monospace> is expected to find the minimal event status modifications for altering the non-significance, but it may require more computation time than the other three options. Appendix A in <xref rid="pone.0268754.s001" ref-type="supplementary-material">S1 File</xref> includes more details of additional arguments. The function <monospace>frag.ma()</monospace> returns an object of class <monospace>“frag.ma”</monospace>; users can apply <monospace>plot()</monospace> to the output via the S3 method for this class to visualize the iterative process of event status modifications for deriving the fragility measure of the MA.</p>
        <p>The function <monospace>frag.ma.alpha()</monospace> assesses the fragility of an MA at multiple significance levels. Its relationship with <monospace>frag.ma()</monospace> is similar to that between <monospace>frag.study()</monospace> and <monospace>frag.study.alpha()</monospace>. Its arguments are the same as <monospace>frag.ma()</monospace>, except that users can specify a range of significance levels using the arguments <monospace>alpha.from</monospace>, <monospace>alpha.to</monospace>, and <monospace>alpha.breaks</monospace>. The function returns an object of classes <monospace>“frag.alpha”</monospace> and <monospace>“frag.ma.alpha”</monospace>; like the output of <monospace>frag.study.alpha()</monospace>, it can be visualized using <monospace>plot()</monospace> via the S3 method for <monospace>“frag.alpha”</monospace>.</p>
        <p>The function <monospace>frag.mas()</monospace> assesses the fragility of multiple MAs; its relationship with <monospace>frag.ma()</monospace> is similar to that between <monospace>frag.study()</monospace> and <monospace>frag.studies()</monospace>. It returns an object of classes <monospace>“frag.mas”</monospace> and <monospace>“frag.multi”</monospace>, and users can visualize the fragility measures among the multiple MAs using <monospace>plot()</monospace> via the S3 method for <monospace>“frag.multi”</monospace>. Its arguments slightly differ from <monospace>frag.ma()</monospace>:</p>
        <p>
          <monospace>frag.mas(e0, n0, e1, n1, ma.id, data, measure = “OR”, alpha = 0.05,</monospace>
        </p>
        <p>
          <monospace> mod.dir = “both”, OR = 1, RR = 1, RD = 0, method = “DL”, test = “z”,</monospace>
        </p>
        <p>
          <monospace> …)</monospace>
        </p>
        <p>The major difference is about the arguments <monospace>e0</monospace>, <monospace>n0</monospace>, <monospace>e1</monospace>, <monospace>n1</monospace>, and <monospace>ma.id</monospace> for inputting data. Users may refer to the structure of the example dataset <monospace>dat.ns</monospace> introduced previously. Specifically, <monospace>ma.id</monospace> is a vector for indexing the multiple MAs, and <monospace>e0</monospace>, <monospace>n0</monospace>, <monospace>e1</monospace>, and <monospace>n1</monospace> specify the event counts and sample sizes of each study in each MA. Like <monospace>frag.ma()</monospace>, users may specify additional arguments from “metafor” for <monospace>frag.mas()</monospace>, as well as <monospace>frag.ma.alpha()</monospace>, to customize the implementation of MAs.</p>
      </sec>
      <sec id="sec011">
        <title>Functions for assessing the fragility of network meta-analyses</title>
        <p>In addition, “fragility” provides two functions <monospace>frag.nma()</monospace> and <monospace>frag.nma.alpha()</monospace> for assessing the fragility of NMAs. These are designed for the similar purposes to <monospace>frag.ma()</monospace> and <monospace>frag.ma.alpha()</monospace>; that is, <monospace>frag.nma()</monospace> deals with an NMA at a specific significance level, while <monospace>frag.nma.alpha()</monospace> assesses the fragility at multiple significance levels. However, these two functions’ arguments may involve more specifications than their counterparts for pairwise MAs, owning to the more complicated structure of NMAs. The functions <monospace>pairwise()</monospace> and <monospace>netmeta()</monospace> imported from “netmeta” [<xref rid="pone.0268754.ref089" ref-type="bibr">89</xref>] are used to implement NMAs. Of note, “fragility” does not provide a function for simultaneously assessing the fragility of multiple NMAs like <monospace>frag.studies()</monospace> and <monospace>frag.mas()</monospace>, because a single NMA can be viewed as a comprehensive collection of many pairwise MAs for comparisons of all available treatments. Usually, only a few NMAs are available on certain common topics. In such cases, users may apply <monospace>frag.nma()</monospace> to each NMA separately for assessing their overall fragility.</p>
        <p>The arguments of <monospace>frag.nma()</monospace> are as follows:</p>
        <p>
          <monospace>frag.nma(sid, tid, e, n, data, measure = “OR”, random = TRUE,</monospace>
        </p>
        <p>
          <monospace> alpha = 0.05, mod.dir = “both”, tid1.f, tid2.f,</monospace>
        </p>
        <p>
          <monospace> OR = 1, RR = 1, RD = 0,</monospace>
        </p>
        <p>
          <monospace> incr, allincr, addincr, allstudies, …)</monospace>
        </p>
        <p>where <monospace>sid</monospace>, <monospace>tid</monospace>, <monospace>e</monospace>, and <monospace>n</monospace> specify study IDs, treatment IDs, their corresponding event counts and sample sizes. One may also specify the dataset for the optional argument <monospace>data</monospace>. We recommend using the natural numbers (starting from 1) to index the studies and treatments; otherwise, the functions imported from “netmeta” may give warnings that treatments are re-sorted according to a certain order. Moreover, the arguments <monospace>measure</monospace>, <monospace>alpha</monospace>, <monospace>mod.dir</monospace>, <monospace>OR</monospace>, <monospace>RR</monospace>, and <monospace>RD</monospace> have the same usage as in <monospace>frag.ma()</monospace> for pairwise MAs. The logical argument <monospace>random</monospace> indicates whether the NMA is performed under the fixed-effects setting (<monospace>FALSE</monospace>) or random-effects setting (<monospace>TRUE</monospace>, the default). The two arguments <monospace>tid1.f</monospace> and <monospace>tid2.f</monospace> specify the treatment comparison(s) of interest for the assessment of fragility; the default is that the fragility is assessed for all treatment comparisons. For example, if <monospace>tid1.f = 1</monospace> and <monospace>tid2.f = 2</monospace>, then the function only assesses the fragility of 1 vs. 2; if <monospace>tid1.f = c(2, 3)</monospace> and <monospace>tid2.f = c(1, 2)</monospace>, then it assesses the fragility of 2 vs. 1 and 3 vs. 2. The four arguments <monospace>incr</monospace>, <monospace>allincr</monospace>, <monospace>addincr</monospace>, and <monospace>allstudies</monospace> are used for handling zero event counts; they are passed to <monospace>pairwise()</monospace> in “netmeta.” Users may additionally specify arguments from <monospace>netmeta()</monospace> to customize the implementation of the NMAs; see its manual for more details [<xref rid="pone.0268754.ref089" ref-type="bibr">89</xref>]. The output of <monospace>frag.nma()</monospace> is of class <monospace>“frag.nma”</monospace>. It can be visualized using <monospace>plot()</monospace> via the S3 method for class <monospace>“frag.nma”</monospace> to show the iterative process of event status modifications for deriving the fragility measure of a specific treatment comparison.</p>
        <p>The function <monospace>frag.nma.alpha()</monospace> assesses the fragility of an NMA at multiple significance levels, similar to <monospace>frag.study.alpha()</monospace> and <monospace>frag.ma.alpha()</monospace>. Most arguments are the same as <monospace>frag.nma()</monospace>, except the arguments <monospace>alpha.from</monospace>, <monospace>alpha.to</monospace>, and <monospace>alpha.breaks</monospace> for specifying the range of candidate significance levels. Because it may be time-consuming to perform many NMAs for deriving the fragility measures, we recommend users to specify a relatively small number of significance levels to <monospace>alpha.breaks</monospace>, especially for large NMAs. The output of <monospace>frag.nma.alpha()</monospace> is of classes <monospace>“frag.alpha”</monospace> and <monospace>“frag.nma.alpha”</monospace>; again, users can use <monospace>plot()</monospace> via the S3 method for <monospace>“frag.alpha”</monospace> to visualize the relationship between fragility measures and significance levels for a specific treatment comparison.</p>
      </sec>
      <sec id="sec012">
        <title>Summary of data types, functions, and output classes</title>
        <p><xref rid="pone.0268754.t002" ref-type="table">Table 2</xref> summarizes the functions and their output classes for each data type. The object produced by each function is a list containing different elements about the input data, relevant estimates, and their fragility measures. It is automatically printed by <monospace>print()</monospace> via the S3 method for its corresponding class(es). The printed messages are informative summaries of the data, analyses, and assessments of the fragility. If users would like to obtain more comprehensive information, they can extract elements from the output list; the elements’ names in the list can be found by applying the function <monospace>names()</monospace>.</p>
        <table-wrap position="float" id="pone.0268754.t002">
          <object-id pub-id-type="doi">10.1371/journal.pone.0268754.t002</object-id>
          <label>Table 2</label>
          <caption>
            <title>Summary of major functions (followed by parentheses) and their output classes (within quotation marks) in the package “fragility” for assessing the fragility of different data types.</title>
          </caption>
          <alternatives>
            <graphic xlink:href="pone.0268754.t002" id="pone.0268754.t002g" position="float"/>
            <table frame="box" rules="all" border="0">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="2" colspan="1">Data type</th>
                  <th align="center" colspan="3" rowspan="1">Function and output class under each scenario</th>
                </tr>
                <tr>
                  <th align="left" rowspan="1" colspan="1">Single significance level and single dataset</th>
                  <th align="left" rowspan="1" colspan="1">Multiple significance levels and single dataset</th>
                  <th align="left" rowspan="1" colspan="1">Single significance level and multiple datasets</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="3" colspan="1">Individual study</td>
                  <td align="left" rowspan="1" colspan="1"><monospace>frag.study()</monospace>;</td>
                  <td align="left" rowspan="1" colspan="1"><monospace>frag.study.alpha()</monospace>;</td>
                  <td align="left" rowspan="1" colspan="1"><monospace>frag.studies()</monospace>;</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"><monospace>“frag.study”</monospace> and</td>
                  <td align="left" rowspan="1" colspan="1"><monospace>“frag.alpha”</monospace> and</td>
                  <td align="left" rowspan="1" colspan="1"><monospace>“frag.multi”</monospace> and</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"><monospace>“frag.study.all”</monospace> (if <monospace>all = TRUE</monospace>)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>“frag.study.alpha”</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>“frag.studies”</monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="3" colspan="1">Pairwise meta-analysis</td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>frag.ma()</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>frag.ma.alpha()</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>frag.ma()</monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>“frag.ma”</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1"><monospace>“frag.alpha”</monospace> and</td>
                  <td align="left" rowspan="1" colspan="1"><monospace>“frag.multi”</monospace> and</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>“frag.ma.alpha”</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>“frag.mas”</monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="3" colspan="1">Network meta-analysis</td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>frag.nma()</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>frag.nma.alpha()</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1">Not applicable</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>“frag.nma”</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1"><monospace>“frag.alpha”</monospace> and</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>“frag.nma.alpha”</monospace>
                  </td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
          </alternatives>
        </table-wrap>
      </sec>
      <sec id="sec013">
        <title>Functions for visualizing the fragility</title>
        <p>The package “fragility” offers functions for visualizing the fragility of individual studies, pairwise and NMAs; they are called by <monospace>plot()</monospace> via the S3 method for certain classes.</p>
        <p>To visualize the fragility of an individual study, users need to specify <monospace>all = TRUE</monospace> in <monospace>frag.study()</monospace> so that all possible event status modifications are considered. The produced object belongs to the class <monospace>“frag.study.all”</monospace>; for this object, the arguments of the visualization function are as follows:</p>
        <p>
          <monospace>plot(x, method, modify0, modify1, trun, xlab, ylab, xlim, ylim,</monospace>
        </p>
        <p>
          <monospace> cex.pts, cex.legend.pval, cex.legend.title,</monospace>
        </p>
        <p>
          <monospace> col.ori, col.ori.hl, col.f.hl, col.sig, lty.ori, lwd.ori,</monospace>
        </p>
        <p>
          <monospace> pch, pch.ori, pch.ori.hl, pch.f, pch.f.hl, pch.trun,</monospace>
        </p>
        <p>
          <monospace> adjust.legend, adjust.seg, legend.pvals, …)</monospace>
        </p>
        <p>where <monospace>x</monospace> is the output of <monospace>frag.study()</monospace> with <monospace>all = TRUE</monospace>. Users may only specify a single statistical method used to calculate the <italic toggle="yes">p</italic> value for the argument <monospace>method</monospace> when visualizing the fragility at one time; it must be an element of <monospace>x$methods</monospace>, i.e., the argument <monospace>methods</monospace> specified for <monospace>frag.study()</monospace>. If <monospace>method</monospace> is not specified, then the first method in <monospace>x$methods</monospace> is used. The arguments <monospace>modify0</monospace> and <monospace>modify1</monospace> specify logical values indicating whether event status is modified in groups 0 and 1, respectively, for the visualization. When both <monospace>modify0</monospace> and <monospace>modify1</monospace> are <monospace>TRUE</monospace>, the generated plot presents <italic toggle="yes">p</italic> values (with different colors representing their magnitudes) based on all possible event status modifications; the modifications in groups 0 and 1 are presented on the x and y axes, respectively. A legend is displayed to relate different colors to <italic toggle="yes">p</italic> value magnitudes. When only one of <monospace>modify0</monospace> and <monospace>modify1</monospace> is <monospace>TRUE</monospace>, a scatter plot is generated. It presents <italic toggle="yes">p</italic> values (on a base-10 logarithmic scale) on the y axis against modifications in group 0 (if <monospace>modify0 = TRUE</monospace>) or group 1 (if <monospace>modify1 = TRUE</monospace>) on the x axis. The default of <monospace>modify0</monospace> and <monospace>modify1</monospace> is <monospace>TRUE</monospace> if the range of modifications in the corresponding treatment group, which is stored in the object <monospace>x</monospace> (i.e., <monospace>x$f0.range</monospace> or <monospace>x$f1.range</monospace>), is not 0; otherwise, the default is <monospace>FALSE</monospace>. Appendix B in <xref rid="pone.0268754.s001" ref-type="supplementary-material">S1 File</xref> includes more details of additional arguments.</p>
        <p>To visualize the fragility of a pairwise MA, users may apply <monospace>plot()</monospace> via the S3 method for class <monospace>“frag.ma”</monospace> to the object <monospace>x</monospace> produced by <monospace>frag.ma()</monospace> as follows:</p>
        <p>
          <monospace>plot(x, xlab, ylab, xlim, ylim, ybreaks = NULL, study.marker = TRUE,</monospace>
        </p>
        <p>
          <monospace> cex.marker, offset.marker, col.line, lwd,</monospace>
        </p>
        <p>
          <monospace> legend, x.legend, y.legend, cex.legend, …)</monospace>
        </p>
        <p>This generates a plot showing the iterative process of event status modifications, where the x axis presents the iterations and the y axis gives the group-specific total event counts. As the total event counts of the two treatment groups may differ greatly, users may specify a range (a vector of two numerical values) for the argument <monospace>ybreaks</monospace> to break the y axis for better visualization. The default of this argument is <monospace>NULL</monospace> (i.e., not breaking the y axis). The specified range should be between the total event counts of the two groups. The axis break is implemented by importing <monospace>axis.break()</monospace> from “plotrix” [<xref rid="pone.0268754.ref096" ref-type="bibr">96</xref>]. The argument <monospace>study.marker</monospace> specifies a logical value indicating whether study labels involved in modifications are presented. When it is <monospace>TRUE</monospace> (the default), an asterisk represents that the corresponding study with an event status modification remains the same as in the previous iteration. The study labels can be adjusted by the arguments <monospace>cex.marker</monospace> (text size) and <monospace>offset.marker</monospace> (distance from lines). The remaining arguments are mainly used to specify certain graphical parameters; again, additional arguments from <monospace>plot.default()</monospace> can be specified for customizing the plot. A legend is automatically presented to identify the two treatment groups; it can be modified by the last three arguments, which are passed to <monospace>legend()</monospace> in “graphics.” The default is to place the legend on the right side with <monospace>x.legend = “right”</monospace> and <monospace>y.legend = NULL</monospace>; in cases that the default legend box overlaps with the lines of the event status modification process, users may specify other coordinates or keywords to change the legend location.</p>
        <p>The visualization function for an NMA is similar to the function above for a pairwise MA. Specifically, the arguments of <monospace>plot()</monospace> via the S3 method for class <monospace>“frag.nma”</monospace> include:</p>
        <p>
          <monospace>plot(x, tid1, tid2, xlab, ylab, xlim, ylim, ybreaks = NULL,</monospace>
        </p>
        <p>
          <monospace> study.marker = TRUE, cex.marker, offset.marker, col.line, lwd,</monospace>
        </p>
        <p>
          <monospace> legend, x.legend, y.legend, cex.legend, …)</monospace>
        </p>
        <p>where <monospace>x</monospace> is the output from <monospace>frag.nma()</monospace>. Most arguments are the same with those for class <monospace>“frag.ma”</monospace> of a pairwise MA. The major difference is regarding the arguments <monospace>tid1</monospace> and <monospace>tid2</monospace>, which specify the two treatments of the comparison of interest (i.e., <monospace>tid1</monospace> vs. <monospace>tid2</monospace>). Only one comparison can be specified by <monospace>tid1</monospace> and <monospace>tid2</monospace> at one time for visualization. If these two arguments are not specified, the first comparison stored in <monospace>x$tid.f</monospace> is used.</p>
        <p>In addition to the three functions above for a single dataset, “fragility” provides two functions for visualizing the relationship between fragility measures and significance levels and for generating overall distributions of fragility measures among multiple datasets. Specifically, for an object <monospace>x</monospace> of class <monospace>“frag.alpha”</monospace> produced by <monospace>frag.study.alpha()</monospace>, <monospace>frag.ma.alpha()</monospace>, or <monospace>frag.nma.alpha()</monospace>, one may visualize it using <monospace>plot()</monospace> via the S3 method for this class with the following arguments:</p>
        <p>
          <monospace>plot(x, method, fragility = “FI”, percentage = TRUE, xlab, ylab,</monospace>
        </p>
        <p>
          <monospace> xlim, ylim, cex.pts, col.line, col.pval, col.sig, lty.pval,</monospace>
        </p>
        <p>
          <monospace> lwd, lwd.pval, pch, pch.inf, tid1, tid2, FQ.nma = FALSE, …)</monospace>
        </p>
        <p>In the generated plot, the x axis presents the significance levels, and the y axis presents the corresponding fragility measures. Appendix B in <xref rid="pone.0268754.s001" ref-type="supplementary-material">S1 File</xref> gives details of these arguments.</p>
        <p>For an object of class <monospace>“frag.multi”</monospace>, the visualization function is:</p>
        <p>
          <monospace>plot(x, method, dir = “both”, fragility = “FI”, percentage = TRUE,</monospace>
        </p>
        <p>
          <monospace> max.f = NULL, bar, names.arg, space = 0, breaks, freq,</monospace>
        </p>
        <p>
          <monospace> reverse = FALSE, xlab, ylab, main = NULL, cex.marker, col.border,</monospace>
        </p>
        <p>
          <monospace> col.sig, trun.marker = TRUE, …)</monospace>
        </p>
        <p>where <monospace>x</monospace> is the output from <monospace>frag.studies()</monospace> and <monospace>frag.mas()</monospace>. This function generates a bar plot or histogram (depending on the specified arguments) to show the overall distribution of fragility measures among the multiple datasets of individual studies or pairwise MAs. Appendix B in <xref rid="pone.0268754.s001" ref-type="supplementary-material">S1 File</xref> gives details of these arguments and the generated plot.</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="results" id="sec014">
    <title>Results</title>
    <p>This section presents worked examples to illustrate the usage of the various functions in “fragility.” These examples are based on the datasets introduced earlier; users may first load them before implementing the following code. We focus on illustrating the usage of several major arguments for each function with detailed interpretations; users may refer to the manual of “fragility” for more examples that specify many other arguments for various purposes. The results were obtained using R (version 4.0.2) with “fragility” (version 1.1).</p>
    <sec id="sec015">
      <title>Example of an individual clinical study</title>
      <p>Recall that the dataset <monospace>dat.ad</monospace> consists of 347 trials; each row presents the data of one trial. We first apply the function <monospace>frag.study()</monospace> to assess the fragility of trial 13; the code and output are in <xref rid="pone.0268754.g001" ref-type="fig">Fig 1</xref>. The produced object <monospace>out.trial13</monospace> is of class <monospace>“frag.study”</monospace>, and the informative output is displayed via the print method for this class. The output consists of three parts. The first part gives the information about the original 2×2 table and the ranges of event status modifications in both groups are presented. The second part displays the information about the significance, including the pre-specified significance level, null value(s) (if using the OR, RR, and/or RD), and the <italic toggle="yes">p</italic> value(s) with the associated method(s). The third part contains the major information about the fragility, including the FI and FQ based on each method considered, the direction of significance change, and the corresponding minimal event status modification(s) for altering significance or non-significance.</p>
      <fig position="float" id="pone.0268754.g001">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g001</object-id>
        <label>Fig 1</label>
        <caption>
          <title>Output from the function <monospace>frag.study()</monospace>.</title>
        </caption>
        <graphic xlink:href="pone.0268754.g001" position="float"/>
      </fig>
      <p>In this example, all arguments besides those receiving data input are set to the default, so all five methods, i.e., Fisher’s exact test, the chi-squared test, OR, RR, and RD, are considered. All methods indicate significant results in the original dataset at the level of 0.05, so the directions of their FIs are significance altered to non-significance. All methods except the RD have FIs of 6, while the RD has an FI of 7. The FI may be derived by multiple minimal event status modifications for some methods. As the produced object <monospace>out.trial13</monospace> is a list, users can apply <monospace>names()</monospace> to obtain the names of all list elements and thus retrieve the results of interest; they may refer to the manual of “fragility” for details about each element. For example, the FIs of all five methods can be retrieved as follows:</p>
      <p>
        <monospace>&gt; out.trial13$FI</monospace>
      </p>
      <p>
        <monospace>Fisher chisq   OR   RR   RD</monospace>
      </p>
      <p>
        <monospace>  6    6   6    6    7</monospace>
      </p>
      <p>To visualize the fragility of trial 13, users need to specify <monospace>all = TRUE</monospace> in the <monospace>frag.study()</monospace> function:</p>
      <p>
        <monospace>&gt; out.trial13.all &lt;- frag.study(e0 = e0, n0 = n0, e1 = e1, n1 = n1,</monospace>
      </p>
      <p>
        <monospace>  data = dat.ad[13,], all = TRUE)</monospace>
      </p>
      <p>The produced output is also of class <monospace>“frag.study.all”</monospace>; it can be visualized as follows:</p>
      <p>
        <monospace>&gt; plot(out.trial13.all, method = “Fisher”,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 6, significance altered to non-significance”,</monospace>
      </p>
      <p>
        <monospace>  cex.pts = 0.5, font.main = 1, cex.main = 0.9)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trial13.all, method = “Fisher”, modify1 = FALSE,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 6, significance altered to non-significance”,</monospace>
      </p>
      <p>
        <monospace>  cex.pts = 0.8, font.main = 1, cex.main = 0.9)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trial13.all, method = “Fisher”, modify0 = FALSE,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 7, significance altered to non-significance”,</monospace>
      </p>
      <p>
        <monospace>  cex.pts = 0.8, font.main = 1, cex.main = 0.9)</monospace>
      </p>
      <p>Here, Fisher’s exact test is used to calculate <italic toggle="yes">p</italic> values. <xref rid="pone.0268754.g002" ref-type="fig">Fig 2a–2c</xref> present the generated plots.</p>
      <fig position="float" id="pone.0268754.g002">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <title>Visualizations of trial 13 in the dataset <monospace>dat.ad</monospace>.</title>
          <p>Points or areas in green indicate non-significant results, and those in red indicate significant ones. Dashed lines represent no modifications in the corresponding groups. Square points represent the original <italic toggle="yes">p</italic> value, and triangle points indicate minimal modifications that alter the significance. In panels (a) and (d), event statuses are modified in both groups. Each point represents the extent of the <italic toggle="yes">p</italic> value corresponding to a specific combination of event status modifications in groups 0 and 1. In panels (c) and (d), event statuses are modified in only one group. Plus points represent truncated <italic toggle="yes">p</italic> values at 10<sup>−10</sup>.</p>
        </caption>
        <graphic xlink:href="pone.0268754.g002" position="float"/>
      </fig>
      <p>The first function implementation in the code above visualizes the fragility of trial 13 by modifying event status in both treatment groups; the argument <monospace>cex.pts</monospace> specifies the size of points in <xref rid="pone.0268754.g002" ref-type="fig">Fig 2a</xref>. Each point represents a <italic toggle="yes">p</italic> value based on certain event status modifications given by the x axis (group 0) and the y axis (group 1). By default, the significance level is 0.05; the <italic toggle="yes">p</italic> values lower than this level (significant results) are presented in red, and those above this level (non-significant results) are in green. The legend on the right side indicates the magnitudes of <italic toggle="yes">p</italic> values; the color opacity of a <italic toggle="yes">p</italic> value changes linearly according to the negative base-10 logarithm of the <italic toggle="yes">p</italic> value. Because <monospace>trun</monospace> is set to 10 by default, <italic toggle="yes">p</italic> values lower than 10<sup>−10</sup> are truncated. The non-significant results are generally around a diagonal line, where the event status is modified so that the even counts in the two groups are close, leading to large <italic toggle="yes">p</italic> values. On the other hand, for points away from the diagonal line, the difference between the modified event counts in the two groups becomes larger, so the corresponding <italic toggle="yes">p</italic> values are smaller. In addition, the vertical and horizontal dashed lines indicate no modifications in groups 0 and 1, respectively; they cross at a square point, corresponding to the <italic toggle="yes">p</italic> value of the original data. This <italic toggle="yes">p</italic> value is located in the red area, implying a significant result; therefore, to assess the fragility of this trial, we aim at modifying event statuses so that the original <italic toggle="yes">p</italic> value is moved to the green area of non-significant results. The three triangle points in the green area indicate three cases of minimal event status modifications that can alter the significance to non-significance. They represent 1) changing 6 non-events in group 0 to events; 2) changing 5 non-events in group 0 to events and 1 event to a non-event in group 1; and 3) changing 4 non-events in group 0 to events and 2 events to non-events in group 1. These match the output of <monospace>out.trial13</monospace> displayed previously. All three cases indicate FI = 6.</p>
      <p>The second function implementation sets <monospace>modify1 = FALSE</monospace> to visualize the fragility by restricting the modifications to group 0 (<xref rid="pone.0268754.g002" ref-type="fig">Fig 2b</xref>). As event status is only modified in group 0, this plot presents the negative base-10 logarithm of <italic toggle="yes">p</italic> values against the corresponding modifications. The <italic toggle="yes">p</italic> values in this plot correspond to those on the horizontal dashed line at 0 in <xref rid="pone.0268754.g002" ref-type="fig">Fig 2a</xref>. The red area at the top indicates significant results, and the green area at the bottom indicates non-significant results. Again, the <italic toggle="yes">p</italic> values lower than 10<sup>−10</sup> are truncated; the truncated <italic toggle="yes">p</italic> values are presented as plus signs. The vertical dashed line at 0 implies the original <italic toggle="yes">p</italic> value (presented as a square point), which is within the red area of significant results. The triangle point represents the minimal event status modification in group 0 for altering the significance to non-significance; it also implies that the FI is 6 when restricting the modifications to group 0 (by changing 6 non-events to events). The numerical value of this FI can be also obtained from the output of <monospace>frag.study()</monospace> with its argument <monospace>all = TRUE</monospace>, i.e., <monospace>out.trial13.all$FI0</monospace>.</p>
      <p>Similarly, the third function implementation sets <monospace>modify0 = FALSE</monospace>; it visualizes the fragility by restricting the modifications to group 1 (<xref rid="pone.0268754.g002" ref-type="fig">Fig 2c</xref>). The FI is 7 with this restriction (by changing 7 events to non-events). The numerical value of this FI can be obtained from <monospace>out.trial13.all$FI1</monospace>.</p>
      <p>If users would like to reduce the type I error rate by lowering the significance level <italic toggle="yes">α</italic> to 0.001, they may simply specify this level for the argument <monospace>alpha</monospace>:</p>
      <p>
        <monospace>&gt; out.trial13.all.2 &lt;- frag.study(e0 = e0, n0 = n0, e1 = e1, n1 = n1,</monospace>
      </p>
      <p>
        <monospace>  data = dat.ad[13,], all = TRUE, alpha = 0.001)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trial13.all.2, method = “Fisher”,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 3, non-significance altered to significance”,</monospace>
      </p>
      <p>
        <monospace>  cex.pts = 0.5, font.main = 1, cex.main = 0.9)</monospace>
      </p>
      <p><xref rid="pone.0268754.g002" ref-type="fig">Fig 2d</xref> shows the generated plot. Compared with <xref rid="pone.0268754.g002" ref-type="fig">Fig 2a</xref> at <italic toggle="yes">α</italic> = 0.05, the original result is no longer significant, and the original <italic toggle="yes">p</italic> value is now within the green area. As the significance level decreases, the green area of non-significant results becomes wider. The original <italic toggle="yes">p</italic> value is close to the border of the green area, implying that this result might be fragile; indeed, the FI becomes 3, and its direction is the non-significance altered to significance. This can be achieved by 1) changing 3 events to non-events in group 0; 2) 2 events to non-events in group 0 and 1 non-event to an event in group 1; or 3) 1 event to a non-event in group 0 and 2 non-events to events in group 1.</p>
    </sec>
    <sec id="sec016">
      <title>Example of a pairwise meta-analysis</title>
      <p>We use the dataset <monospace>dat.ns</monospace> to illustrate the assessment of the fragility of pairwise MAs. Recall that this dataset contains 564 pairwise MAs on nutrition support. We apply the function <monospace>frag.ma()</monospace> to the first MA that investigates the overall all-cause mortality; see <xref rid="pone.0268754.g003" ref-type="fig">Fig 3</xref>. All arguments besides those receiving data input are set to the default; that is, the effect measure is the OR with the null value at 1, the significance level is 0.05, the meta-analysis is performed via the DL method, and the CI of the overall effect size is derived based on the normal distribution. The OR is analyzed on a logarithmic scale; the null value of the log OR is 0. The informative output gives a summary of the original data, the evaluation of significance, and the assessment of the fragility. In this example, the CI of the overall log OR of the original data covers 0, indicating a non-significant effect of nutrition support on all-cause mortality. The FI is 14 for altering the non-significance to significance, and the FQ is 0.1%. Due to the space limit, the output does not provide complete results. The produced object <monospace>out.ma1</monospace> is a list that contains many results produced during the iterative process of deriving the FI, including the study and treatment group that are involved in each event status modification, the estimated overall effect size with its CI in each iteration, as well as the data with modified event status in the final iteration where the non-significance is just altered. Users may apply <monospace>names()</monospace> to obtain the names of all elements of the produced object.</p>
      <fig position="float" id="pone.0268754.g003">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g003</object-id>
        <label>Fig 3</label>
        <caption>
          <title>Output from the function <monospace>frag.ma()</monospace>.</title>
        </caption>
        <graphic xlink:href="pone.0268754.g003" position="float"/>
      </fig>
      <p>The package “fragility” does not provide functions to produce classic plots for the pairwise MA, such as the forest plot and funnel plot, because many existing popular packages such as “metafor” [<xref rid="pone.0268754.ref088" ref-type="bibr">88</xref>] and “meta” [<xref rid="pone.0268754.ref097" ref-type="bibr">97</xref>] have included these features. Nevertheless, the process of deriving the FI can be visualized as follows:</p>
      <p>
        <monospace>&gt; plot(out.ma1, ybreaks = c(840, 880), font.main = 1, cex.main = 0.9,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 14, non-significance altered to significance”)</monospace>
      </p>
      <p><xref rid="pone.0268754.g004" ref-type="fig">Fig 4</xref> presents the produced plot, which shows the total event counts in the two treatment groups during the iterations. It contains two lines that depict the process, where the blue and red lines represent groups 0 and 1, respectively. As the argument <monospace>ybreaks</monospace> is specified as <monospace>c(840, 880)</monospace>, the plot omits this range on the y axis for better visualization. The numbers around the blue line indicate the studies that are involved in the event status modifications during the iterations. Each asterisk indicates that a study remains unchanged as in the previous iteration; that is, the first asterisk represents study 43, and the second represents study 45. No event status is modified in group 1 for deriving the FI in this example.</p>
      <fig position="float" id="pone.0268754.g004">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g004</object-id>
        <label>Fig 4</label>
        <caption>
          <title>Event status modifications in the first pairwise meta-analysis in the dataset <monospace>dat.ns</monospace>.</title>
          <p>Each line represents changes in the total event count in a certain group. The numbers around each line indicate the studies involved in the event status modifications during the iterations; each asterisk indicates that a study remains unchanged as in the previous iteration.</p>
        </caption>
        <graphic xlink:href="pone.0268754.g004" position="float"/>
      </fig>
    </sec>
    <sec id="sec017">
      <title>Example of a network meta-analysis</title>
      <p>The function <monospace>frag.nma()</monospace> assesses the fragility of an NMA. We apply it to the dataset <monospace>dat.sc</monospace> of the NMA on smoking cessation, which contains 24 studies comparing a total of 4 treatments; see <xref rid="pone.0268754.g005" ref-type="fig">Fig 5</xref>. We do not specify the arguments <monospace>tid1.f</monospace> and <monospace>tid2.f</monospace>, so the fragility of each treatment comparison is assessed. Because many NMAs need to be performed during the iterative algorithm for each comparison, the computation time is around 1 hour; the actual time depends on users’ processors.</p>
      <fig position="float" id="pone.0268754.g005">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g005</object-id>
        <label>Fig 5</label>
        <caption>
          <title>Output from the function <monospace>frag.nma()</monospace>.</title>
        </caption>
        <graphic xlink:href="pone.0268754.g005" position="float"/>
      </fig>
      <p>This NMA contains 4 treatments, so the results of FIs and FQs are presented in 4×4 matrices. The informative output only displays some important characteristics of the NMA and results about fragility. As in the previous examples, more detailed results (e.g., directions of the altered significance or non-significance, studies and treatment groups involved in event status modifications) can be retrieved from the elements of the produced object <monospace>out.nma</monospace>, whose names can be obtained via applying <monospace>names()</monospace>. In this example, the FI is as small as 3 for the comparison 4 vs. 1 (a relatively fragile comparison), and it is as large as 32 for 3 vs. 1 (a less fragile comparison).</p>
      <p>The visualization of the process of deriving the FI in an NMA is similar to that in a pairwise MA. The major difference is that the visualization in the NMA needs to be implemented for each treatment comparison separately. We apply <monospace>plot()</monospace> to the produced object <monospace>out.nma</monospace> that is of class <monospace>“frag.nma”</monospace>:</p>
      <p>
        <monospace>&gt; plot(out.nma, tid1 = 2, tid2 = 1, ybreaks = c(170, 595),</monospace>
      </p>
      <p>
        <monospace>  x.legend = “topright”, font.main = 1, cex.main = 0.9,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 18, non-significance altered to significance”)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.nma, tid1 = 3, tid2 = 1, ybreaks = c(635, 1200),</monospace>
      </p>
      <p>
        <monospace>  x.legend = “bottomright”, font.main = 1, cex.main = 0.9,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 32, significance altered to non-significance”)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.nma, tid1 = 4, tid2 = 1, ybreaks = c(105, 600),</monospace>
      </p>
      <p>
        <monospace>  font.main = 1, cex.main = 0.9,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 3, significance altered to non-significance”)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.nma, tid1 = 3, tid2 = 2, ybreaks = c(160, 1205),</monospace>
      </p>
      <p>
        <monospace>  font.main = 1, cex.main = 0.9,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 19, non-significance altered to significance”)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.nma, tid1 = 4, tid2 = 2, ybreaks = c(110, 140),</monospace>
      </p>
      <p>
        <monospace>  x.legend = “topright”, font.main = 1, cex.main = 0.9,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 12, non-significance altered to significance”)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.nma, tid1 = 4, tid2 = 3, ybreaks = c(130, 1205),</monospace>
      </p>
      <p>
        <monospace>  x.legend = “bottomright”, font.main = 1, cex.main = 0.9,</monospace>
      </p>
      <p>
        <monospace>  main = “FI = 23, non-significance altered to significance”)</monospace>
      </p>
      <p><xref rid="pone.0268754.g006" ref-type="fig">Fig 6</xref> presents the produced plots. The argument <monospace>ybreaks</monospace> is specified differently for each comparison because the ranges of the involved total event counts differ. Again, an asterisk represents that a study with modified event status remains unchanged as in the previous iteration. These plots indicate event status is generally modified in a few studies to alter the significance or non-significance. For example, to derive the FI of the comparison 2 vs. 1 in <xref rid="pone.0268754.g006" ref-type="fig">Fig 6a</xref>, only studies 2, 16, and 22 among the 24 studies are involved in event status modifications.</p>
      <fig position="float" id="pone.0268754.g006">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g006</object-id>
        <label>Fig 6</label>
        <caption>
          <title>Event status modifications in the network meta-analysis dataset <monospace>dat.sc</monospace>.</title>
          <p>Each line represents changes in the total event count in a certain group. The numbers around each line indicate the studies involved in the event status modifications during the iterations; each asterisk indicates that a study remains unchanged as in the previous iteration. (a) Comparison 2 vs. 1. (b) Comparison 3 vs. 1. (c) Comparison 4 vs. 1. (d) Comparison 3 vs. 2. (e) Comparison 4 vs. 2. (f) Comparison 4 vs. 3.</p>
        </caption>
        <graphic xlink:href="pone.0268754.g006" position="float"/>
      </fig>
      <p>The function <monospace>frag.nma()</monospace> can be similarly applied to the dataset <monospace>dat.copd</monospace>. This dataset serves as a toy example; its fragility can be assessed much faster due to its small size. Its results are not presented in this article. If an NMA contains many treatments, the assessment of its fragility may take a long time. In this case, users are recommended to only assess the fragility of certain treatment comparisons of primary interest by specifying <monospace>tid1.f</monospace> and <monospace>tid2.f</monospace>. Moreover, “fragility” does not provide functions to visualize the NMA, such as the treatment network plot and treatment rank plot, because many existing packages such as “gemtc” [<xref rid="pone.0268754.ref098" ref-type="bibr">98</xref>], “netmeta” [<xref rid="pone.0268754.ref089" ref-type="bibr">89</xref>], and “pcnetmeta” [<xref rid="pone.0268754.ref099" ref-type="bibr">99</xref>] have included these features.</p>
    </sec>
    <sec id="sec018">
      <title>Example of assessing the fragility at multiple significance levels</title>
      <p>The previous examples present the assessment and visualization of the fragility of individual studies, pairwise MAs, and NMAs at a specific significance level. As there are ongoing debates on the choice of statistical significance level [<xref rid="pone.0268754.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0268754.ref057" ref-type="bibr">57</xref>], users might want to assess the fragility at multiple significance levels. They may apply the functions <monospace>frag.study.alpha()</monospace>, <monospace>frag.ma.alpha()</monospace>, and <monospace>frag.nma.alpha()</monospace> to individual studies, pairwise MAs, and NMAs, respectively, for such purposes. Their usage is similar to their counterparts <monospace>frag.study()</monospace>, <monospace>frag.ma()</monospace>, and <monospace>frag.nma()</monospace>. The produced objects are all of class <monospace>“frag.alpha”</monospace>, which can be visualized using <monospace>plot()</monospace> via the S3 method for this class. We focus on an example of an individual study; the code can be similarly applied to pairwise MAs and NMAs.</p>
      <p>We continue to use trial 13 in the dataset <monospace>dat.ad</monospace> for illustrating <monospace>frag.study.alpha()</monospace>; see <xref rid="pone.0268754.g007" ref-type="fig">Fig 7</xref>. The default options are used to specify the range of significance levels, i.e., 100 equally-spaced values between 0.005 and 0.05. The <italic toggle="yes">p</italic> values are derived based on all five methods, i.e., Fisher’s exact test, the chi-squared test, OR, RR, and RD. Like the output produced by <monospace>frag.study()</monospace>, the informative output displays summaries in three parts, which are about original data, significance tests, and fragility. Compared with the output produced by <monospace>frag.study()</monospace>, the major difference is in the last part about fragility; the output of <monospace>frag.study.alpha()</monospace> gives the average fragility measures in the range of specified significance levels. The produced object <monospace>out.trial13.alpha</monospace> is a list, and users can retrieve more detailed information, such as the FI and FQ at each significance level, from this list.</p>
      <fig position="float" id="pone.0268754.g007">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g007</object-id>
        <label>Fig 7</label>
        <caption>
          <title>Output from the function <monospace>frag.study.alpha()</monospace>.</title>
        </caption>
        <graphic xlink:href="pone.0268754.g007" position="float"/>
      </fig>
      <p>The results can be visualized via <monospace>plot()</monospace> as follows:</p>
      <p>
        <monospace>&gt; plot(out.trial13.alpha)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trial13.alpha, fragility = “FQ”)</monospace>
      </p>
      <p>In the first line, the fragility measure is the FI by default; in the second line, the fragility measure is the FQ. <xref rid="pone.0268754.g008" ref-type="fig">Fig 8a and 8b</xref> present the generated plots. As the argument <monospace>method</monospace> is not specified, the plots are based on the default option, i.e., Fisher’s exact test. Because the FQ is the FI divided by the total sample size in the study, which is a constant, the two plots have the same shape; they only differ with respect to the scale on the y axis. Because the FIs must be integers, the plots appear to be step functions. All points in the plots are in red, indicating that the original results are significant at all levels, and the FIs and FQs represent that the significance is altered to non-significance. As the significance level increases from 0.005 to 0.05, the FI increases from 1 to 6. These correspond to the previous output of <monospace>out.trial13.alpha</monospace>, and the average FI is 4.23.</p>
      <fig position="float" id="pone.0268754.g008">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g008</object-id>
        <label>Fig 8</label>
        <caption>
          <title>Visualizations of trial 13 in the <monospace>dat.ad</monospace> dataset at multiple significance levels.</title>
          <p>(a) Fragility index at α from 0.005 to 0.05. (b) Fragility quotient at α from 0.005 to 0.05. (c) Fragility index at α from 0.001 to 0.1. (d) Fragility index at α from 0.001 to 0.1 with the x axis on a logarithmic scale.</p>
        </caption>
        <graphic xlink:href="pone.0268754.g008" position="float"/>
      </fig>
      <p>Users may specify additional arguments; for example, we change the code to:</p>
      <p>
        <monospace>&gt; out.trial13.alpha.2 &lt;- frag.study.alpha(e0, n0, e1, n1,</monospace>
      </p>
      <p>
        <monospace>  data = dat.ad[13,], alpha.from = 0.001, alpha.to = 0.1,</monospace>
      </p>
      <p>
        <monospace>  alpha.breaks = 500)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trial13.alpha.2)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trial13.alpha.2, log = “x”)</monospace>
      </p>
      <p>The significance levels range from 0.001 to 0.1; 500 equally-spaced values are chosen within this range; the results are visualized in <xref rid="pone.0268754.g008" ref-type="fig">Fig 8c</xref>. Other arguments from <monospace>plot.default()</monospace> can be imported; here, we specify <monospace>log = “x”</monospace> to present the significance levels on a logarithmic scale as in <xref rid="pone.0268754.g008" ref-type="fig">Fig 8d</xref>. From the previous output of <monospace>out.trial13.alpha</monospace>, the <italic toggle="yes">p</italic> value of the original data based on Fisher’s exact test is 0.004, so the result is significant if the significance level is above 0.004 but is non-significant if the level is below 0.004. The vertical dashed line in <xref rid="pone.0268754.g008" ref-type="fig">Fig 8c</xref> indicates the original <italic toggle="yes">p</italic> value; the FIs on its left side (points in green) represent the non-significance altered to significance, and those on its right side (points in red) represent the significance altered to non-significance. As the significance level increases from 0.001 to 0.1, the FI first decreases from 3 to 1 and then increases from 1 to 8.</p>
    </sec>
    <sec id="sec019">
      <title>Example of assessing the fragility of multiple datasets</title>
      <p>As multiple clinical studies or pairwise MAs (e.g., with different disease outcomes) may be available on certain common topics, clinicians may be interested in the overall distributions of the fragility measures of these studies or pairwise MAs. The functions <monospace>frag.studies()</monospace> and <monospace>frag.mas()</monospace> can be used for such purposes. Such a function is not provided for NMAs in “fragility,” because usually only a few NMAs are available on common topics. The usage of <monospace>frag.studies()</monospace> and <monospace>frag.mas()</monospace> is similar to that of <monospace>frag.study()</monospace> and <monospace>frag.ma()</monospace>, respectively. The produced objects of both functions are of class <monospace>“frag.multi”</monospace>; they can be visualized using <monospace>plot()</monospace> via the S3 method for this class.</p>
      <p>Specifically, we can assess the fragility of all trials contained in the dataset <monospace>dat.ad</monospace> as in <xref rid="pone.0268754.g009" ref-type="fig">Fig 9</xref>. By default, all five methods (Fisher’s exact test, the chi-squared test, OR, RR, and RD) are used to derive the fragility measures. The informative output displays a summary of the original data, significance tests, and fragility measures (e.g., medians, ranges, and interquartile ranges [IQRs]). When presenting the fragility measures, the 347 trials are distinguished into two groups, i.e., those with originally significant results and non-significant ones. Users can retrieve complete results from the elements of the output list <monospace>out.trials</monospace>; for example, the FIs of all trials are stored in <monospace>out.trials$FI</monospace>.</p>
      <fig position="float" id="pone.0268754.g009">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g009</object-id>
        <label>Fig 9</label>
        <caption>
          <title>Output from the function <monospace>frag.studies()</monospace>.</title>
        </caption>
        <graphic xlink:href="pone.0268754.g009" position="float"/>
      </fig>
      <p>The fragility measures of all trials can be visualized as follows:</p>
      <p>
        <monospace>&gt; plot(out.trials, method = “Fisher”, cex.name = 0.6)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trials, method = “Fisher”, max.f = 16, cex.name = 0.6)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trials, dir = “sig2nonsig”, method = “Fisher”,</monospace>
      </p>
      <p>
        <monospace>  cex.name = 0.6)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trials, dir = “nonsig2sig”, method = “Fisher”,</monospace>
      </p>
      <p>
        <monospace>  cex.name = 0.6)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trials, method = “Fisher”, fragility = “FQ”, max.f = 20)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.trials, method = “Fisher”, fragility = “FQ”, max.f = 20,</monospace>
      </p>
      <p>
        <monospace>  breaks = 20)</monospace>
      </p>
      <p>Six plots are produced for different illustrative purposes, as shown in <xref rid="pone.0268754.g010" ref-type="fig">Fig 10</xref>. They are based on Fisher’s exact test. In the first four function implementations, the argument <monospace>fragility</monospace> uses the default option, i.e., <monospace>“FI”</monospace>, and <monospace>bar</monospace> is <monospace>TRUE</monospace> by default, so <xref rid="pone.0268754.g010" ref-type="fig">Fig 10a–10d</xref> present bar plots of FIs. The argument <monospace>cex.name</monospace> is passed to <monospace>barplot()</monospace> for adjusting the text size on the x axis; if the size is too large, many values may disappear due to space limit. <xref rid="pone.0268754.g010" ref-type="fig">Fig 10a</xref> presents the overall distribution of FIs of all 347 trials. The FIs range from 1 to 19; many trials have FIs between 1 and 10, implying that their significance could be altered by changing the event statuses of at most 10 patients. The bars in red represent trials with originally significant results, so their FIs indicate the significance altered to non-significance; the bars in green represent trials with originally non-significant results, which are altered to be significant. Most trials originally have non-significant results. The FIs of some trials have extreme values, which may affect the visualization effect of the overall distribution. As in the second function implementation of the code above, users can specify <monospace>max.f</monospace> to truncate FIs above the specified value. <xref rid="pone.0268754.g010" ref-type="fig">Fig 10b</xref> presents the overall distribution with FIs truncated at 16; all trials with FIs above 16 are stacked at the rightmost bar. If users want to focus on the direction of FIs that alter the significance to non-significance or its inverse, <monospace>dir</monospace> can be specified as <monospace>“sig2nonsig”</monospace> or <monospace>“nonsig2sig”</monospace>, leading to the bar plots in <xref rid="pone.0268754.g010" ref-type="fig">Fig 10c and 10d</xref>, respectively. By default, this argument is <monospace>“both”</monospace>, i.e., both directions are presented as in <xref rid="pone.0268754.g010" ref-type="fig">Fig 10a and 10b</xref>.</p>
      <fig position="float" id="pone.0268754.g010">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g010</object-id>
        <label>Fig 10</label>
        <caption>
          <title>Distributions of fragility measures of the clinical trials in the dataset <monospace>dat.ad</monospace>.</title>
          <p>(a) Bar plot of fragility indexes of all trials. (b) Bar plot fragility indexes of all trials truncated at 16. (c) Bar plot of fragility indexes of trials whose significance altered to non-significance. (d) Bar plot of fragility indexes of trials whose non-significance altered to significance. (e) Histogram of fragility quotients of all trials. (f) Histogram of fragility quotients of all trials with more breaks.</p>
        </caption>
        <graphic xlink:href="pone.0268754.g010" position="float"/>
      </fig>
      <p>Alternatively, users can specify <monospace>fragility = “FQ”</monospace> to produce plots for FQs as in the last two function implementations in the code above. As FQs can take any values within 0%–100%, instead of only integers like FIs, the histogram rather than the bar plot is produced for FQs. <xref rid="pone.0268754.g010" ref-type="fig">Fig 10e</xref> presents the overall distribution of FQs, truncated at 20%. If <monospace>breaks</monospace> is not specified, the number of breaks in the histogram is automatically determined by <monospace>hist()</monospace>. Users may adjust this argument to change the number of breaks as in <xref rid="pone.0268754.g010" ref-type="fig">Fig 10f</xref>.</p>
      <p>We also apply <monospace>frag.mas()</monospace> to the dataset <monospace>dat.ns</monospace> to assess the fragility of multiple pairwise MAs, as in <xref rid="pone.0268754.g011" ref-type="fig">Fig 11</xref>. The effect measure of these MAs is the OR (<monospace>measure = “OR”</monospace>) by default. The output is similar to that of <monospace>out.trials</monospace>. It displays a summary of the input MAs, information about significance, and fragility measures. Among the total of 564 pairwise MAs, 97 have significant overall ORs, and their FIs range from 1 to 167; 467 have non-significant overall ORs with FIs ranging from 1 to 61.</p>
      <fig position="float" id="pone.0268754.g011">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g011</object-id>
        <label>Fig 11</label>
        <caption>
          <title>Output from the function <monospace>frag.mas()</monospace>.</title>
        </caption>
        <graphic xlink:href="pone.0268754.g011" position="float"/>
      </fig>
      <p>The produced object <monospace>out.mas</monospace> is of class <monospace>“frag.multi”</monospace>, and can be visualized as follows:</p>
      <p>
        <monospace>&gt; plot(out.mas, max.f = 40, cex.name = 0.5)</monospace>
      </p>
      <p>
        <monospace>&gt; plot(out.mas, fragility = “FQ”, breaks = 20)</monospace>
      </p>
      <p>The first line produces the bar plot of FIs of all 564 MAs in <xref rid="pone.0268754.g012" ref-type="fig">Fig 12a</xref>, and the second line produces the histogram of FQs in <xref rid="pone.0268754.g012" ref-type="fig">Fig 12b</xref>. As displayed in the output of <monospace>out.mas</monospace>, the FIs may take large values up to 167, so <monospace>max.f</monospace> is specified as 40 for truncation. Most MAs have FIs less than 15 and FQs less than 1%.</p>
      <fig position="float" id="pone.0268754.g012">
        <object-id pub-id-type="doi">10.1371/journal.pone.0268754.g012</object-id>
        <label>Fig 12</label>
        <caption>
          <title>Distributions of fragility measures of the pairwise meta-analyses in the dataset <monospace>dat.ns</monospace>.</title>
          <p>(a) Bar plot of fragility indexes. (b) Histogram of fragility quotients.</p>
        </caption>
        <graphic xlink:href="pone.0268754.g012" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec020">
    <title>Discussion</title>
    <p>This article has reviewed methods for assessing and visualizing the fragility of an individual study, pairwise MA, and NMA with a binary outcome; the package “fragility” is designed for implementing these methods. We have focused on introducing the usage of many user-friendly functions provided by this package and illustrating them via several worked examples.</p>
    <p>The FI and FQ are useful tools to assess clinical results’ fragility; many researchers are becoming interested in these measures due to the growing concerns about research reproducibility and replicability. Nevertheless, it may be limited to assess the fragility based entirely on the numerical value of the FI or FQ. Most existing software programs do not provide much additional information about the FI or FQ besides its numerical value. The package “fragility” offers a variety of results that may aid the assessment of fragility. For example, the package produces various plots that visualize the studies and treatments involved in event status modifications in the iterative process for computing the FI or FQ of a pairwise MA or NMA. Such plots may indicate studies or treatments that are potentially influential in the meta-analytic results; clinicians may carefully examine the reliability (e.g., methodological quality) of the associated studies. In addition, users can specify certain directions of event status modifications in each treatment group for an individual study. The package provides information about different scenarios when the significance or non-significance is altered. It is crucial to incorporate such detailed information with clinicians’ opinions on a case-by-case basis; for some rare diseases, it may be more sensible to modify events to non-events.</p>
    <p>There are still several limitations of the “fragility” package. First, using this package requires researchers to possess some coding skills; clinicians without coding training might not directly use this package for assessing the fragility of clinical studies. Second, the current version of the “fragility” package can only deal with clinical studies with binary outcomes. Recently, Caldwell et al. [<xref rid="pone.0268754.ref100" ref-type="bibr">100</xref>] proposed a method to define the FI of studies with continuous outcomes. If this method is further validated in practical applications, we will consider incorporating it into the future releases of the “fragility” package. Third, the existing literature lacks a guideline or rule of thumb to interpret the magnitude of the FI or FQ (i.e., the extent of fragility). On the one hand, the interpretation might depend on the clinical setting, e.g., whether the outcomes of some patients are possibly modified. On the other hand, in future work, we plan to systematically collect many clinical studies, pairwise MAs, and NMAs across different specialties (e.g., from the Cochrane Library), obtain their FIs and FQs, and derive the empirical distributions for all datasets and those within subgroups of specific research areas. Such empirical distributions will be incorporated in future versions of “fragility,” and they will further assist users in properly interpreting the fragility of clinical results.</p>
  </sec>
  <sec id="sec021" sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="pone.0268754.s001" position="float" content-type="local-data">
      <label>S1 File</label>
      <caption>
        <title>Additional information of functions’ arguments.</title>
        <p>(PDF)</p>
      </caption>
      <media xlink:href="pone.0268754.s001.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ref-list>
    <title>References</title>
    <ref id="pone.0268754.ref001">
      <label>1</label>
      <mixed-citation publication-type="journal"><name><surname>Ioannidis</surname><given-names>JPA</given-names></name>, <name><surname>Ntzani</surname><given-names>EE</given-names></name>, <name><surname>Trikalinos</surname><given-names>TA</given-names></name>, <name><surname>Contopoulos-Ioannidis</surname><given-names>DG</given-names></name>. <article-title>Replication validity of genetic association studies</article-title>. <source>Nature Genetics</source>. <year>2001</year>;<volume>29</volume>(<issue>3</issue>):<fpage>306</fpage>–<lpage>309</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ng749</pub-id><?supplied-pmid 11600885?><pub-id pub-id-type="pmid">11600885</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref002">
      <label>2</label>
      <mixed-citation publication-type="journal"><name><surname>Ioannidis</surname><given-names>JPA</given-names></name>. <article-title>Why most published research findings are false</article-title>. <source>PLOS Medicine</source>. <year>2005</year>;<volume>2</volume>(<issue>8</issue>):<fpage>e124</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pmed.0020124</pub-id><?supplied-pmid 16060722?><pub-id pub-id-type="pmid">16060722</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref003">
      <label>3</label>
      <mixed-citation publication-type="journal"><name><surname>Richter</surname><given-names>SH</given-names></name>, <name><surname>Garner</surname><given-names>JP</given-names></name>, <name><surname>Würbel</surname><given-names>H</given-names></name>. <article-title>Environmental standardization: cure or cause of poor reproducibility in animal experiments?</article-title><source>Nature Methods</source>. <year>2009</year>;<volume>6</volume>(<issue>4</issue>):<fpage>257</fpage>–<lpage>261</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nmeth.1312</pub-id><?supplied-pmid 19333241?><pub-id pub-id-type="pmid">19333241</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref004">
      <label>4</label>
      <mixed-citation publication-type="journal"><collab>Open Science Collaboration</collab>. <article-title>Estimating the reproducibility of psychological science</article-title>. <source>Science</source>. <year>2015</year>;<volume>349</volume>(<issue>6251</issue>):<fpage>aac4716</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.aac4716</pub-id><?supplied-pmid 26315443?><pub-id pub-id-type="pmid">26315443</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref005">
      <label>5</label>
      <mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>M</given-names></name>. <article-title>Is there a reproducibility crisis?</article-title><source>Nature</source>. <year>2016</year>;<volume>533</volume>(<issue>7604</issue>):<fpage>452</fpage>–<lpage>454</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/533452a</pub-id><?supplied-pmid 27225100?><pub-id pub-id-type="pmid">27225100</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref006">
      <label>6</label>
      <mixed-citation publication-type="journal"><name><surname>Negrini</surname><given-names>S</given-names></name>, <name><surname>Arienti</surname><given-names>C</given-names></name>, <name><surname>Pollet</surname><given-names>J</given-names></name>, <name><surname>Engkasan</surname><given-names>JP</given-names></name>, <name><surname>Francisco</surname><given-names>GE</given-names></name>, <name><surname>Frontera</surname><given-names>WR</given-names></name>, <etal>et al</etal>. <article-title>Clinical replicability of rehabilitation interventions in randomized controlled trials reported in main journals is inadequate</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2019</year>;<volume>114</volume>:<fpage>108</fpage>–<lpage>117</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2019.06.008</pub-id><?supplied-pmid 31220570?><pub-id pub-id-type="pmid">31220570</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref007">
      <label>7</label>
      <mixed-citation publication-type="journal"><name><surname>Nuzzo</surname><given-names>R</given-names></name>. <article-title>Estimating the reproducibility of psychological science</article-title>. <source>Nature</source>. <year>2014</year>;<volume>506</volume>(<issue>7487</issue>):<fpage>150</fpage>–<lpage>152</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/506150a</pub-id><?supplied-pmid 24522584?><pub-id pub-id-type="pmid">24522584</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref008">
      <label>8</label>
      <mixed-citation publication-type="journal"><name><surname>Halsey</surname><given-names>LG</given-names></name>, <name><surname>Curran-Everett</surname><given-names>D</given-names></name>, <name><surname>Vowler</surname><given-names>SL</given-names></name>, <name><surname>Drummond</surname><given-names>GB</given-names></name>. <article-title>The fickle <italic toggle="yes">P</italic> value generates irreproducible results</article-title>. <source>Nature Methods</source>. <year>2015</year>;<volume>12</volume>(<issue>3</issue>):<fpage>179</fpage>–<lpage>185</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nmeth.3288</pub-id><?supplied-pmid 25719825?><pub-id pub-id-type="pmid">25719825</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref009">
      <label>9</label>
      <mixed-citation publication-type="journal"><name><surname>Goodman</surname><given-names>SN</given-names></name>. <article-title>Toward evidence-based medical statistics. 1: the <italic toggle="yes">P</italic> value fallacy</article-title>. <source>Annals of Internal Medicine</source>. <year>1999</year>;<volume>130</volume>(<issue>12</issue>):<fpage>995</fpage>–<lpage>1004</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7326/0003-4819-130-12-199906150-00008</pub-id><?supplied-pmid 10383371?><pub-id pub-id-type="pmid">10383371</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref010">
      <label>10</label>
      <mixed-citation publication-type="journal"><name><surname>Sterne</surname><given-names>JAC</given-names></name>, <name><surname>Davey Smith</surname><given-names>G</given-names></name>. <article-title>Sifting the evidence—what’s wrong with significance tests?</article-title><source>BMJ</source>. <year>2001</year>;<volume>322</volume>:<fpage>226</fpage>–<lpage>231</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.322.7280.226</pub-id><?supplied-pmid 11159626?><pub-id pub-id-type="pmid">11159626</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref011">
      <label>11</label>
      <mixed-citation publication-type="journal"><name><surname>Dickersin</surname><given-names>K</given-names></name>. <article-title>The existence of publication bias and risk factors for its occurrence</article-title>. <source>JAMA</source>. <year>1990</year>;<volume>263</volume>(<issue>10</issue>):<fpage>1385</fpage>–<lpage>1389</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.263.10.1385</pub-id><?supplied-pmid 2406472?><pub-id pub-id-type="pmid">2406472</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref012">
      <label>12</label>
      <mixed-citation publication-type="journal"><name><surname>Sutton</surname><given-names>AJ</given-names></name>, <name><surname>Duval</surname><given-names>SJ</given-names></name>, <name><surname>Tweedie</surname><given-names>R</given-names></name>, <name><surname>Abrams</surname><given-names>KR</given-names></name>, <name><surname>Jones</surname><given-names>DR</given-names></name>. <article-title>Empirical assessment of effect of publication bias on meta-analyses</article-title>. <source>BMJ</source>. <year>2000</year>;<volume>320</volume>(<issue>7249</issue>):<fpage>1574</fpage>–<lpage>1577</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.320.7249.1574</pub-id><?supplied-pmid 10845965?><pub-id pub-id-type="pmid">10845965</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref013">
      <label>13</label>
      <mixed-citation publication-type="journal"><name><surname>Turner</surname><given-names>EH</given-names></name>, <name><surname>Matthews</surname><given-names>AM</given-names></name>, <name><surname>Linardatos</surname><given-names>E</given-names></name>, <name><surname>Tell</surname><given-names>RA</given-names></name>, <name><surname>Rosenthal</surname><given-names>R</given-names></name>. <article-title>Selective publication of antidepressant trials and its influence on apparent efficacy</article-title>. <source>New England Journal of Medicine</source>. <year>2008</year>;<volume>358</volume>(<issue>3</issue>):<fpage>252</fpage>–<lpage>260</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMsa065779</pub-id><?supplied-pmid 18199864?><pub-id pub-id-type="pmid">18199864</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref014">
      <label>14</label>
      <mixed-citation publication-type="journal"><name><surname>Mathieu</surname><given-names>S</given-names></name>, <name><surname>Boutron</surname><given-names>I</given-names></name>, <name><surname>Moher</surname><given-names>D</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <name><surname>Ravaud</surname><given-names>P</given-names></name>. <article-title>Comparison of registered and published primary outcomes in randomized controlled trials</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>(<issue>9</issue>):<fpage>977</fpage>–<lpage>984</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2009.1242</pub-id><?supplied-pmid 19724045?><pub-id pub-id-type="pmid">19724045</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref015">
      <label>15</label>
      <mixed-citation publication-type="journal"><name><surname>Nüesch</surname><given-names>E</given-names></name>, <name><surname>Trelle</surname><given-names>S</given-names></name>, <name><surname>Reichenbach</surname><given-names>S</given-names></name>, <name><surname>Rutjes</surname><given-names>AWS</given-names></name>, <name><surname>Tschannen</surname><given-names>B</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <etal>et al</etal>. <article-title>Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>341</volume>:<fpage>c3515</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.c3515</pub-id><?supplied-pmid 20639294?><pub-id pub-id-type="pmid">20639294</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref016">
      <label>16</label>
      <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Chu</surname><given-names>H</given-names></name>, <name><surname>Murad</surname><given-names>MH</given-names></name>, <name><surname>Hong</surname><given-names>C</given-names></name>, <name><surname>Qu</surname><given-names>Z</given-names></name>, <name><surname>Cole</surname><given-names>SR</given-names></name>, <etal>et al</etal>. <article-title>Empirical comparison of publication bias tests in meta-analysis</article-title>. <source>Journal of General Internal Medicine</source>. <year>2018</year>;<volume>33</volume>(<issue>8</issue>):<fpage>1260</fpage>–<lpage>1267</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11606-018-4425-7</pub-id><?supplied-pmid 29663281?><pub-id pub-id-type="pmid">29663281</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref017">
      <label>17</label>
      <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Chu</surname><given-names>H</given-names></name>. <article-title>Quantifying publication bias in meta-analysis</article-title>. <source>Biometrics</source>. <year>2018</year>;<volume>74</volume>(<issue>3</issue>):<fpage>785</fpage>–<lpage>794</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/biom.12817</pub-id><?supplied-pmid 29141096?><pub-id pub-id-type="pmid">29141096</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref018">
      <label>18</label>
      <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Shi</surname><given-names>L</given-names></name>, <name><surname>Chu</surname><given-names>H</given-names></name>, <name><surname>Murad</surname><given-names>MH</given-names></name>. <article-title>The magnitude of small-study effects in the <italic toggle="yes">Cochrane Database of Systematic Reviews</italic>: an empirical study of nearly 30 000 meta-analyses</article-title>. <source>BMJ Evidence-Based Medicine</source>. <year>2020</year>;<volume>25</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmjebm-2019-111191</pub-id><?supplied-pmid 31273125?><pub-id pub-id-type="pmid">31273125</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref019">
      <label>19</label>
      <mixed-citation publication-type="journal"><name><surname>Greenland</surname><given-names>S</given-names></name>, <name><surname>Poole</surname><given-names>C</given-names></name>. <article-title>Living with <italic toggle="yes">P</italic> values: resurrecting a Bayesian perspective on frequentist statistics</article-title>. <source>Epidemiology</source>. <year>2013</year>;<volume>24</volume>(<issue>1</issue>):<fpage>62</fpage>–<lpage>68</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/EDE.0b013e3182785741</pub-id><?supplied-pmid 23232611?><pub-id pub-id-type="pmid">23232611</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref020">
      <label>20</label>
      <mixed-citation publication-type="journal"><name><surname>Wasserstein</surname><given-names>RL</given-names></name>, <name><surname>Lazar</surname><given-names>NA</given-names></name>. <article-title>The ASA statement on <italic toggle="yes">p</italic>-values: context, process, and purpose</article-title>. <source>The American Statistician</source>. <year>2016</year>;<volume>70</volume>(<issue>2</issue>):<fpage>129</fpage>–<lpage>133</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00031305.2016.1154108</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref021">
      <label>21</label>
      <mixed-citation publication-type="journal"><name><surname>Lash</surname><given-names>TL</given-names></name>. <article-title>The harm done to reproducibility by the culture of null hypothesis significance testing</article-title>. <source>American Journal of Epidemiology</source>. <year>2017</year>;<volume>186</volume>(<issue>6</issue>):<fpage>627</fpage>–<lpage>635</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/aje/kwx261</pub-id><?supplied-pmid 28938715?><pub-id pub-id-type="pmid">28938715</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref022">
      <label>22</label>
      <mixed-citation publication-type="journal"><name><surname>Amrhein</surname><given-names>V</given-names></name>, <name><surname>Greenland</surname><given-names>S</given-names></name>, <name><surname>McShane</surname><given-names>B</given-names></name>. <article-title>Scientists rise up against statistical significance</article-title>. <source>Nature</source>. <year>2019</year>;<volume>567</volume>:<fpage>305</fpage>–<lpage>307</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/d41586-019-00857-9</pub-id><?supplied-pmid 30894741?><pub-id pub-id-type="pmid">30894741</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref023">
      <label>23</label>
      <mixed-citation publication-type="journal"><name><surname>Zarin</surname><given-names>DA</given-names></name>, <name><surname>Tse</surname><given-names>T</given-names></name>, <name><surname>Williams</surname><given-names>RJ</given-names></name>, <name><surname>Califf</surname><given-names>RM</given-names></name>, <name><surname>Ide</surname><given-names>NC</given-names></name>. <article-title>The ClinicalTrials.gov results database—update and key issues</article-title>. <source>New England Journal of Medicine</source>. <year>2011</year>;<volume>364</volume>(<issue>9</issue>):<fpage>852</fpage>–<lpage>860</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMsa1012065</pub-id><?supplied-pmid 21366476?><pub-id pub-id-type="pmid">21366476</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref024">
      <label>24</label>
      <mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>M</given-names></name>, <name><surname>Srinathan</surname><given-names>SK</given-names></name>, <name><surname>McAuley</surname><given-names>DF</given-names></name>, <name><surname>Mrkobrada</surname><given-names>M</given-names></name>, <name><surname>Levine</surname><given-names>O</given-names></name>, <name><surname>Ribic</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>The statistical significance of randomized controlled trial results is frequently fragile: a case for a fragility index</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2014</year>;<volume>67</volume>(<issue>6</issue>):<fpage>622</fpage>–<lpage>628</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2013.10.019</pub-id><?supplied-pmid 24508144?><pub-id pub-id-type="pmid">24508144</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref025">
      <label>25</label>
      <mixed-citation publication-type="journal"><name><surname>Feinstein</surname><given-names>AR</given-names></name>. <article-title>The unit fragility index: an additional appraisal of ‘statistical significance’ for a contrast of two proportions</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>1990</year>;<volume>43</volume>(<issue>2</issue>):<fpage>201</fpage>–<lpage>209</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0895-4356(90)90186-S</pub-id><?supplied-pmid 2303850?><pub-id pub-id-type="pmid">2303850</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref026">
      <label>26</label>
      <mixed-citation publication-type="journal"><name><surname>Walter</surname><given-names>SD</given-names></name>. <article-title>Statistical significance and fragility criteria for assessing a difference of two proportions</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>1991</year>;<volume>44</volume>(<issue>12</issue>):<fpage>1373</fpage>–<lpage>1378</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0895-4356(91)90098-T</pub-id><?supplied-pmid 1753268?><pub-id pub-id-type="pmid">1753268</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref027">
      <label>27</label>
      <mixed-citation publication-type="journal"><name><surname>Evaniew</surname><given-names>N</given-names></name>, <name><surname>Files</surname><given-names>C</given-names></name>, <name><surname>Smith</surname><given-names>C</given-names></name>, <name><surname>Bhandari</surname><given-names>M</given-names></name>, <name><surname>Ghert</surname><given-names>M</given-names></name>, <name><surname>Walsh</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey</article-title>. <source>The Spine Journal</source>. <year>2015</year>;<volume>15</volume>(<issue>10</issue>):<fpage>2188</fpage>–<lpage>2197</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.spinee.2015.06.004</pub-id><?supplied-pmid 26072464?><pub-id pub-id-type="pmid">26072464</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref028">
      <label>28</label>
      <mixed-citation publication-type="journal"><name><surname>Ridgeon</surname><given-names>EE</given-names></name>, <name><surname>Young</surname><given-names>PJ</given-names></name>, <name><surname>Bellomo</surname><given-names>R</given-names></name>, <name><surname>Mucchetti</surname><given-names>M</given-names></name>, <name><surname>Lembo</surname><given-names>R</given-names></name>, <name><surname>Landoni</surname><given-names>G</given-names></name>. <article-title>The fragility index in multicenter randomized controlled critical care trials</article-title>. <source>Critical Care Medicine</source>. <year>2016</year>;<volume>44</volume>(<issue>7</issue>):<fpage>1278</fpage>–<lpage>1284</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/CCM.0000000000001670</pub-id><?supplied-pmid 26963326?><pub-id pub-id-type="pmid">26963326</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref029">
      <label>29</label>
      <mixed-citation publication-type="journal"><name><surname>Matics</surname><given-names>TJ</given-names></name>, <name><surname>Khan</surname><given-names>N</given-names></name>, <name><surname>Jani</surname><given-names>P</given-names></name>, <name><surname>Kane</surname><given-names>JM</given-names></name>. <article-title>The fragility index in a cohort of pediatric randomized controlled trials</article-title>. <source>Journal of Clinical Medicine</source>. <year>2017</year>;<volume>6</volume>(<issue>8</issue>):<fpage>79</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/jcm6080079</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref030">
      <label>30</label>
      <mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>C</given-names></name>, <name><surname>Shamsudeen</surname><given-names>I</given-names></name>, <name><surname>Farrokhyar</surname><given-names>F</given-names></name>, <name><surname>Sabri</surname><given-names>K</given-names></name>. <article-title>Fragility of results in ophthalmology randomized controlled trials: a systematic review</article-title>. <source>Ophthalmology</source>. <year>2018</year>;<volume>125</volume>(<issue>5</issue>):<fpage>642</fpage>–<lpage>648</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2017.11.015</pub-id><?supplied-pmid 29241744?><pub-id pub-id-type="pmid">29241744</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref031">
      <label>31</label>
      <mixed-citation publication-type="journal"><name><surname>Del Paggio</surname><given-names>JC</given-names></name>, <name><surname>Tannock</surname><given-names>IF</given-names></name>. <article-title>The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis</article-title>. <source>The Lancet Oncology</source>. <year>2019</year>;<volume>20</volume>(<issue>8</issue>):<fpage>1065</fpage>–<lpage>1069</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30338-9</pub-id><?supplied-pmid 31296490?><pub-id pub-id-type="pmid">31296490</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref032">
      <label>32</label>
      <mixed-citation publication-type="journal"><name><surname>Tignanelli</surname><given-names>CJ</given-names></name>, <name><surname>Napolitano</surname><given-names>LM</given-names></name>. <article-title>The fragility index in randomized clinical trials as a means of optimizing patient care</article-title>. <source>JAMA Surgery</source>. <year>2019</year>;<volume>154</volume>(<issue>1</issue>):<fpage>74</fpage>–<lpage>79</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamasurg.2018.4318</pub-id><?supplied-pmid 30422256?><pub-id pub-id-type="pmid">30422256</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref033">
      <label>33</label>
      <mixed-citation publication-type="journal"><name><surname>Giannini</surname><given-names>A</given-names></name>, <name><surname>Di Donato</surname><given-names>V</given-names></name>, <name><surname>Schiavi</surname><given-names>MC</given-names></name>, <name><surname>May</surname><given-names>J</given-names></name>, <name><surname>Panici</surname><given-names>PB</given-names></name>, <name><surname>Congiu</surname><given-names>MA</given-names></name>. <article-title>Predictors of postoperative overall and severe complications after surgical treatment for endometrial cancer: the role of the fragility index</article-title>. <source>International Journal of Gynecology &amp; Obstetrics</source>. <year>2020</year>;<volume>148</volume>(<issue>2</issue>):<fpage>174</fpage>–<lpage>180</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ijgo.13020</pub-id><?supplied-pmid 31657456?><pub-id pub-id-type="pmid">31657456</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref034">
      <label>34</label>
      <mixed-citation publication-type="journal"><name><surname>Gurevitch</surname><given-names>J</given-names></name>, <name><surname>Koricheva</surname><given-names>J</given-names></name>, <name><surname>Nakagawa</surname><given-names>S</given-names></name>, <name><surname>Stewart</surname><given-names>G</given-names></name>. <article-title>Meta-analysis and the science of research synthesis</article-title>. <source>Nature</source>. <year>2018</year>;<volume>555</volume>(<issue>7695</issue>):<fpage>175</fpage>–<lpage>182</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature25753</pub-id><?supplied-pmid 29517004?><pub-id pub-id-type="pmid">29517004</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref035">
      <label>35</label>
      <mixed-citation publication-type="journal"><name><surname>Niforatos</surname><given-names>JD</given-names></name>, <name><surname>Weaver</surname><given-names>M</given-names></name>, <name><surname>Johansen</surname><given-names>ME</given-names></name>. <article-title>Assessment of publication trends of systematic reviews and randomized clinical trials, 1995 to 2017</article-title>. <source>JAMA Internal Medicine</source>. <year>2019</year>;<volume>179</volume>(<issue>11</issue>):<fpage>1593</fpage>–<lpage>1594</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamainternmed.2019.3013</pub-id><?supplied-pmid 31355871?><pub-id pub-id-type="pmid">31355871</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref036">
      <label>36</label>
      <mixed-citation publication-type="journal"><name><surname>Ioannidis</surname><given-names>JPA</given-names></name>. <article-title>The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses</article-title>. <source>The Milbank Quarterly</source>. <year>2016</year>;<volume>94</volume>(<issue>3</issue>):<fpage>485</fpage>–<lpage>514</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/1468-0009.12210</pub-id><?supplied-pmid 27620683?><pub-id pub-id-type="pmid">27620683</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref037">
      <label>37</label>
      <mixed-citation publication-type="journal"><name><surname>Naudet</surname><given-names>F</given-names></name>, <name><surname>Schuit</surname><given-names>E</given-names></name>, <name><surname>Ioannidis</surname><given-names>JPA</given-names></name>. <article-title>Overlapping network meta-analyses on the same topic: survey of published studies</article-title>. <source>International Journal of Epidemiology</source>. <year>2017</year>;<volume>46</volume>(<issue>6</issue>):<fpage>1999</fpage>–<lpage>2008</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/ije/dyx138</pub-id><?supplied-pmid 29040566?><pub-id pub-id-type="pmid">29040566</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref038">
      <label>38</label>
      <mixed-citation publication-type="journal"><name><surname>Hacke</surname><given-names>C</given-names></name>, <name><surname>Nunan</surname><given-names>D</given-names></name>. <article-title>Discrepancies in meta-analyses answering the same clinical question were hard to explain: a meta-epidemiological study</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2020</year>;<volume>119</volume>:<fpage>47</fpage>–<lpage>56</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2019.11.015</pub-id><?supplied-pmid 31783099?><pub-id pub-id-type="pmid">31783099</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref039">
      <label>39</label>
      <mixed-citation publication-type="journal"><name><surname>Sideri</surname><given-names>S</given-names></name>, <name><surname>Papageorgiou</surname><given-names>SN</given-names></name>, <name><surname>Eliades</surname><given-names>T</given-names></name>. <article-title>Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2018</year>;<volume>100</volume>:<fpage>103</fpage>–<lpage>110</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2018.01.003</pub-id><?supplied-pmid 29339215?><pub-id pub-id-type="pmid">29339215</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref040">
      <label>40</label>
      <mixed-citation publication-type="journal"><name><surname>Seidler</surname><given-names>AL</given-names></name>, <name><surname>Hunter</surname><given-names>KE</given-names></name>, <name><surname>Cheyne</surname><given-names>S</given-names></name>, <name><surname>Ghersi</surname><given-names>D</given-names></name>, <name><surname>Berlin</surname><given-names>JA</given-names></name>, <name><surname>Askie</surname><given-names>L</given-names></name>. <article-title>A guide to prospective meta-analysis</article-title>. <source>BMJ</source>. <year>2019</year>;<volume>367</volume>:<fpage>l5342</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.l5342</pub-id><?supplied-pmid 31597627?><pub-id pub-id-type="pmid">31597627</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref041">
      <label>41</label>
      <mixed-citation publication-type="journal"><name><surname>Atal</surname><given-names>I</given-names></name>, <name><surname>Porcher</surname><given-names>R</given-names></name>, <name><surname>Boutron</surname><given-names>I</given-names></name>, <name><surname>Ravaud</surname><given-names>P</given-names></name>. <article-title>The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2019</year>;<volume>111</volume>:<fpage>32</fpage>–<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2019.03.012</pub-id><?supplied-pmid 30940600?><pub-id pub-id-type="pmid">30940600</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref042">
      <label>42</label>
      <mixed-citation publication-type="journal"><name><surname>Xing</surname><given-names>A</given-names></name>, <name><surname>Chu</surname><given-names>H</given-names></name>, <name><surname>Lin</surname><given-names>L</given-names></name>. <article-title>Fragility index of network meta-analysis with application to smoking cessation data</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2020</year>;<volume>127</volume>:<fpage>29</fpage>–<lpage>39</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2020.07.003</pub-id><?supplied-pmid 32659361?><pub-id pub-id-type="pmid">32659361</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref043">
      <label>43</label>
      <mixed-citation publication-type="journal"><name><surname>Carter</surname><given-names>RE</given-names></name>, <name><surname>McKie</surname><given-names>PM</given-names></name>, <name><surname>Storlie</surname><given-names>CB</given-names></name>. <article-title>The fragility index: a <italic toggle="yes">P</italic>-value in sheep’s clothing?</article-title><source>European Heart Journal</source>. <year>2017</year>;<volume>38</volume>(<issue>5</issue>):<fpage>346</fpage>–<lpage>348</lpage>. <?supplied-pmid 28417139?><pub-id pub-id-type="pmid">28417139</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref044">
      <label>44</label>
      <mixed-citation publication-type="journal"><name><surname>Acuna</surname><given-names>SA</given-names></name>, <name><surname>Sue-Chue-Lam</surname><given-names>C</given-names></name>, <name><surname>Dossa</surname><given-names>F</given-names></name>. <article-title>The fragility index—<italic toggle="yes">P</italic> values reimagined, flaws and all</article-title>. <source>JAMA Surgery</source>. <year>2019</year>;<volume>154</volume>(<issue>7</issue>):<fpage>674</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamasurg.2019.0567</pub-id><?supplied-pmid 30994897?><pub-id pub-id-type="pmid">30994897</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref045">
      <label>45</label>
      <mixed-citation publication-type="journal"><name><surname>Tignanelli</surname><given-names>CJ</given-names></name>, <name><surname>Napolitano</surname><given-names>LM</given-names></name>. <article-title>The fragility index—<italic toggle="yes">P</italic> values reimagined, flaws and all—reply</article-title>. <source>JAMA Surgery</source>. <year>2019</year>;<volume>154</volume>(<issue>7</issue>):<fpage>674</fpage>–<lpage>675</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamasurg.2019.0567</pub-id><?supplied-pmid 30994914?><pub-id pub-id-type="pmid">30994914</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref046">
      <label>46</label>
      <mixed-citation publication-type="journal"><name><surname>Walter</surname><given-names>SD</given-names></name>, <name><surname>Thabane</surname><given-names>L</given-names></name>, <name><surname>Briel</surname><given-names>M</given-names></name>. <article-title>The fragility of trial results involves more than statistical significance alone</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2020</year>;<volume>124</volume>:<fpage>34</fpage>–<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2020.02.011</pub-id><?supplied-pmid 32298777?><pub-id pub-id-type="pmid">32298777</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref047">
      <label>47</label>
      <mixed-citation publication-type="journal"><name><surname>Bomze</surname><given-names>D</given-names></name>, <name><surname>Meirson</surname><given-names>T</given-names></name>. <article-title>A critique of the fragility index</article-title>. <source>The Lancet Oncology</source>. <year>2019</year>;<volume>20</volume>(<issue>10</issue>):<fpage>e551</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30582-0</pub-id><?supplied-pmid 31578993?><pub-id pub-id-type="pmid">31578993</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref048">
      <label>48</label>
      <mixed-citation publication-type="journal"><name><surname>Desnoyers</surname><given-names>A</given-names></name>, <name><surname>Nadler</surname><given-names>MB</given-names></name>, <name><surname>Wilson</surname><given-names>BE</given-names></name>, <name><surname>Amir</surname><given-names>E</given-names></name>. <article-title>A critique of the fragility index</article-title>. <source>The Lancet Oncology</source>. <year>2019</year>;<volume>20</volume>(<issue>10</issue>):<fpage>e552</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30583-2</pub-id><?supplied-pmid 31578994?><pub-id pub-id-type="pmid">31578994</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref049">
      <label>49</label>
      <mixed-citation publication-type="journal"><name><surname>Machado</surname><given-names>T</given-names></name>, <name><surname>Duarte</surname><given-names>GS</given-names></name>, <name><surname>Gon¸calves</surname><given-names>N</given-names></name>, <name><surname>Ferreira</surname><given-names>JJ</given-names></name>, <name><surname>Costa</surname><given-names>J</given-names></name>. <article-title>A critique of the fragility index</article-title>. <source>The Lancet Oncology</source>. <year>2019</year>;<volume>20</volume>(<issue>10</issue>):<fpage>e553</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30581-9</pub-id><?supplied-pmid 31578995?><pub-id pub-id-type="pmid">31578995</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref050">
      <label>50</label>
      <mixed-citation publication-type="other">Johnson K. fragilityindex: Fragility Index. 2017. Available from: <ext-link xlink:href="https://github.com/kippjohnson/fragilityindex" ext-link-type="uri">https://github.com/kippjohnson/fragilityindex</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref051">
      <label>51</label>
      <mixed-citation publication-type="other">Linden A. metafrag: Stata Module to Compute the Fragility Index for Meta-Analysis. 2019. Available from: <ext-link xlink:href="https://EconPapers.repec.org/RePEc:boc:bocode:s458717" ext-link-type="uri">https://EconPapers.repec.org/RePEc:boc:bocode:s458717</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref052">
      <label>52</label>
      <mixed-citation publication-type="other">Lin L, Chu H. fragility: Assessing and Visualizing Fragility of Clinical Results with Binary Outcomes. 2020. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package=fragility" ext-link-type="uri">https://CRAN.R-project.org/package=fragility</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref053">
      <label>53</label>
      <mixed-citation publication-type="book"><name><surname>Agresti</surname><given-names>A</given-names></name>. <source>Categorical Data Analysis</source>. <edition>3rd ed</edition>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>; <year>2013</year>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref054">
      <label>54</label>
      <mixed-citation publication-type="journal"><name><surname>Walter</surname><given-names>S</given-names></name>. <article-title>The estimation and interpretation of attributable risk in health research</article-title>. <source>Biometrics</source>. <year>1976</year>;<volume>32</volume>(<issue>4</issue>):<fpage>829</fpage>–<lpage>849</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2307/2529268</pub-id><?supplied-pmid 1009228?><pub-id pub-id-type="pmid">1009228</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref055">
      <label>55</label>
      <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>L</given-names></name>. <article-title>Factors that impact fragility index and their visualizations</article-title>. <source>Journal of Evaluation in Clinical Practice</source>. <year>2021</year>;<volume>27</volume>(<issue>2</issue>):<fpage>356</fpage>–<lpage>364</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/jep.13428</pub-id><?supplied-pmid 32524768?><pub-id pub-id-type="pmid">32524768</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref056">
      <label>56</label>
      <mixed-citation publication-type="journal"><name><surname>Benjamin</surname><given-names>DJ</given-names></name>, <name><surname>Berger</surname><given-names>JO</given-names></name>, <name><surname>Johannesson</surname><given-names>M</given-names></name>, <name><surname>Nosek</surname><given-names>BA</given-names></name>, <name><surname>Wagenmakers</surname><given-names>EJ</given-names></name>, <name><surname>Berk</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Redefine statistical significance</article-title>. <source>Nature Human Behaviour</source>. <year>2018</year>;<volume>2</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41562-017-0189-z</pub-id><?supplied-pmid 30980045?><pub-id pub-id-type="pmid">30980045</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref057">
      <label>57</label>
      <mixed-citation publication-type="journal"><name><surname>Ioannidis</surname><given-names>JPA</given-names></name>. <article-title>The proposal to lower <italic toggle="yes">P</italic> value thresholds to.005</article-title>. <source>JAMA</source>. <year>2018</year>;<volume>319</volume>(<issue>14</issue>):<fpage>1429</fpage>–<lpage>1430</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2018.1536</pub-id><?supplied-pmid 29566133?><pub-id pub-id-type="pmid">29566133</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref058">
      <label>58</label>
      <mixed-citation publication-type="journal"><name><surname>Ahmed</surname><given-names>W</given-names></name>, <name><surname>Fowler</surname><given-names>RA</given-names></name>, <name><surname>McCredie</surname><given-names>VA</given-names></name>. <article-title>Does sample size matter when interpreting the fragility index?</article-title><source>Critical Care Medicine</source>. <year>2016</year>;<volume>44</volume>(<issue>11</issue>):<fpage>e1142</fpage>–<lpage>e1143</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/CCM.0000000000001976</pub-id><?supplied-pmid 27755081?><pub-id pub-id-type="pmid">27755081</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref059">
      <label>59</label>
      <mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>TC</given-names></name>, <name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>, <name><surname>Thomas</surname><given-names>A</given-names></name>. <article-title>Bayesian approaches to random-effects meta-analysis: a comparative study</article-title>. <source>Statistics in Medicine</source>. <year>1995</year>;<volume>14</volume>(<issue>24</issue>):<fpage>2685</fpage>–<lpage>2699</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.4780142408</pub-id><?supplied-pmid 8619108?><pub-id pub-id-type="pmid">8619108</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref060">
      <label>60</label>
      <mixed-citation publication-type="journal"><name><surname>Warn</surname><given-names>DE</given-names></name>, <name><surname>Thompson</surname><given-names>SG</given-names></name>, <name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>. <article-title>Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales</article-title>. <source>Statistics in Medicine</source>. <year>2002</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1601</fpage>–<lpage>1623</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.1189</pub-id><?supplied-pmid 12111922?><pub-id pub-id-type="pmid">12111922</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref061">
      <label>61</label>
      <mixed-citation publication-type="journal"><name><surname>Stijnen</surname><given-names>T</given-names></name>, <name><surname>Hamza</surname><given-names>TH</given-names></name>, <name><surname>Özdemir</surname><given-names>P</given-names></name>. <article-title>Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data</article-title>. <source>Statistics in Medicine</source>. <year>2010</year>;<volume>29</volume>(<issue>29</issue>):<fpage>3046</fpage>–<lpage>3067</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.4040</pub-id><?supplied-pmid 20827667?><pub-id pub-id-type="pmid">20827667</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref062">
      <label>62</label>
      <mixed-citation publication-type="journal"><name><surname>Chu</surname><given-names>H</given-names></name>, <name><surname>Nie</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Sun</surname><given-names>W</given-names></name>. <article-title>Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk</article-title>. <source>Statistical Methods in Medical Research</source>. <year>2012</year>;<volume>21</volume>(<issue>6</issue>):<fpage>621</fpage>–<lpage>633</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/0962280210393712</pub-id><?supplied-pmid 21177306?><pub-id pub-id-type="pmid">21177306</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref063">
      <label>63</label>
      <mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>D</given-names></name>, <name><surname>Law</surname><given-names>M</given-names></name>, <name><surname>Stijnen</surname><given-names>T</given-names></name>, <name><surname>Viechtbauer</surname><given-names>W</given-names></name>, <name><surname>White</surname><given-names>IR</given-names></name>. <article-title>A comparison of seven random-effects models for meta-analyses that estimate the summary odds ratio</article-title>. <source>Statistics in Medicine</source>. <year>2018</year>;<volume>37</volume>(<issue>7</issue>):<fpage>1059</fpage>–<lpage>1085</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.7588</pub-id><?supplied-pmid 29315733?><pub-id pub-id-type="pmid">29315733</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref064">
      <label>64</label>
      <mixed-citation publication-type="journal"><name><surname>Borenstein</surname><given-names>M</given-names></name>, <name><surname>Hedges</surname><given-names>LV</given-names></name>, <name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Rothstein</surname><given-names>HR</given-names></name>. <article-title>A basic introduction to fixed-effect and random-effects models for meta-analysis</article-title>. <source>Research Synthesis Methods</source>. <year>2010</year>;<volume>1</volume>(<issue>2</issue>):<fpage>97</fpage>–<lpage>111</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jrsm.12</pub-id><?supplied-pmid 26061376?><pub-id pub-id-type="pmid">26061376</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref065">
      <label>65</label>
      <mixed-citation publication-type="journal"><name><surname>Riley</surname><given-names>RD</given-names></name>, <name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Deeks</surname><given-names>JJ</given-names></name>. <article-title>Interpretation of random effects meta-analyses</article-title>. <source>BMJ</source>. <year>2011</year>;<volume>342</volume>:<fpage>d549</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.d549</pub-id><?supplied-pmid 21310794?><pub-id pub-id-type="pmid">21310794</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref066">
      <label>66</label>
      <mixed-citation publication-type="journal"><name><surname>DerSimonian</surname><given-names>R</given-names></name>, <name><surname>Laird</surname><given-names>N</given-names></name>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Controlled Clinical Trials</source>. <year>1986</year>;<volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>188</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id><?supplied-pmid 3802833?><pub-id pub-id-type="pmid">3802833</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref067">
      <label>67</label>
      <mixed-citation publication-type="journal"><name><surname>Cornell</surname><given-names>JE</given-names></name>, <name><surname>Mulrow</surname><given-names>CD</given-names></name>, <name><surname>Localio</surname><given-names>R</given-names></name>, <name><surname>Stack</surname><given-names>CB</given-names></name>, <name><surname>Meibohm</surname><given-names>AR</given-names></name>, <name><surname>Guallar</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Random-effects meta-analysis of inconsistent effects: a time for change</article-title>. <source>Annals of Internal Medicine</source>. <year>2014</year>;<volume>160</volume>(<issue>4</issue>):<fpage>267</fpage>–<lpage>270</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7326/M13-2886</pub-id><?supplied-pmid 24727843?><pub-id pub-id-type="pmid">24727843</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref068">
      <label>68</label>
      <mixed-citation publication-type="journal"><name><surname>Langan</surname><given-names>D</given-names></name>, <name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Jackson</surname><given-names>D</given-names></name>, <name><surname>Bowden</surname><given-names>J</given-names></name>, <name><surname>Veroniki</surname><given-names>AA</given-names></name>, <name><surname>Kontopantelis</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses</article-title>. <source>Research Synthesis Methods</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>83</fpage>–<lpage>98</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jrsm.1316</pub-id><?supplied-pmid 30067315?><pub-id pub-id-type="pmid">30067315</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref069">
      <label>69</label>
      <mixed-citation publication-type="journal"><name><surname>Hartung</surname><given-names>J</given-names></name>, <name><surname>Knapp</surname><given-names>G</given-names></name>. <article-title>A refined method for the meta-analysis of controlled clinical trials with binary outcome</article-title>. <source>Statistics in Medicine</source>. <year>2001</year>;<volume>20</volume>(<issue>24</issue>):<fpage>3875</fpage>–<lpage>3889</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.1009</pub-id><?supplied-pmid 11782040?><pub-id pub-id-type="pmid">11782040</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref070">
      <label>70</label>
      <mixed-citation publication-type="journal"><name><surname>Sidik</surname><given-names>K</given-names></name>, <name><surname>Jonkman</surname><given-names>JN</given-names></name>. <article-title>A simple confidence interval for meta-analysis</article-title>. <source>Statistics in Medicine</source>. <year>2002</year>;<volume>21</volume>(<issue>21</issue>):<fpage>3153</fpage>–<lpage>3159</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.1262</pub-id><?supplied-pmid 12375296?><pub-id pub-id-type="pmid">12375296</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref071">
      <label>71</label>
      <mixed-citation publication-type="journal"><name><surname>IntHout</surname><given-names>J</given-names></name>, <name><surname>Ioannidis</surname><given-names>JPA</given-names></name>, <name><surname>Borm</surname><given-names>GF</given-names></name>. <article-title>The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method</article-title>. <source>BMC Medical Research Methodology</source>. <year>2014</year>;<volume>14</volume>(<issue>1</issue>):<fpage>25</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2288-14-25</pub-id><?supplied-pmid 24548571?><pub-id pub-id-type="pmid">24548571</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref072">
      <label>72</label>
      <mixed-citation publication-type="journal"><name><surname>Lumley</surname><given-names>T</given-names></name>. <article-title>Network meta-analysis for indirect treatment comparisons</article-title>. <source>Statistics in Medicine</source>. <year>2002</year>;<volume>21</volume>(<issue>16</issue>):<fpage>2313</fpage>–<lpage>2324</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.1201</pub-id><?supplied-pmid 12210616?><pub-id pub-id-type="pmid">12210616</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref073">
      <label>73</label>
      <mixed-citation publication-type="journal"><name><surname>Cipriani</surname><given-names>A</given-names></name>, <name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Geddes</surname><given-names>JR</given-names></name>, <name><surname>Salanti</surname><given-names>G</given-names></name>. <article-title>Conceptual and technical challenges in network meta-analysis</article-title>. <source>Annals of Internal Medicine</source>. <year>2013</year>;<volume>159</volume>(<issue>2</issue>):<fpage>130</fpage>–<lpage>137</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7326/0003-4819-159-2-201307160-00008</pub-id><?supplied-pmid 23856683?><pub-id pub-id-type="pmid">23856683</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref074">
      <label>74</label>
      <mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Welton</surname><given-names>NJ</given-names></name>. <article-title>Network meta-analysis: a norm for comparative effectiveness?</article-title><source>The Lancet</source>. <year>2015</year>;<volume>386</volume>(<issue>9994</issue>):<fpage>628</fpage>–<lpage>630</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref075">
      <label>75</label>
      <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Chu</surname><given-names>H</given-names></name>, <name><surname>Hodges</surname><given-names>JS</given-names></name>. <article-title>Sensitivity to excluding treatments in network meta-analysis</article-title>. <source>Epidemiology</source>. <year>2016</year>;<volume>27</volume>(<issue>4</issue>):<fpage>562</fpage>–<lpage>569</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/EDE.0000000000000482</pub-id><?supplied-pmid 27007642?><pub-id pub-id-type="pmid">27007642</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref076">
      <label>76</label>
      <mixed-citation publication-type="journal"><name><surname>Riley</surname><given-names>RD</given-names></name>, <name><surname>Jackson</surname><given-names>D</given-names></name>, <name><surname>Salanti</surname><given-names>G</given-names></name>, <name><surname>Burke</surname><given-names>DL</given-names></name>, <name><surname>Price</surname><given-names>M</given-names></name>, <name><surname>Kirkham</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples</article-title>. <source>BMJ</source>. <year>2017</year>;<volume>358</volume>:<fpage>j3932</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.j3932</pub-id><?supplied-pmid 28903924?><pub-id pub-id-type="pmid">28903924</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref077">
      <label>77</label>
      <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Xing</surname><given-names>A</given-names></name>, <name><surname>Kofler</surname><given-names>MJ</given-names></name>, <name><surname>Murad</surname><given-names>MH</given-names></name>. <article-title>Borrowing of strength from indirect evidence in 40 network meta-analyses</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2019</year>;<volume>106</volume>:<fpage>41</fpage>–<lpage>49</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2018.10.007</pub-id><?supplied-pmid 30342086?><pub-id pub-id-type="pmid">30342086</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref078">
      <label>78</label>
      <mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>G</given-names></name>, <name><surname>Ades</surname><given-names>AE</given-names></name>. <article-title>Combination of direct and indirect evidence in mixed treatment comparisons</article-title>. <source>Statistics in Medicine</source>. <year>2004</year>;<volume>23</volume>(<issue>20</issue>):<fpage>3105</fpage>–<lpage>3124</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.1875</pub-id><?supplied-pmid 15449338?><pub-id pub-id-type="pmid">15449338</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref079">
      <label>79</label>
      <mixed-citation publication-type="journal"><name><surname>Rücker</surname><given-names>G</given-names></name>. <article-title>Network meta-analysis, electrical networks and graph theory</article-title>. <source>Research Synthesis Methods</source>. <year>2012</year>;<volume>3</volume>(<issue>4</issue>):<fpage>312</fpage>–<lpage>324</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jrsm.1058</pub-id><?supplied-pmid 26053424?><pub-id pub-id-type="pmid">26053424</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref080">
      <label>80</label>
      <mixed-citation publication-type="journal"><name><surname>White</surname><given-names>IR</given-names></name>, <name><surname>Barrett</surname><given-names>JK</given-names></name>, <name><surname>Jackson</surname><given-names>D</given-names></name>, <name><surname>Higgins</surname><given-names>JPT</given-names></name>. <article-title>Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression</article-title>. <source>Research Synthesis Methods</source>. <year>2012</year>;<volume>3</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>125</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jrsm.1045</pub-id><?supplied-pmid 26062085?><pub-id pub-id-type="pmid">26062085</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref081">
      <label>81</label>
      <mixed-citation publication-type="journal"><name><surname>Dias</surname><given-names>S</given-names></name>, <name><surname>Sutton</surname><given-names>AJ</given-names></name>, <name><surname>Ades</surname><given-names>AE</given-names></name>, <name><surname>Welton</surname><given-names>NJ</given-names></name>. <article-title>Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials</article-title>. <source>Medical Decision Making</source>. <year>2013</year>;<volume>33</volume>(<issue>5</issue>):<fpage>607</fpage>–<lpage>617</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/0272989X12458724</pub-id><?supplied-pmid 23104435?><pub-id pub-id-type="pmid">23104435</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref082">
      <label>82</label>
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Carlin</surname><given-names>BP</given-names></name>, <name><surname>Neaton</surname><given-names>JD</given-names></name>, <name><surname>Soon</surname><given-names>GG</given-names></name>, <name><surname>Nie</surname><given-names>L</given-names></name>, <name><surname>Kane</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Network meta-analysis of randomized clinical trials: reporting the proper summaries</article-title>. <source>Clinical Trials</source>. <year>2014</year>;<volume>11</volume>(<issue>2</issue>):<fpage>246</fpage>–<lpage>262</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1740774513498322</pub-id><?supplied-pmid 24096635?><pub-id pub-id-type="pmid">24096635</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref083">
      <label>83</label>
      <mixed-citation publication-type="journal"><name><surname>Efthimiou</surname><given-names>O</given-names></name>, <name><surname>Debray</surname><given-names>TPA</given-names></name>, <name><surname>van Valkenhoef</surname><given-names>G</given-names></name>, <name><surname>Trelle</surname><given-names>S</given-names></name>, <name><surname>Panayidou</surname><given-names>K</given-names></name>, <name><surname>Moons</surname><given-names>KGM</given-names></name>, <etal>et al</etal>. <article-title>GetReal in network meta-analysis: a review of the methodology</article-title>. <source>Research Synthesis Methods</source>. <year>2016</year>;<volume>7</volume>(<issue>3</issue>):<fpage>236</fpage>–<lpage>263</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jrsm.1195</pub-id><?supplied-pmid 26754852?><pub-id pub-id-type="pmid">26754852</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref084">
      <label>84</label>
      <mixed-citation publication-type="journal"><name><surname>Hong</surname><given-names>H</given-names></name>, <name><surname>Chu</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Carlin</surname><given-names>BP</given-names></name>. <article-title>A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons</article-title>. <source>Research Synthesis Methods</source>. <year>2016</year>;<volume>7</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jrsm.1153</pub-id><?supplied-pmid 26536149?><pub-id pub-id-type="pmid">26536149</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref085">
      <label>85</label>
      <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Hodges</surname><given-names>JS</given-names></name>, <name><surname>Chu</surname><given-names>H</given-names></name>. <article-title>Performing arm-based network meta-analysis in R with the pcnetmeta package</article-title>. <source>Journal of Statistical Software</source>. <year>2017</year>;<volume>80</volume>(<issue>5</issue>):<fpage>1</fpage>–<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18637/jss.v080.i05</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref086">
      <label>86</label>
      <mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>D</given-names></name>, <name><surname>Bujkiewicz</surname><given-names>S</given-names></name>, <name><surname>Law</surname><given-names>M</given-names></name>, <name><surname>Riley</surname><given-names>RD</given-names></name>, <name><surname>White</surname><given-names>IR</given-names></name>. <article-title>A matrix-based method of moments for fitting multivariate network meta-analysis models with multiple outcomes and random inconsistency effects</article-title>. <source>Biometrics</source>. <year>2018</year>;<volume>74</volume>(<issue>2</issue>):<fpage>548</fpage>–<lpage>556</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/biom.12762</pub-id><?supplied-pmid 28806485?><pub-id pub-id-type="pmid">28806485</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref087">
      <label>87</label>
      <mixed-citation publication-type="journal"><name><surname>White</surname><given-names>IR</given-names></name>, <name><surname>Turner</surname><given-names>RM</given-names></name>, <name><surname>Karahalios</surname><given-names>A</given-names></name>, <name><surname>Salanti</surname><given-names>G</given-names></name>. <article-title>A comparison of arm-based and contrast-based models for network meta-analysis</article-title>. <source>Statistics in Medicine</source>. <year>2019</year>;<volume>38</volume>(<issue>27</issue>):<fpage>5197</fpage>–<lpage>5213</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.8360</pub-id><?supplied-pmid 31583750?><pub-id pub-id-type="pmid">31583750</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref088">
      <label>88</label>
      <mixed-citation publication-type="other">Viechtbauer W. metafor: Meta-Analysis Package for R. 2020. Available <ext-link xlink:href="https://CRAN.R-project.org/package=metafor" ext-link-type="uri">https://CRAN.R-project.org/package=metafor</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref089">
      <label>89</label>
      <mixed-citation publication-type="other">Rücker G, Krahn U, König J, Efthimiou O, Schwarzer G. netmeta: Network Meta-Analysis using Frequentist Methods. 2020. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package=netmeta" ext-link-type="uri">https://CRAN.R-project.org/package=netmeta</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref090">
      <label>90</label>
      <mixed-citation publication-type="journal"><name><surname>Cipriani</surname><given-names>A</given-names></name>, <name><surname>Furukawa</surname><given-names>TA</given-names></name>, <name><surname>Salanti</surname><given-names>G</given-names></name>, <name><surname>Chaimani</surname><given-names>A</given-names></name>, <name><surname>Atkinson</surname><given-names>LZ</given-names></name>, <name><surname>Ogawa</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis</article-title>. <source>The Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10128</issue>):<fpage>1357</fpage>–<lpage>1366</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(17)32802-7</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref091">
      <label>91</label>
      <mixed-citation publication-type="journal"><name><surname>Feinberg</surname><given-names>J</given-names></name>, <name><surname>Nielsen</surname><given-names>EE</given-names></name>, <name><surname>Korang</surname><given-names>SK</given-names></name>, <name><surname>Halberg Engell</surname><given-names>K</given-names></name>, <name><surname>Nielsen</surname><given-names>MS</given-names></name>, <name><surname>Zhang</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Nutrition support in hospitalised adults at nutritional risk</article-title>. <source>Cochrane Database of Systematic Reviews</source>. <year>2017</year>;<volume>5</volume>:Art. No.: CD011598. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/14651858.CD011598.pub2</pub-id><?supplied-pmid 28524930?><pub-id pub-id-type="pmid">28524930</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref092">
      <label>92</label>
      <mixed-citation publication-type="journal"><name><surname>Woods</surname><given-names>BS</given-names></name>, <name><surname>Hawkins</surname><given-names>N</given-names></name>, <name><surname>Scott</surname><given-names>DA</given-names></name>. <article-title>Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial</article-title>. <source>BMC Medical Research Methodology</source>. <year>2010</year>;<volume>10</volume>:<fpage>54</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2288-10-54</pub-id><?supplied-pmid 20537177?><pub-id pub-id-type="pmid">20537177</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref093">
      <label>93</label>
      <mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>G</given-names></name>, <name><surname>Ades</surname><given-names>A</given-names></name>. <article-title>Assessing evidence inconsistency in mixed treatment comparisons</article-title>. <source>Journal of the American Statistical Association</source>. <year>2006</year>;<volume>101</volume>(<issue>474</issue>):<fpage>447</fpage>–<lpage>459</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1198/016214505000001302</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref094">
      <label>94</label>
      <mixed-citation publication-type="journal"><name><surname>Hasselblad</surname><given-names>V</given-names></name>. <article-title>Meta-analysis of multitreatment studies</article-title>. <source>Medical Decision Making</source>. <year>1998</year>;<volume>18</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>43</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/0272989X9801800110</pub-id><?supplied-pmid 9456207?><pub-id pub-id-type="pmid">9456207</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref095">
      <label>95</label>
      <mixed-citation publication-type="journal"><name><surname>Viechtbauer</surname><given-names>W</given-names></name>. <article-title>Conducting meta-analyses in R with the metafor package</article-title>. <source>Journal of Statistical Software</source>. <year>2010</year>;<volume>36</volume>(<issue>3</issue>):<fpage>1</fpage>–<lpage>48</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18637/jss.v036.i03</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0268754.ref096">
      <label>96</label>
      <mixed-citation publication-type="other">Lemon J, Bolker B, Oom S, Klein E, Rowlingson B, Wickham H, et al. plotrix: Various Plotting Functions. 2020. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package=plotrix" ext-link-type="uri">https://CRAN.R-project.org/package=plotrix</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref097">
      <label>97</label>
      <mixed-citation publication-type="other">Schwarzer G. meta: General Package for Meta-Analysis. 2020. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package=meta" ext-link-type="uri">https://CRAN.R-project.org/package=meta</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref098">
      <label>98</label>
      <mixed-citation publication-type="other">van Valkenhoef G, Kuiper J. gemtc: Network Meta-Analysis Using Bayesian Methods. 2020. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package=gemtc" ext-link-type="uri">https://CRAN.R-project.org/package=gemtc</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref099">
      <label>99</label>
      <mixed-citation publication-type="other">Lin L, Zhang J, Chu H. pcnetmeta: Patient-Centered Network Meta-Analysis. 2017. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package=pcnetmeta" ext-link-type="uri">https://CRAN.R-project.org/package=pcnetmeta</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0268754.ref100">
      <label>100</label>
      <mixed-citation publication-type="journal"><name><surname>Caldwell</surname><given-names>JME</given-names></name>, <name><surname>Youssefzadeh</surname><given-names>K</given-names></name>, <name><surname>Limpisvasti</surname><given-names>O</given-names></name>. <article-title>A method for calculating the fragility index of continuous outcomes</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2021</year>;<volume>136</volume>:<fpage>20</fpage>–<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2021.02.023</pub-id><?supplied-pmid 33684509?><pub-id pub-id-type="pmid">33684509</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0268754.r001" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0268754.r001</article-id>
    <title-group>
      <article-title>Decision Letter 0</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gagniuc</surname>
          <given-names>Paul Aurelian</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 Paul Aurelian Gagniuc</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Paul Aurelian Gagniuc</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0268754" id="rel-obj001" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>0</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">23 Nov 2021</named-content>
    </p>
    <p><!-- <div> -->PONE-D-21-32479<!-- </div> --><!-- <div> -->Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package<!-- </div> --><!-- <div> -->PLOS ONE</p>
    <p>Dear Dr. Lin,</p>
    <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
    <p>Please submit your revised manuscript by Jan 07 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
    <p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p>
    <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
    <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
    <p>We look forward to receiving your revised manuscript.</p>
    <p>Kind regards,</p>
    <p>Paul Aurelian Gagniuc, PhD</p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
    <p>Journal Requirements:</p>
    <p>When submitting your revision, we need you to address these additional requirements.</p>
    <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
    <p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p>
    <p>
      <ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
    </p>
    <p>2. Thank you for stating the following financial disclosure:</p>
    <p>“This research was supported in part by the U.S. National Institutes of Health/National Library of Medicine grant R01 LM012982 (LL and HC) and National Institutes of Health/National Center for Advancing Translational Sciences grant UL1 TR001427 (LL). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”</p>
    <p>Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."</p>
    <p>If this statement is not correct you must amend it as needed.</p>
    <p>Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.</p>
    <p>3. Thank you for stating the following in the Acknowledgments Section of your manuscript:</p>
    <p>“This research was supported in part by the U.S. National Institutes of Health/National Library of Medicine grant R01 LM012982 (LL and HC) and National Institutes of Health/National Center for Advancing Translational Sciences grant UL1 TR001427 (LL). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”</p>
    <p>We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.</p>
    <p>Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:</p>
    <p>“This research was supported in part by the U.S. National Institutes of Health/National Library of Medicine grant R01 LM012982 (LL and HC) and National Institutes of Health/National Center for Advancing Translational Sciences grant UL1 TR001427 (LL). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”</p>
    <p>Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."</p>
    <p>Please include your amended statements within your cover letter; we will change the online submission form on your behalf.</p>
    <p>4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <ext-link xlink:href="http://journals.plos.org/plosone/s/data-availability" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability</ext-link>.</p>
    <p>Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <ext-link xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories</ext-link>. Any potentially identifying patient information must be fully anonymized.</p>
    <p>Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <ext-link xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions</ext-link>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.</p>
    <p>We will update your Data Availability statement to reflect the information you provide in your cover letter.</p>
    <p>[Note: HTML markup is below. Please do not edit.]</p>
    <p>Reviewers' comments:</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <!-- <font color="black"> -->
      <bold>Comments to the Author</bold>
    </p>
    <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
    <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>Reviewer #3: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->2. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>Reviewer #3: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
    <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.<!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>Reviewer #3: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
    <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>Reviewer #3: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->5. Review Comments to the Author</p>
    <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
    <p>Reviewer #1: The Fragility Index (FI) is an intuitive statistical metric used primarily in the medical literature to assess the statistical significance of study results. Lin et a. has developed an R package to calculate the frailty index in an user-friendly way. It allows both to calculate the FI of the meta-analysis (MA) to compare couple of treatments at a time, e.g. the efficacy of a drug versus placebo - and Network-Meta-Analysis (NMA), to compare multiple treatments - for example the efficacy of multiple drugs.</p>
    <p>The first part of the article is devoted to the mathematical definition of the FI index and provides a brief overview of the methods commonly used to calculate the pvalue (Fisher's exact test, chi-squared, OR, RR and RD), and to quantify the FI for multiple levels of significance. The second part presents the functions of the R package and the applications to (i) individual clinical study (ii) pairwise meta analysis (iii) network meta analysis (iv) fragility at multiple levels of significance (v) fragility of multiple datasets .</p>
    <p>The paper is overall well written, although the following points would deserve to be addressed in addition to the more minor points mentioned below.</p>
    <p>Majors:</p>
    <p>* section “Assessing Fragility” (from line 375 to line 723). Here the authors describe the functions of the R package with all the options. While this is interesting when using the package, it’s really hard to follow this section when reading the paper. Moreover It seems redundant with the documentation available at <ext-link xlink:href="https://cran.r-project.org/web/packages/fragility/fragility.pdf" ext-link-type="uri">https://cran.r-project.org/web/packages/fragility/fragility.pdf</ext-link>. The authors should consider rewriting this section, focusing on a few applications rather than listing all possible options .</p>
    <p>* Fig 2. is not clear. The authors should give more details on how the plot is generated and how to interpret it. Same comment for Fig.3</p>
    <p>* section "Example of assessing fragility of mutliple dataset" (from line 1004 to line 1254). Here the authors plot the fragility measures of all trials. I find it difficult to appreciate the novelty of this section as the authors describe how to make the plots, but not how to interpret them. The authors should should consider rewriting this section.</p>
    <p>Minors:</p>
    <p>*There is no link to the CRAN page of the package (and so it is not easy to find the documentation) and it's not explained how to install it.</p>
    <p>*Caption of Fig.1 is not clear. The authors should expand it and provide more details</p>
    <p>Reviewer #2: This was an interesting manuscript describing a new R package for calculating and visualizing fragility of clinical studies, with clear worked examples to introduce the usage of the package.</p>
    <p>I have a few questions/comments which, if addressed, would hopefully improve the manuscript.</p>
    <p>1. Page 18: The author showed an example of an individual clinical study with demonstration of the number of modifications in each group for achieving non-significance altered from significance. However, in my perspective, the direction of modification in each group is less clear by indicating the number of non-events changed in group 0 and the number of events changed in group 1. For example, maybe it would be clearer to demonstrate the number of events add/minus in group 0 and the number of events add/minus in group 1?</p>
    <p>2. Page 38: “Similar to assessing the fragility of an individual study and a pairwise MA, the FI is</p>
    <p>defined as NA if the significance or non-significance cannot be altered.” Suppose we have three groups A,B and C, if the significance of comparing B vs A (or non-significance) cannot be altered by modifications in groups A and B, will you further consider modifications in group C or directly define it as NA. Maybe worth notify this somewhere.</p>
    <p>3. Page 7: The explanation of deriving FI for MA under each step is not intuitive in my perspective. Could you please demonstrate a simple example here or illustrate a few iterations in the Example of a pairwise meta-analysis section?</p>
    <p>4. The authors considered several tests with calculation of the corresponding FI. In practice, should we expect the FI to be similar across these tests? If the FI is very different among these tests, what does it imply?</p>
    <p>Reviewer #3: The authors introduce an R package called fragility. The package contains functions and visualization tools that aid researchers in calculating the fragility index of their findings. An FI is a number that indicates how many observations must be shifted from one study sample to another for the statistical conclusion of the study to change. For example, if FI = 3, then three observations have to move from "event" to "non event" in order for a study in which the null hypothesis was rejected to become a study in which the null hypothesis is not rejected.</p>
    <p>The package is necessary and the write up describes it in great detail - sometimes too much detail. The manuscript is 44 pages long (including references and supplements). A large proportion of the manuscript gives painstaking instructions on the functions in the fragility package and their many arguments and options for those arguments.</p>
    <p>I request a reorganization of the paper. I would like to see Results section organized as a section on "Use Cases". By use cases, I mean having a case where the fragility index indicates an extremely fragile result (for all types of analyses - single study, MA, and NMA), and where the FI indicates a moderately fragile result, and where the FI indicates a robust result. The authors spend a great deal of white space in explaining the arguments of the functions. The reading is rather soporific. It would be better to show how the output and plots change as the FI changes for each of the three types of designs. That also means rearranging the plots. For example, a plot like Figure 1(a) for a fragile study should be placed next to the same rendering for a moderate and robust study. Such placement would help the reader understand what features of the plot are important.</p>
    <p>I would like to see better explication of the plots (i.e. Figure 1). Perhaps this could be done with more detailed captions. I found it hard to examine the plots and the text, and then go back and forth to determine what features about the plots are being described in the text. I spent a few minutes with each one and I am still not sure that I really understand them. It seems to me that having clear, easy to explain, output for researchers is part of the reason this package exists. If the plots are hard to understand, then are they serving the researchers using this package?</p>
    <p>A note on plotting symbols and colors: the triangles representing original p-values are quite small. I thought they were scratches on my screen at first. Finally, red and green is not a good color combination to show contrast. Red/green colorblindness is the most common type in the adult population. RColorBrewer has a list of color combinations that are meant to show divergence. One of those should be used.</p>
    <p>I'm also a little concerned that the package, or the FI itself, seems to address only binary outcomes. The examples are about observations moving from events to non-events, but what if the measurements are quantitative and they change slightly? Such a situation might happen in the case of an outlier in the data. If the outlier were removed, how does that affect the fragility of the outcome? That said, the package is useful as it currently stands.</p>
    <p>I think that researchers need to know about this package. It claims to make usage of FI easier, but as with all things R, there is a steep learning curve. A Shiny app would be much more helpful.</p>
    <p>Minor Details:</p>
    <p>The sentence at line 8 needs to be reworded. I think that "greatly" is the wrong adverb here, but I am not quite sure what the authors are trying to say; therefore, I can't suggest another word.</p>
    <p>Line 1267 contains a sentence about user specification in the function call, but it follows a sentence about the many aids in assessment contained in the fragility package. I would change the sentence to one that describes the detailed output or the plots that are available.</p>
    <p>I attached a PDF of the paper with minor grammatical and syntactical adjustments. They are not comprehensive. For example, the authors use the word "so" quite often as a conjunction. However, it isn't. "therefore" or "hence" or no conjunction at all should be used instead.</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!-- </font> --></p>
    <p>Reviewer #1: No</p>
    <p>Reviewer #2: No</p>
    <p>Reviewer #3: No</p>
    <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
    <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
    <supplementary-material id="pone.0268754.s002" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">PONE-D-21-32479.pdf</named-content></p>
      </caption>
      <media xlink:href="pone.0268754.s002.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0268754.r002">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0268754.r002</article-id>
    <title-group>
      <article-title>Author response to Decision Letter 0</article-title>
    </title-group>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0268754" id="rel-obj002" related-article-type="editor-report"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="author-response-date">13 Apr 2022</named-content>
    </p>
    <p>We thank the reviewers for providing many helpful comments on our manuscript. We have incorporated these suggestions in the revised manuscript. Our responses are detailed in the [square brackets] as follows.</p>
    <p>Reviewer #1:</p>
    <p>The Fragility Index (FI) is an intuitive statistical metric used primarily in the medical literature to assess the statistical significance of study results. Lin et a. has developed an R package to calculate the frailty index in an user-friendly way. It allows both to calculate the FI of the meta-analysis (MA) to compare couple of treatments at a time, e.g. the efficacy of a drug versus placebo - and Network-Meta-Analysis (NMA), to compare multiple treatments - for example the efficacy of multiple drugs.</p>
    <p>The first part of the article is devoted to the mathematical definition of the FI index and provides a brief overview of the methods commonly used to calculate the pvalue (Fisher's exact test, chi-squared, OR, RR and RD), and to quantify the FI for multiple levels of significance. The second part presents the functions of the R package and the applications to (i) individual clinical study (ii) pairwise meta analysis (iii) network meta analysis (iv) fragility at multiple levels of significance (v) fragility of multiple datasets .</p>
    <p>The paper is overall well written, although the following points would deserve to be addressed in addition to the more minor points mentioned below.</p>
    <p>[Response: Thank you very much for taking the time to perform the review of our manuscript. We appreciate your positive comments regarding this manuscript and many helpful suggestions. We have incorporated your suggestions into the revised manuscript. Please see our detailed responses below.]</p>
    <p>Majors:</p>
    <p>* section “Assessing Fragility” (from line 375 to line 723). Here the authors describe the functions of the R package with all the options. While this is interesting when using the package, it’s really hard to follow this section when reading the paper. Moreover It seems redundant with the documentation available at <ext-link xlink:href="https://cran.r-project.org/web/packages/fragility/fragility.pdf" ext-link-type="uri">https://cran.r-project.org/web/packages/fragility/fragility.pdf</ext-link>. The authors should consider rewriting this section, focusing on a few applications rather than listing all possible options.</p>
    <p>[Response: Thanks a lot for this suggestion. In the revised manuscript, we have moved some details of less important arguments to the supplemental file “Additional information of functions' arguments.” We have reduced the main content devoted to describing the functions. Also, to group the descriptions of the functions more clearly, we have split the original subsection into three subsections for individual studies, pairwise meta-analyses, and network meta-analyses accordingly. Although the manual of our package also lists the meaning of each argument of each function, we try to explain them in more detail so that they are more accessible for users.]</p>
    <p>* Fig 2. is not clear. The authors should give more details on how the plot is generated and how to interpret it. Same comment for Fig.3</p>
    <p>[Response: Thanks for the suggestion. We have added the following details to the captions of Fig 2 and Fig 3 (now Fig 4 and Fig 6): “Each line represents changes in the total event count in a certain group. The numbers around each line indicate the studies involved in the event status modifications during the iterations; each asterisk indicates that a study remains unchanged as in the previous iteration.”]</p>
    <p>* section "Example of assessing fragility of mutliple dataset" (from line 1004 to line 1254). Here the authors plot the fragility measures of all trials. I find it difficult to appreciate the novelty of this section as the authors describe how to make the plots, but not how to interpret them. The authors should should consider rewriting this section.</p>
    <p>[Response: This article focuses on introducing how to use the “fragility” R package and implementing case studies. Considering the manuscript’s length, we did not plan to give too many interpretations, as these have been done in many earlier works on empirical analyses of FI, including the original paper by Walsh et al. that proposed the FI. In the revised manuscript, we have added some interpretations in the section “Example of assessing fragility of multiple dataset.” For example, we added: “The FIs range from 1 to 19; many trials have FIs between 1 and 10, implying that their significance could be altered by changing the event statuses of at most 10 patients.” Also, as mentioned in the manuscript, the current literature still has some debates about the FI’s interpretation, so we have tried to avoid being involved in such debates. We have included these as a limitation in the discussion section.]</p>
    <p>Minors:</p>
    <p>*There is no link to the CRAN page of the package (and so it is not easy to find the documentation) and it's not explained how to install it.</p>
    <p>[Response: Thanks for this comment. The link was originally provided in the reference list. To make it easier for users to access this package and install it, we have added more details at the beginning of the subsection “Using the R package fragility.” In short, users can easily install the package in R using the command install.packages("fragility").]</p>
    <p>*Caption of Fig.1 is not clear. The authors should expand it and provide more details</p>
    <p>[Response: In the revised manuscript, we have added the following details to the caption of Fig 1 (now Fig 2). “Points or areas in green indicate non-significant results, and those in red indicate significant ones. Dashed lines represent no modifications in the corresponding groups. Square points represent the original p value, and triangle points indicate minimal modifications that alter the significance. In panels (a) and (d), event statuses are modified in both groups. Each point represents the extent of the p value corresponding to a specific combination of event status modifications in groups 0 and 1. In panels (c) and (d), event statuses are modified in only one group. Plus points represent truncated p values at 10^{−10}.”]</p>
    <p>Reviewer #2:</p>
    <p>This was an interesting manuscript describing a new R package for calculating and visualizing fragility of clinical studies, with clear worked examples to introduce the usage of the package.</p>
    <p>I have a few questions/comments which, if addressed, would hopefully improve the manuscript.</p>
    <p>[Response: Thanks a lot for taking the time to perform the review. Please see our responses as follows.]</p>
    <p>1. Page 18: The author showed an example of an individual clinical study with demonstration of the number of modifications in each group for achieving non-significance altered from significance. However, in my perspective, the direction of modification in each group is less clear by indicating the number of non-events changed in group 0 and the number of events changed in group 1. For example, maybe it would be clearer to demonstrate the number of events add/minus in group 0 and the number of events add/minus in group 1?</p>
    <p>[Response: Thanks for this comment. The idea of the fragility index is based on modifying event status in some treatment groups. The total samples remain unchanged; we only modified the event status (from events to non-events or from non-events to events) for some samples. Therefore, in our function’s output, we use languages like “inversing status of certain events or non-events in certain groups,” instead of “adding or reducing certain events.”]</p>
    <p>2. Page 38: “Similar to assessing the fragility of an individual study and a pairwise MA, the FI is</p>
    <p>defined as NA if the significance or non-significance cannot be altered.” Suppose we have three groups A,B and C, if the significance of comparing B vs A (or non-significance) cannot be altered by modifications in groups A and B, will you further consider modifications in group C or directly define it as NA. Maybe worth notify this somewhere.</p>
    <p>[Response: Many thanks for raising this question. We have mentioned that we only consider event status modifications in the relevant two groups for a treatment comparison because of the long run time for multiple NMAs via iterations. In the revised manuscript, we have added cautionary notes following this sentence: “Of note, as mentioned above, the calculation of the NMA’s FI for comparison B vs. A is based only on modifying event status in groups A and B. It is possible that the change of significance cannot be achieved by any event status modification in groups~A and B, but it could be achieved by modifications in other groups. Therefore, users should interpret an FI value of NA in the contexts of the event status modifications in the relevant two groups A and B only.”]</p>
    <p>3. Page 7: The explanation of deriving FI for MA under each step is not intuitive in my perspective. Could you please demonstrate a simple example here or illustrate a few iterations in the Example of a pairwise meta-analysis section?</p>
    <p>[Response: Thanks for this comment. We agree that the only texts may not illustrate the iterative algorithm for deriving the FI of a meta-analysis very clearly. Initially, we planned to illustrate the process, but this manuscript has already contained many figures, so we eventually decided not to include additional visualizations for the iterative algorithm, and this manuscript emphasizes introducing the “fragility” package. We have also offered a worked example of a meta-analysis, and the full iterations can be seen in Fig 4 (previous Fig 2). In the revised manuscript, at the end of the relevant paragraph, we added the following sentences. “For visualizations of the iterative steps for deriving the FI of the MA, readers may refer to Fig 4 in Atal et al. We will also provide a worked example later to demonstrate the process.”]</p>
    <p>4. The authors considered several tests with calculation of the corresponding FI. In practice, should we expect the FI to be similar across these tests? If the FI is very different among these tests, what does it imply?</p>
    <p>[Response: We provide multiple methods for calculating p-values and thus deriving the FI to offer flexibility for users if they want to use different methods. However, we are not suggesting that users should try all methods and compare the resulting FI values. Researchers are commended for using the method specified in the original study’s protocol for deriving the FI. In the subsection “Fragility of an individual clinical study” of the revised manuscript, we have added the following paragraph. “Of note, this article discusses multiple methods for testing the association between treatment and outcome and thus deriving the FI. We hope that they offer flexibility for users when assessing clinical studies' fragility based on different tools. We do not suggest that users should try all methods because this practice could lead to “fragility-hacking.” Users are recommended to use the statistical method specified in the study protocol for deriving the FI.”]</p>
    <p>Reviewer #3:</p>
    <p>The authors introduce an R package called fragility. The package contains functions and visualization tools that aid researchers in calculating the fragility index of their findings. An FI is a number that indicates how many observations must be shifted from one study sample to another for the statistical conclusion of the study to change. For example, if FI = 3, then three observations have to move from "event" to "non event" in order for a study in which the null hypothesis was rejected to become a study in which the null hypothesis is not rejected.</p>
    <p>The package is necessary and the write up describes it in great detail - sometimes too much detail. The manuscript is 44 pages long (including references and supplements). A large proportion of the manuscript gives painstaking instructions on the functions in the fragility package and their many arguments and options for those arguments.</p>
    <p>[Response: Thank you very much for providing many helpful suggestions on our manuscript. We have substantially restructured the manuscript. Please see our detailed responses below.]</p>
    <p>I request a reorganization of the paper. I would like to see Results section organized as a section on "Use Cases". By use cases, I mean having a case where the fragility index indicates an extremely fragile result (for all types of analyses - single study, MA, and NMA), and where the FI indicates a moderately fragile result, and where the FI indicates a robust result. The authors spend a great deal of white space in explaining the arguments of the functions. The reading is rather soporific. It would be better to show how the output and plots change as the FI changes for each of the three types of designs. That also means rearranging the plots. For example, a plot like Figure 1(a) for a fragile study should be placed next to the same rendering for a moderate and robust study. Such placement would help the reader understand what features of the plot are important.</p>
    <p>[Response: Thanks a lot for this suggestion. In the revised manuscript, we have moved some details of less important arguments to the supplemental file “Additional information of functions' arguments.” We have reduced the main content devoted to describing the functions. Also, to group the descriptions of the functions more clearly, we have split the original subsection into three subsections for individual studies, pairwise meta-analyses, and network meta-analyses accordingly. Although the manual of our package also lists the meaning of each argument of each function, we try to explain them in more detail so that they are more accessible for users.</p>
    <p>As for the suggestion of organizing the results section as “use cases,” we think it might be beyond this manuscript’s goal. This manuscript focuses on introducing how to use the “fragility” R package and implementing case studies. Considering the manuscript’s length, we did not plan to give too many interpretations, as these have been done in many earlier works on empirical analyses of FI, including the original paper by Walsh et al. that proposed the FI. More importantly, as mentioned in the manuscript, the current literature still has some debates about the FI’s interpretation. We have tried to avoid being involved in such debates. As discussed in the last section, there are no widely accepted rules for claiming very fragile, moderately fragile, slightly fragile, and no fragile studies/meta-analyses based on the FI or FQ values. In the future, we plan to systematically apply the FI and FQ to many studies and meta-analyses and thus derive evidence-based guidelines for interpreting the magnitudes of the fragility measures.]</p>
    <p>I would like to see better explication of the plots (i.e. Figure 1). Perhaps this could be done with more detailed captions. I found it hard to examine the plots and the text, and then go back and forth to determine what features about the plots are being described in the text. I spent a few minutes with each one and I am still not sure that I really understand them. It seems to me that having clear, easy to explain, output for researchers is part of the reason this package exists. If the plots are hard to understand, then are they serving the researchers using this package?</p>
    <p>[Response: Thanks a lot for this suggestion. In the revised manuscript, we have added the following details to the caption of Fig 1 (now Fig 2): “Points or areas in green indicate non-significant results, and those in red indicate significant ones. Dashed lines represent no modifications in the corresponding groups. Square points represent the original p value, and triangle points indicate minimal modifications that alter the significance. In panels (a) and (d), event statuses are modified in both groups. Each point represents the extent of the p value corresponding to a specific combination of event status modifications in groups 0 and 1. In panels (c) and (d), event statuses are modified in only one group. Plus points represent truncated p values at 10^{−10}.” We have added the following to the captions of Fig 2 and Fig 3 (now Fig 4 and Fig 6): “Each line represents changes in the total event count in a certain group. The numbers around each line indicate the studies involved in the event status modifications during the iterations; each asterisk indicates that a study remains unchanged as in the previous iteration.”]</p>
    <p>A note on plotting symbols and colors: the triangles representing original p-values are quite small. I thought they were scratches on my screen at first. Finally, red and green is not a good color combination to show contrast. Red/green colorblindness is the most common type in the adult population. RColorBrewer has a list of color combinations that are meant to show divergence. One of those should be used.</p>
    <p>[Response: As for the triangles in Fig 1a and Fig 1d (now Fig 2a and Fig 2d), we have slightly increased the point sizes. Please kindly note that the point sizes can be adjusted using the argument cex.pts in the function plot.frag.study.all().</p>
    <p>As for the colors, users can change the colors for significance and non-significance using the argument col.sig in the function plot.frag.study.all(). We respectively argue that it is quite common to use red/green to show contrast in some scientific disciplines, at least in the literature of evidence synthesis. For example, in the assessment of the risk of bias, green is typically used for studies with a low risk of bias, and red is typically used for studies with a high risk of bias. See, e.g., <ext-link xlink:href="https://doi.org/10.1136/bmj.l4898" ext-link-type="uri">https://doi.org/10.1136/bmj.l4898</ext-link>. In PLOS ONE, many articles also use red/green for contrasts; see, e.g., <ext-link xlink:href="https://doi.org/10.1371/journal.pone.0217401.g003" ext-link-type="uri">https://doi.org/10.1371/journal.pone.0217401.g003</ext-link> and <ext-link xlink:href="https://doi.org/10.1371/journal.pone.0025389.g002" ext-link-type="uri">https://doi.org/10.1371/journal.pone.0025389.g002</ext-link>.]</p>
    <p>I'm also a little concerned that the package, or the FI itself, seems to address only binary outcomes. The examples are about observations moving from events to non-events, but what if the measurements are quantitative and they change slightly? Such a situation might happen in the case of an outlier in the data. If the outlier were removed, how does that affect the fragility of the outcome? That said, the package is useful as it currently stands.</p>
    <p>[Response: Thanks for this comment. In the current practice of using the FI, nearly all studies deal with binary outcomes. Recently, Caldwell et al. (<ext-link xlink:href="https://doi.org/10.1016/j.jclinepi.2021.02.023" ext-link-type="uri">https://doi.org/10.1016/j.jclinepi.2021.02.023</ext-link>) proposed a method to calculate the FI for continuous outcomes. Nevertheless, to our knowledge, this method has not been widely used for assessing the fragility of studies with continuous outcomes. In the revised manuscript, we have added the following as one of our limitations in the discussion section: “Second, the current version of the “fragility” package can only deal with clinical studies with binary outcomes. Recently, Caldwell et al. proposed a method to define the FI of studies with continuous outcomes. If this method is further validated in practical applications, we will consider incorporating it into the future releases of the “fragility” package.”]</p>
    <p>I think that researchers need to know about this package. It claims to make usage of FI easier, but as with all things R, there is a steep learning curve. A Shiny app would be much more helpful.</p>
    <p>[Response: We agree that using this R package requires researchers to possess some coding skills. As mentioned in the introduction, some webpages (e.g., <ext-link xlink:href="https://clincalc.com/Stats/FragilityIndex.aspx" ext-link-type="uri">https://clincalc.com/Stats/FragilityIndex.aspx</ext-link> and <ext-link xlink:href="https://clinicalepidemio.fr/fragility_ma/" ext-link-type="uri">https://clinicalepidemio.fr/fragility_ma/</ext-link>) can be used to derive the FI for an individual study and a meta-analysis. Nevertheless, our R package “fragility” offers many more additional features than these webpage-based tools. If users just want to obtain numeric values of the FI, they could use the webpage-based tools. If they would like to make further analyses and better learn the fragility of clinical studies, they could consider using our package. Developing a Shiny app for implementing all the features offered by our current “fragility” R package is currently beyond our expertise. To the best of our knowledge, no Shiny app is available for implementing network meta-analyses, so it’s unlikely that a Shiny app for deriving the FI for NMA could be developed in the near future. In the last paragraph of the discussion section, we have added the following as our limitations. “There are still several limitations of the ``fragility'' package. First, using this package requires researchers to possess some coding skills; clinicians without coding training might not directly use this package for assessing the fragility of clinical studies.”]</p>
    <p>Minor Details:</p>
    <p>The sentence at line 8 needs to be reworded. I think that "greatly" is the wrong adverb here, but I am not quite sure what the authors are trying to say; therefore, I can't suggest another word.</p>
    <p>[Response: Sorry that there was a typo in this sentence. We have changed it to “This bias may distort clinical conclusions toward an artificially favorable direction and thus greatly threaten their reliability.”]</p>
    <p>Line 1267 contains a sentence about user specification in the function call, but it follows a sentence about the many aids in assessment contained in the fragility package. I would change the sentence to one that describes the detailed output or the plots that are available.</p>
    <p>[Response: Thanks for this suggestion. We have changed the relevant sentences as follows. “For example, the package produces various plots that visualize the studies and treatments involved in event status modifications in the iterative process for computing the FI or FQ of a pairwise MA or NMA. Such plots may indicate studies or treatments that are potentially influential in the meta-analytic results; clinicians may carefully examine the reliability (e.g., methodological quality) of the associated studies.”]</p>
    <p>I attached a PDF of the paper with minor grammatical and syntactical adjustments. They are not comprehensive. For example, the authors use the word "so" quite often as a conjunction. However, it isn't. "therefore" or "hence" or no conjunction at all should be used instead.</p>
    <p>[Response: Thanks a lot for carefully reviewing the whole manuscript. We appreciate your corrections. We have made changes accordingly and double-checked the manuscript in the revision.]</p>
    <supplementary-material id="pone.0268754.s003" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">Response.pdf</named-content></p>
      </caption>
      <media xlink:href="pone.0268754.s003.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pone.0268754.r003" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0268754.r003</article-id>
    <title-group>
      <article-title>Decision Letter 1</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gagniuc</surname>
          <given-names>Paul Aurelian</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 Paul Aurelian Gagniuc</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Paul Aurelian Gagniuc</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0268754" id="rel-obj003" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">9 May 2022</named-content>
    </p>
    <p>Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package</p>
    <p>PONE-D-21-32479R1</p>
    <p>Dear Dr. Lin,</p>
    <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
    <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
    <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link xlink:href="http://www.editorialmanager.com/pone/" ext-link-type="uri">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
    <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
    <p>Kind regards,</p>
    <p>Paul Aurelian Gagniuc, PhD</p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
    <p>Additional Editor Comments (optional):</p>
    <p>Reviewers' comments:</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <!-- <font color="black"> -->
      <bold>Comments to the Author</bold>
    </p>
    <p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.<!-- </font> --></p>
    <p>Reviewer #1: All comments have been addressed</p>
    <p>Reviewer #2: All comments have been addressed</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->2. Is the manuscript technically sound, and do the data support the conclusions?</p>
    <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->3. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
    <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.<!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
    <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->6. Review Comments to the Author</p>
    <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
    <p>Reviewer #1: I would like to thank the authors for attempting to address my main concerns, and I think the revised paper is substantially improved.</p>
    <p>I appreciated the effort they have done to improve the readability of paper by moving most of the technical details to the supplementary and leaving in the main text only the main functions.</p>
    <p>They have added the captions and more extensive explanations to Fig.2 and 3 and some interpretations of the Fragility Index which in my opinion are of great use to non-specialists.</p>
    <p>Also all the minor comments have been addressed.</p>
    <p>Reviewer #2: The paper has been written in a more concise way. I am satisfied with the work done by the authors to address my questions.</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!-- </font> --></p>
    <p>Reviewer #1: No</p>
    <p>Reviewer #2: No</p>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0268754.r004" specific-use="acceptance-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0268754.r004</article-id>
    <title-group>
      <article-title>Acceptance letter</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gagniuc</surname>
          <given-names>Paul Aurelian</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 Paul Aurelian Gagniuc</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Paul Aurelian Gagniuc</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0268754" id="rel-obj004" related-article-type="reviewed-article"/>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">11 May 2022</named-content>
    </p>
    <p>PONE-D-21-32479R1 </p>
    <p>Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package </p>
    <p>Dear Dr. Lin:</p>
    <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
    <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
    <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
    <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
    <p>Kind regards, </p>
    <p>PLOS ONE Editorial Office Staff</p>
    <p>on behalf of</p>
    <p>Dr. Paul Aurelian Gagniuc </p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
  </body>
</sub-article>
